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Summary  
Prions are the causative agent of transmissible spongiform encephalopathies in animals 
and humans such as scrapie, bovine spongiform encephalopathy (BSE) and Creutzfeldt-
Jakob disease (CJD). Prions are thought to be composed essentially of a misfolded and 
aberrantly aggregated isoform of the cellular prion protein (PrP) and to replicate by 
seeded PrP polymerization. Prions replicate without a nucleic acid genome. However, 
prions derived from the same cellular prion protein may exist in the form of distinct 
strains that differ in their phenotypic characteristics. It is thought that prions encode 
strain specific information in distinct protein conformations and/or by interaction with 
cofactor molecules. Against this background the present study examined the effects of 
different cofactor molecules on the proteinaceous seeding activity of four hamster 
adapted prion agents (263K, BSE-H, ME7-H and 22A-H) using serial protein 
misfolding cyclic amplification (PMCA) as in vitro assay for PrP misfolding and 
aggregation. The study revealed strain dependent differences of PMCA conditions and 
cofactors required for efficient in vitro replication. PMCA had to be specifically adapted 
for each prion strain. The EDTA concentration and incubation times per PMCA cycle 
were found to be of great significance for efficient amplification. In turn, addition of 
selected metal ions basically inhibited amplification. All prion strains showed a general 
requirement for nucleic acids during PMCA. However, under nucleic acid deficiency 
the prion strains exhibited different abilities to use certain polyanions for the 
reconstitution of PrP conversion in PMCA assays. The impact of cofactors was assessed 
by comparative analyses of selected biological, biochemical and biophysical properties 
of PMCA products (PrPres) and native prion seeds (PrPSc). The biological seeding 
activity as monitored in a primary hamster glial cell assay, and biochemical properties 
such as electrophoretic migration in SDS-gels, were affected differently by different 
cofactors. FT-IR spectroscopy was used in an analytical pilot study to structurally 
characterize PrPres from PMCA products in order to investigate if varying cofactor 
conditions during PMCA caused detectable alterations in protein conformations. 
Largely preliminary data revealed spectral differences between parent and progeny 
PrPres for all prion strains, but no variations due to different cofactor conditions. In this 
study a novel PMCA derived BSE-H isolate that replicated efficiently in the absence of 
nucleic acids (and without the addition of other cofactors) was generated. Infectivity of 
this novel isolate in the cell assay suggested that it may be infectious in animals. 
Furthermore, metal ions were applied for the first time in a long-term assay (approx. 
80 days) to glial cells to investigate metal effects on prion propagation. Metal ions 
selectively inhibited the seeding activity of 263K prions in PMCA as well as in the cell 
assay. Finally, a novel approach for the assessment of prion infectivity in unknown 
samples by jointly performed PMCA- and cell assay titrations without the need of 
bioassays in laboratory rodents was presented in this work. This will contribute to a 
reduction and replacement of animal bioassays in prion research. 
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Zusammenfassung 
Prionen sind das infektiöse Agens transmissibler spongiformer Enzephalopathien von 
Tieren und Menschen, wie beispielsweise der Scrapie, bovinen spongiformen 
Enzephalopathie (BSE) und Creutzfeldt-Jakob-Krankheit (CJD). Prionen bestehen 
hauptsächlich, wenn nicht ausschließlich, aus einer abnormal gefalteten und 
aggregierten Isoform des zellulären Prionproteins (PrP). Die Replikation von Prionen 
findet mutmaßlich durch keiminduzierte Polymerisation („seeded polymerization“) des 
Prionproteins statt. Prionen replizieren ohne genomische Nukleinsäuren, jedoch ist die 
Existenz verschiedener Prionstämme bekannt, die unterschiedliche stammartige 
Eigenschaften aufweisen, aber vom selben zellulären Prionprotein abstammen können. 
Es wird vermutet, dass stammspezifische Informationen durch die jeweilige 
Konformation des Proteins und/oder durch Interaktion mit Kofaktoren definiert werden. 
In dieser Arbeit wurde die Auswirkung von verschiedenen Kofaktoren auf die 
Keimaktivität („seeding activity”) von vier Hamster-adaptierten Prionstämmen (263K, 
BSE-H, ME7-H und 22A-H) in vitro mittels der Methode der „Protein Misfolding 
Cyclic Amplification“ (PMCA) untersucht. Dabei wurden stammabhängige 
Unterschiede bezüglich der Anforderungen an die in vitro Replikationsbedingungen in 
der PMCA, sowie Kofaktor-Selektivitäten festgestellt. Die PMCA-Bedingungen wurden 
für jeden Prionstamm angepasst. Um eine effiziente Amplifikation zu erreichen, waren 
die EDTA Konzentration und die Inkubationszeit pro PMCA-Zyklus von 
entscheidender Bedeutung. Im Gegenzug führte der Zusatz von bestimmten Metallionen 
im Wesentlichen zu einer Hemmung der Amplifikation. Alle Stämme zeigten eine 
generelle Abhängigkeit von Nukleinsäuren in der PMCA. Jedoch wurden unter 
Bedingungen von Nukleinsäuremangel Stammunterschiede im Hinblick auf die 
Rekonstitution der Amplifikation mit bestimmten polyanionischen Kofaktoren 
beobachtet. Der Einfluss von Kofaktoren wurde durch den Vergleich ausgewählter 
biologischer, biochemischer und biophysikalischer Eigenschaften von in vitro erzeugten 
PMCA Produkten (PrPres) mit denen nativer Prionkeime (PrPSc) untersucht. Dabei 
wurde beobachtet, dass Kofaktoren Stammeigenschaften, wie die biologische 
Keimaktivität in primären Hamster-Gliazellkulturen und biochemische Eigenschaften, 
wie die Migration in SDS-Gelen, beeinflussen können. Um festzustellen, ob 
unterschiedliche Kofaktorbedingungen während der PMCA messbare Veränderungen 
der Proteinkonformation hervorrufen, wurde PrPres von PMCA Produkten mittels  
FT-IR Spektroskopie in einer Pilotstudie charakterisiert. Erste Untersuchungen zeigten 
spektrale Unterschiede zwischen den Proteinkeimen und deren PMCA Produkten bei 
allen Stämmen. Konformationelle Änderungen bedingt durch unterschiedliche 
Kofaktoren konnten zunächst nicht festgestellt werden. Außerdem wurde in dieser 
Arbeit mittels PMCA ein neues BSE-H Agens, welches vollkommen unabhängig von 
Nukleinsäuren replizierte, erzeugt. Dieses Agens war im Zellassay infektiös, was darauf 
hindeutet, dass es auch in Tieren infektiös sein könnte. Weiterhin wurden in dieser 
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Arbeit erstmals Metallionen in einem Langzeitversuch in einem Gliazell-Assay für 
Prionen eingesetzt. Metallionen inhibierten die Keimaktivität von 263K Prionen sowohl 
in der PMCA als auch im Zell-Assay selektiv. Schließlich, konnte ein neuer Ansatz zur 
Bestimmung von Prioninfektiosität in unbekannten Proben durch parallel durchgeführte 
PMCA- und Zell-Assays unter Verzicht auf Tierversuche aufgezeigt werden. Dies 
liefert einen Beitrag zur Reduktion und zum Ersatz von Tierversuchen in der 
Prionforschung. 
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1. Introduction 
 
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of 
fatal and infectious neurodegenerative disorders caused by prions that affect many 
mammalian species [Prusiner, 1982; Prusiner, 1998]. They include Creutzfeldt-Jakob 
disease (CJD) and its variant (vCJD), Fatal Familial Insomnia (FFI), Gerstmann-
Sträussler-Scheinker syndrome (GSS) and kuru in humans, scrapie in sheep and goats, 
bovine spongiform encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) 
in deer and elk. Prion diseases occur in sporadic, hereditary and acquired forms. TSEs 
are characterized, in general, by cognitive impairments, extensive brain damage and 
neuronal dysfunction which lead to the loss of motor control, paralysis, and dementia. A 
spongiform degeneration (vacuolation) is accompanied by gliosis, loss of neurons as 
well as pathological deposits of prion protein (PrP) as found by microscopic 
examination of the CNS. The key event in TSE development is the conformational 
transition of the cellular prion protein (PrPC) into an abnormal misfolded and 
aggregated isoform (PrPSc).  
The first cases of scrapie, a TSE that affects sheep and goats, were observed in the 
United Kingdom (UK) in the 18th century. The name scrapie is derived from the 
observation that affected animals show compulsive scraping due to an itching sensation. 
It has been recognized early, around 1759, that scrapie is infectious. However, its 
experimental transmissibility has been shown not before 1936. Other clinical signs 
include excessive lip smacking, abnormal gait, tremors, weight loss and behavioral 
changes such as aggression or apprehension, sensitivity to noise and movement 
[Hörnlimann et al., 2007].  
The prion disease kuru among the Fore people in Papua New Guinea was observed in 
the 1950s. The Fore people did practice a ritualistic cannibalism, that resulted in 
transmission of the disease and killed a large number of the local population [Gajdusek 
and Zigas, 1957]. Creutzfeldt-Jakob disease was first reported in 1920 [Creutzfeldt, 
1920; Jakob, 1921]. A connection between scrapie, kuru and CJD was made in 1959. In 
1966, the transmissibility of kuru was established by passaging the disease to 
intracerebrally inoculated chimpanzees and two years later, the transmission of CJD to 
chimpanzees after intracerebral inoculation was reported (for review see: [Prusiner, 
1998]). 
Human prion diseases can arise as sporadic, hereditary or acquired disease, with the 
latter being caused by infection. The forms of CJD are briefly explained in the 
following paragraphs.  
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Most cases of CJD are sporadic forms (sCJD). Sporadic forms are assumed to be of an 
endogenous origin, which is however unknown. This origin could be a somatic mutation 
of the PrP gene (PRNP), or a spontaneous conversion of PrPC into PrPSc. sCJD occurs 
usually at advanced age (≥ 60 years).  
Familial CJD (fCJD) is an inherited prion disease. Different mutations in the human PrP 
gene have been linked to this disease form and are believed causative.  
Iatrogenic forms of CJD occurred due to improperly sterilized medical instruments or 
grafts from infected and undetected donors. Young adults were reported to have 
developed CJD after treatment with human growth hormone or gonadotropin derived 
from infected and undetected donors. 
A new form of human prion disease, termed variant CJD (vCJD), appeared in the UK 
approximately 10 years after the outbreak of the BSE epidemic. First patients were 
observed in Britain in 1994. In contrast to sCJD which occurs usually at a median age of 
66 years, vCJD patients are on average 28 years old when symptoms occur. The 
occurrence of vCJD was ascribed to the consumption of BSE infected meat products. 
The BSE epidemic was caused by meat and bone meal that was fed primarily to dairy 
cows. The meat and bone meal was prepared from the offal of sheep, cattle, pigs and 
chickens. In the late 1970s, altered production methods for meat and bone meal used 
lower temperatures and shorter incubation times than before, and omitted fat extraction 
as done before. Since scrapie had occurred in the UK before, it is thought that these 
changes in the production process allowed scrapie prions from sheep to “survive” and to 
be transmitted into cattle. However, the real origin of BSE in cattle has not been 
definite. Alternatively, bovine prions (presumably of sporadic origin) might have been 
present and would be distributed by the feeding practices of meat and bone meal. Due to 
regulations, e.g. the ban to feed meat and bone meal to sheep and cattle since 1988, the 
BSE epidemic declined since 1993. In 2013, there have been only two BSE cases in the 
UK (October 2013), whereas over 37 000 cases were reported in 1992 [OIE, 2013]. Due 
to the restricted geographical occurrence and chronology of BSE and vCJD, as well as 
experimental evidence as to the similarity of the causative agents, it is assumed that 
BSE is the origin of human vCJD [Hörnlimann et al., 2007; Prusiner, 1998]. vCJD has 
been reported with 177 cases in the UK so far, among which none patient is still alive 
(October 2013 [NCJDRSU, 2013]). There has not been a German case of vCJD so far. 
Furthermore, 3 secondary cases of vCJD in the UK were reported. These patients had 
probably become infected by blood transfusions from individuals who developed vCJD 
after the blood donation. The experimental transmission of BSE by blood among 
primates was reported in 2002 [Bons et al., 2002; Zou et al., 2008].  
Since long incubation times were observed in TSEs, it was originally believed that the 
causative agent was a ‘‘slow virus’’ [Sigurdsson, 1954]. However, the agent related to 
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TSEs was highly resistant to inactivation by treatments that affect nucleic acids, such as 
ionizing radiation and ultraviolet light as well as inactivation by chemicals and heat 
treatments. Such treatments would effectively inactivate conventional pathogens, such 
as viruses and bacteria. Attempts to identify nucleic acids as part of the infectious agent 
were not successful, and it was suggested that a protein alone could possibly transmit 
TSEs and replicate in infected individuals in the absence of nucleic acids [Alper et al., 
1967; Griffith, 1967; Hunter et al., 1976]. In the 1980s, the neuroscientist Stanley 
Prusiner characterized the infectious agent and demonstrated that infectivity of scrapie 
was reduced by procedures that modify proteins. He introduced the concept of the 
“prion” and coined the term derived from “proteinaceous infectious particle” to 
distinguish the TSE agent from conventional pathogens, such as viruses and bacteria. 
According to the “protein only” hypothesis the infectious agent of TSEs is composed 
mainly, if not entirely, of PrPSc, an aggregated misfolded conformer of the normal host 
glycoprotein PrPC [Prusiner, 1982]. Interaction of PrPSc with PrPC induces a structural 
transition in the latter which is refolded into the β-sheet enriched, aggregated PrPSc 
conformer. In this way, the pathogenic PrPSc replicates and accumulates without a 
nucleic acid genome.  
 
1.1 Structure of PrPC and PrPSc 
The cellular prion protein PrPC is ubiquitary expressed in mammals. PrPC is encoded by 
the Prnp (mice) / PRNP (humans) gene, which is localized on chromosome 20 in 
humans and highly conserved among mammals. Human PrP consists of 253 amino 
acids. It is synthesized on the rough endoplasmic reticulum and transits through the 
Golgi apparatus to the cell surface. During protein processing the signal peptide 
comprising amino acids 1-22 is cleaved off. A glycosyl-phosphatidyl-inositol (GPI) 
anchor at the carboxy-terminus of the protein attaches it to the outer surface of the cell 
membrane. In addition to the GPI-anchored form of PrP also transmembrane forms 
were reported, and an incorporation into lipid rafts which are regions of the membrane 
enriched in cholesterol and sphingolipids was shown [Linden et al., 2008; Stewart and 
Harris, 2003]. A disulfide bond exists between Csy179 and Cys214. Further 
posttranslational modifications include the glycosylation of Asn181 and Asn197 with 
complex glycans resulting in non-, mono- or diglycosylated PrP forms. The mature 
protein has a molecular mass of about 33-35 kDa.  
PrPC is expressed in many tissues of the central and peripheral nervous system, the 
immune system, lymphoreticular and intestinal system [Dodelet and Cashman, 1998; 
Linden et al., 2008; Shi et al., 2009b]. PrPC is predominantly expressed in neurons pre- 
and post-synaptically and is also found in glial cells [Linden et al., 2008]. 
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al., 1996]. The disulfide bond 
cellular PrP was obtained by 
is depicted in Figure 1-1. 
 
 
Figure 1-1:  Structure of human PrP
sequence that comprises the octarepeat region 
three α-helices and an antiparallel 
disulfide bond. 
 
PrPC and PrPSc, the patho
sequences and share the same posttranslational modifications. However, both forms of 
the protein have different biochemical and biophysical properties, such as solubility and 
susceptibility to proteinase K (PK
tertiary and aggregate structures and are utilized to distinguish both isoforms 
[Hörnlimann et al., 2007]. PrP
detergents. In contrast, PrP
PrPC is rapidly degraded by PK, PrP
therefore, in a biochemical sense
results in formation of a protease resistant core fragment, desig
                                                
1
 PrP27-30 is used to designate the PK
humans; PrPres designates, in a biochemical sense, PK
PrP27-30 as well as PK-resistant PMCA 
products. While PrP27-30 is per se associated with infectivity, PrPres may or may not 
with infectivity. 
C
 contains a flexible random coil sequence whereas a 
-terminally [Riek et al., 1997]. The unstructured 
an eight amino acid
The globular domain of human PrP
and a β-sheet formed by two antiparallel β-
interconnects helices H2 and H3. The structure of human 
nuclear magnetic resonance (NMR) [Zahn 
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according to its approximate molecular mass of 27-30 kDa, which is generated by 
amino-terminal truncation around amino acid 90 [Prusiner et al., 1983]. PrP 27-30 
conveys prion infectivity. However, under specific conditions PrPSc was also found to 
be sensitive to PK [Safar et al., 2005].  
 
As PrPSc forms aggregates, is insoluble and not amenable to crystallization, its three-
dimensional structure could not be resolved so far by high-resolution techniques such as 
X-ray diffraction and NMR. Fourier-transform infrared (FT-IR) spectroscopy and 
circular dichroism (CD) studies showed that PrPC has a high content of α-helices (42 %) 
and only a minor β-sheet content (3 %) [Pan et al., 1993]. However upon the conversion 
from PrPC to PrPSc the content of β-sheet increases dramatically to about 43 % while the 
content of α-helices decreases to about 30 % [Caughey et al., 1991; Safar et al., 1993]. 
Electron crystallographic analysis of 2D crystals of PrP 27-30 allowed a modeling of 
PrPSc structure. Govaerts et al. [Govaerts et al., 2004] proposed that monomers attain a 
left-handed, β-helical fold with two remaining α-helices. The left-handed β-helices 
readily form trimers that assemble in a disc structure. Stacking of those discs leads to 
assembly into prion fibrils (Figure 1-2).  
 
 
 
Figure 1-2:  Model of PrPSc structure [Govaerts et al., 2004]. (A) Model of a PrP 27-30 monomer. (B) 
Trimeric model of PrP 27-30. (C) Model of a PrP 27-30 fiber built up by assembly of five 
trimeric discs. 
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1.2 Physiological functions of PrP 
Despite many efforts to elucidate the physiological role of PrPC a precise function of 
normal PrP has not been determined so far. PrPC is highly expressed in the CNS of 
mammals and its sequence is highly conserved throughout different mammalian species 
which implies an important functional role. However, PrP knockout mice basically 
showed a normal development and no striking pathology. Older mice showed 
demyelination in the peripheral nervous system without clinical symptoms [Bueler et 
al., 1992; Manson et al., 1994]. The behavior was normal except for alterations in 
circadian rhythm and sleep pattern. PrP deficient mice were resistant against infection 
with Scrapie prions [Bueler et al., 1993; Weissmann and Flechsig, 2003], which shows 
that PrPC must be present in order to develop a TSE. Many different molecules are 
known to interact with PrPC and could be involved in its function. Many proposed 
functions of PrP are attributed to its property as a metal binding protein. The protein 
was speculated to have a function as metal transporter, since metal levels in brains of 
knockout mice, prion infected mice and wild type mice were different. Copper was 
found to modulate the expression of PrPC. A function in the uptake of copper and iron 
and thus a role in cellular copper and iron metabolism was suggested. A loss of function 
due to aggregation of PrPC has been thought to disturb cellular iron and copper 
homeostasis, resulting in neurotoxicity [Hodak et al., 2009]. As PrPC is present at pre- 
and post-synaptic sites of neurons it was suggested to function in the binding and 
reuptake of copper into cells after the release of copper into the synaptic cleft upon 
depolarization [Linden et al., 2008]. Additionally, since PrPC is localized to the lipid 
membrane, a role as membrane receptor and involvement in signal transduction has 
been hypothesized. Furthermore, PrPC can protect against oxidative damage and a 
function as an antioxidant has been discussed. However, a function as cell adhesion 
molecule, a role in cell communication and as signal transducer were discussed as well. 
Moreover, the protein has been discussed to be involved in cell proliferation and 
differentiation, regulation of cellular homeostasis, growth and function of synapses 
(reviewed by [Choi et al., 2006; Linden et al., 2008]). 
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1.3 Models for the conversion of PrPC to PrPSc 
The precise mechanism for the propagation and spread of prions in vivo has not been 
determined so far. However, the conformational change from cellular PrP to its 
pathological isoform PrPSc is considered as an essential event in prion replication. In the 
following the two mainly discussed models for prion replication are introduced. 
According to Stanley Prusiner and colleagues [Prusiner, 1991] prions may multiply by 
template-directed refolding. This concept is referred to as heterodimer model  
(Figure 1-3A). According to this model, the spontaneous conversion from PrPC into 
PrPSc in the absence of PrPSc is a very rare event and prevented by a high energy barrier. 
However, when PrPSc is present a heterodimer with PrPC may be formed. The 
rearrangement of the structure of PrPC is then induced and thus the heterodimer 
becomes a homodimer. Formation of homodimers from PrPC has been observed, but a 
heterodimer could not be detected experimentally [Hörnlimann et al., 2007].  
Alternatively, the model of nucleation-dependent, or seeded, PrP polymerization has 
been proposed [Jarrett and Lansbury, 1993]. According to this concept, PrPC and PrPSc 
exist in their monomeric forms in an equilibrium that is however shifted towards PrPC 
(Figure 1-3B). An initial oligomerization of PrPSc occurs very slowly. However, highly 
ordered oligomeric structures stabilize the PrPSc conformation. If such an oligomer is 
present, further PrPSc monomers are recruited that become incorporated into the 
growing aggregates and thus promote the further conversion of PrPC into PrPSc. This 
eventually leads to the formation of amyloid fibrils. PrPSc aggregates that are capable to 
promote PrPC conversion into PrPSc are referred to as seeds or nuclei. According to this 
hypothesis monomeric PrPSc is not infectious, only its highly ordered aggregates bear 
infectivity. Fragmentation of aggregates generates novel nuclei that can recruit more 
PrPSc monomers and thus propagate PrPSc aggregation. The generation of novel seeds 
from pre-existing aggregates by fragmentation is termed secondary fragmentation.  
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Figure 1-3:  Models for conversion of PrPC into PrPSc [Aguzzi and Polymenidou, 2004]. (A) The 
conversion from PrPC into PrPSc is induced by template-directed refolding when a 
heterodimer between PrPC and PrPSc is formed. Spontaneous conversion from PrPC to 
PrPSc in the absence of PrPSc is a very rare event and occurs very slow. (B) Seeded 
nucleation model. PrPC and PrPSc exist in an equilibrium that is shifted towards the side of 
PrPC. The formation of highly ordered PrPSc aggregates leads to recruitment, stabilization 
and incorporation of monomeric PrPSc and aggregate growth. 
 
1.4 In vitro amplification of prions by protein misfolding cyclic 
amplification (PMCA) 
In 2001 Claudio Soto and colleagues presented a method to amplify misfolded prion 
protein in vitro by a technique called protein misfolding cyclic amplification (PMCA) 
[Saborio et al., 2001]. In PMCA minute amounts of brain PrPSc are incubated in an 
excess of PrPC. The method utilized brain homogenate (BH) from healthy, uninfected 
hamsters and terminally diseased animals (PrPSc) as PrPC and seed sources, respectively, 
and is thus a cell-free system. In repetitive cycles of incubation and sonication PK 
resistant aggregates are formed. According to the concept of “seeded polymerization” 
PK resistant aggregates are being produced by the recruitment of PrPC molecules and 
their incorporation into growing PrPSc aggregates.  
Incubation was performed at 37 °C (body temperature) for 30 minutes. During this 
phase PrPSc-seeds become elongated (Figure 1-4). As instable monomeric PrPSc or an 
intermediate form of partially misfolded PrPC may be recruited and incorporated into 
PrPSc-oligomers the pathological conformation is stabilized. Polymerization occurs at 
the ends of PrPSc-seeds. The subsequent sonication brakes down large aggregates into 
smaller oligomers or polymers and thus multiplies the number of existing PrPSc-seeds 
by secondary nucleation. Novel PrPSc-seeds in turn promote further polymerization and 
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PrP conversion. In this manner, under optimal PMCA conditions, an exponential 
multiplication of conversion active seeds occurs. Cycles of incubation and sonication 
can be repeated as often as required in an automated manner using programmable 
ultrasonic devices [Castilla et al., 2006]. By this way of accelerated prion replication 
with PMCA even minute amounts of PrPSc seeds can be amplified to become detectable, 
in the form of PrPres, by Western blotting.  
 
 
Figure 1-4:  Protein misfolding cyclic amplification [Soto et al., 2002]. Minute amounts of PrPSc seeds 
are incubated at 37 °C in an excess of PrPC. During incubation PrPSc-aggregates recruit 
PrPC molecules which become incorporated, in a converted misfolded conformation, into 
the oligomer/polymer leading to growing aggregates. Ultrasound brakes down large 
aggregates into smaller ones and thus multiplies the number of PrPSc-seeds. Cycles of 
incubation and sonication are repeated several times. In this manner minute quantities of 
PrPSc seeds become amplified to detectable levels by Western blot.  
 
A substantial improvement of the PMCA technique was the serial PMCA (sPMCA) 
[Bieschke et al., 2004] that was subsequently automated by Castilla et al. (2005a). After 
several amplification cycles an aliquot of the reaction mixture is diluted into fresh 
Introduction 
17 
normal brain homogenate and subjected to a new round of alternating amplification 
cycles. By performing sequential passages, the initial seeding material is diluted with 
every passage step. It was shown that PrPSc can be propagated in principle infinitely in 
serial PMCA. Which demonstrates that the newly generated PK resistant PrP 
amplificate, that can be detected in the Western blot as PrPres, is able to 
autocatalytically promote PrP misfolding [Bieschke et al., 2004; Castilla et al., 2005a]. 
In vitro generated PrPres was shown to have similar properties as PrP 27-30 from 
infectious brain homogenate. Such properties were assessed by biochemical methods 
which include electrophoretic mobility, glycosylation profile, resistance to PK and 
resistance to denaturation with guanidine hydrochloride. Furthermore, it was 
demonstrated that PMCA PrPres is infectious to wildtype laboratory rodents, which 
developed disease upon experimental transmission. By analysis of behavior, 
neurological and biochemical properties, the disease was not distinguishable from 
infections with prion brain homogenate [Castilla et al., 2008b; Weber et al., 2006]. It 
was reported that infectious PrPSc particles of a minimal size of approximately 
26 molecules are required to induce a specific and reproducible amplification in PMCA 
to enable detection [Saa et al., 2006].  
Since PrPSc is the only validated surrogate marker for prion diseases their diagnosis is 
often based on the detection of PrPSc in tissue samples. In this regard PMCA has been 
successfully applied to detect the presence of PrPSc in blood, urine and feces of scrapie 
infected hamsters [Castilla et al., 2005b; Gonzalez-Romero et al., 2008; Kruger et al., 
2009]. Furthermore, PMCA could detect infections in pre-symptomatic animals [Soto et 
al., 2005]. The detection of prions in milk from sheep infected with scrapie before 
clinical onset of disease by PMCA was also reported [Maddison et al., 2009]. PMCA is 
a promising tool not only for the diagnosis of TSEs but also for the identification and 
evaluation of inhibitors for prion replication in regard to novel therapeutic targets. 
PMCA has been also shown to be a valuable tool to study prions in regard to achieve a 
better understanding of the molecular nature of the infectious prion agent. PMCA has 
been used to study the strength and molecular determinants of transmission barriers 
between different species [Barria et al., 2011; Castilla et al., 2008a]. Using purified 
PrPC and PrPSc from the brains of healthy and diseased animals, respectively, 
Supattapone and co-workers could generate infectious PrPres in serial PMCA in the 
presence of synthetic poly(A) RNA anions [Deleault et al., 2007]. PMCA has therefore 
been applied to study conversion factors that may be involved in prion propagation. 
Earlier, the same group had applied a modified PMCA assay that used BH and 
continuous shaking instead of ultrasound to study the effect of putative PrP conversion 
factors [Deleault et al., 2003]. In other experiments, it was demonstrated that also 
bacterially expressed recombinant PrP (rPrP) could be used as substrate for PMCA 
[Atarashi et al., 2007]. However, those PMCA amplificates were not or only at a very 
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low level infectious. Furthermore, it has been reported that reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) enhanced the propagation of PrPSc in BH in 
PMCA [Shi et al., 2009a]. Heparin was shown to enhance the in vitro propagation of 
vCJD-associated PrPres in PMCA which could have implications for the development 
of highly sensitive in vitro screening tests that are able to detect minute amounts of 
PrPSc in blood or other body fluids [Yokoyama et al., 2011]. 
 
1.5 Cofactor molecules of PrP conversion 
Since the conformational transition from PrPC into PrPSc in the absence of PrPSc 
aggregates is hindered by a high energy barrier (see Figure 1-3), it has been suggested 
that other molecules are crucial for spontaneous (or genetically triggered) prion 
formation which may function as adjuvants that lower the energy barrier and thus 
catalyze or facilitate the PrP conversion reaction [Gomes et al., 2012; Silva et al., 
2010]. Accordingly, such putative cofactors may also accelerate the conversion of PrP 
by PrPSc seeds, i.e. prion replication. The in vitro conversion of PrP in a cell-free system 
that used only purified proteins [Kocisko et al., 1994] was less efficient than sPMCA 
that employed crude brain homogenates [Castilla et al., 2005a]. This indicated that 
additional factors were required for efficient conversion and that brain homogenate is 
likely to contain such factors. Furthermore, in vitro produced protease-resistant prion 
protein generated from recombinant prion protein carries none or only very low 
infectivity [Hill et al., 1999; Makarava et al., 2010]. As an explanation, PrPres 
composed of rPrP may just not have an infectious conformation, however, cofactors 
may also be required for conveying infectivity [Klingeborn et al., 2011].  
 
1.5.1 Non-metal cofactors for prion conversion 
Many potential ligands for PrPC have been identified, of which cellular adhesion 
molecules, extracellular matrix molecules, glycosaminoglycans (GAGs), and nucleic 
acids have emerged as candidates for conversion factors. Recently, polyanions, such as 
nucleic acids and GAGs, and furthermore lipids have been found to influence prion 
propagation and infectivity.  
Proteoglycans and GAGs have been implicated in the pathogenesis of prion diseases 
[Ben-Zaken et al., 2003; Caughey and Raymond, 1993; Shaked et al., 2001; Wong et 
al., 2001b] and have been detected in amyloid plaques of prion diseases [McBride et al., 
1998; Snow et al., 1989; Snow et al., 1990]. Proteoglycans are glycoproteins that 
consist of a core protein which is covalently linked to one or more glycosaminoglycan 
chains. GAGs are linear polyanionic polysaccharides composed of a repetitive 
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disaccharide unit that can be sulfated. They include heparin, heparan sulfate, 
chondroitin sulfate or pentosan sulfate. GAGs are involved in numerous biological 
activities and functions, including cell-cell and cell-matrix interactions, regulation of 
cell growth and proliferation, roles in brain development and wound repair [Capila and 
Linhardt, 2002; Silva et al., 2010].  
Various studies have demonstrated that prion conversion did not occur when purified 
PrPC and PrPSc were mixed and incubated in vitro [Abid et al., 2010; Deleault et al., 
2010; Saborio et al., 1999]. Conversion was only observed when other cellular 
components were present. Supattapone and colleagues have shown that various 
polyanions, such as different kinds of nucleic acids (mammalian and invertebrate RNA, 
synthetic RNA and DNAs) and proteoglycans (heparan sulfate proteoglycan) can 
function as cellular conversion factors to enable PrPC → PrPSc conversion by PMCA of 
infectious material [Deleault et al., 2005; Deleault et al., 2007; Deleault et al., 2003; 
Geoghegan et al., 2007]. It has been shown that treatment of PrPC substrates (e.g. 
normal brain homogenate) with various enzymes that degrade nucleic acids abolish 
PrPSc amplification. It was furthermore demonstrated that the addition of RNA 
molecules isolated from hamster brain reconstituted the amplification of PrPres in 
PMCA samples which were pre-treated with nucleases. Another study showed that 
heparan sulfate and pentosan sulfate stimulated the cell-free conversion of PrP [Wong et 
al., 2001b]. Cofactor molecules were proposed to act as scaffolds or surfaces that 
facilitate interaction between PrPC and PrPSc molecules and in this way accelerate the 
conversion process [Wong et al., 2001b]. Later it was hypothesized that polyanionic 
compounds were able to stimulate PrPres amplification in vitro by mimicking 
negatively charged surfaces of specific accessory proteins and that such proteins would 
facilitate prion propagation [Deleault et al., 2005]. Wang et al. succeeded in generating 
infectious synthetic prions from recombinant PrP by PMCA when lipids and mouse-
extracted RNA molecules were present as cofactors [Wang et al., 2010].  
Lipids are another type of cofactors that were shown to promote prion propagation in 
cell-free conversion assays [Baron and Caughey, 2003]. Lipids, particularly 
sphingomyelin, galactosylceramide and cholesterol, were detected in scrapie hamster 
prions purified from infected hamster brain [Klein et al., 1998; Riesner, 2003]. 
However, preparations with high infectivity titers contained fewer lipid molecules than 
low titer samples. That phospholipids may be crucial for replication of infectious mouse 
scrapie-associated PrPres by PMCA was indicated by several different recent reports 
[Deleault et al., 2012a; Deleault et al., 2012b; Wang et al., 2010].  
The precise mechanism by which cofactors influence prion formation, propagation and 
infectivity is still unclear. Cofactors could be involved in several steps of PrP 
conversion. As cofactor binding to PrPC can alter its conformation in terms of an 
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increased β-sheet content [
that PrPC may be rendered susceptible to conversion upon cofactor binding. 
mentioned above, cofactors may also facilitate PrP conversion by concentrating both 
PrPSc and PrPC in close proximity 
molecules. Furthermore, cofactors could stabilize infectious PrP conformations by 
forming a complex with PrP
Possible roles by which cofactors might participate in prion replication are depicted in 
Figure 1-5. 
 
 
Figure 1-5:  Possible roles by which cofactors might participate in prion replication 
Cofactors could become incorporated into the infectious agent, and could thus determine 
the folding characteristics of prions. (b) 
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1.5.2 Metal ions as cofactors for prion conversion 
In the search for modulators and causes of prion diseases metal ions increasingly 
became a target in research. The prion protein is known to bind divalent metal ions such 
as copper, zinc and manganese and thus may function as a metal binding protein or 
metal transporter. Metals are bound preferentially to the octapeptide repeat sequence 
(PHGGSWGQ) towards the N-terminus of PrP. Binding affinities increase from 
manganese to zinc to copper [Jackson et al., 2001]. Diseased individuals were found to 
have an altered brain metal content with differences in iron, lower copper and higher 
manganese levels [Wong et al., 2001a]. An increase of total iron level and a change in 
the Fe2+/Fe3+ ratio in favor of Fe3+ was observed in scrapie infected mice [Kim et al., 
2000]. Higher levels of Mn2+ were observed in whole brain, mitochondria and scrapie 
associated fibril (SAF) enriched fractions of diseased animals [Kim et al., 2005]. It was 
suggested that Mn2+ may participate in the PrP conversion mechanism in vivo and in the 
pathogenesis of prion diseases. It was shown that PrPC normally binds Cu2+ ions in vivo, 
whereas PrPSc becomes depleted of Cu2+ and enriched in Mn2+ and to a lesser extent of 
Zn2+ [Brown et al., 1997; Thackray et al., 2002; Wong et al., 2001a]. A loss of function 
due to aggregation of PrPC possibly disturbs cellular iron and copper homeostasis and 
may be neurotoxic [Hodak et al., 2009].  
Metal ions are usually strictly regulated and bound to proteins. However, as described in 
the literature about 300 µM zinc [Assaf and Chung, 1984; Frederickson and Bush, 
2001; Howell et al., 1984] are transiently present as free ions in the synaptic cleft in the 
brain, and low concentrations of free copper are also found in the extracellular space 
[Rana et al., 2009; Schlief et al., 2005]. Metal concentrations in the brain are in a range 
of 70 µM Cu2+, 350 µM Zn2+ and 340 µM Fe2+ [Bush and Tanzi, 2008; Rana et al., 
2009]. It was however reported that Cu2+ concentrations of 15 µM are released within 
the synaptic cleft during synaptic vesicle release and higher concentrations between 100 
and 300 µM are achieved during neuronal depolarization [Vassallo and Herms, 2003]. 
As PrPC is known to be partly localized near neuronal synapses and was suggested to be 
involved in the regulation of Zn2+ and Cu2+ homeostasis a disruption of this function 
may lead to neuronal damage [Choi et al., 2006; Rana et al., 2009].  
Many studies focused on the effects of metal ions on the induction of PK resistance, PrP 
refolding, β-sheet- and fibril formation. The results are often contradictory, which 
implies a complex role of metal ions in the pathogenesis of prion disease, and so far it 
could not be determined whether the observed metal imbalances in prion diseased 
brains are a cause or a result of PrP conversion and aggregation (reviewed by [Choi et 
al., 2006; Rana et al., 2009; Singh et al., 2010]). Earlier studies reported that the 
application of copper chelators resulted in a spongiform-like degeneration in the brain 
of laboratory animals [Blakemore, 1972; Pattison and Jebbett, 1971], and later it was 
found that oral administration of copper prolonged scrapie incubation times in hamsters 
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[Hijazi et al., 2003]. In contrast to that, others reported a delay in the onset of the 
disease when chelating copper [Sigurdsson et al., 2003]. Using in vitro PMCA studies, 
Kim et al. showed that conversion of PrPC from normal hamster brain homogenate into 
PrPres could be induced by Mn2+, Cu2+ and Fe2+ [Kim et al., 2005]. Further results have 
also shown that manganese could induce a strong pro-aggregatory effect on PrP [Giese 
et al., 2004]. Moreover, besides copper also zinc was reported to enhance the 
aggregation of a PrP derived peptide [Jobling et al., 2001]. However, an inhibition of 
PrPres amplification and PrP conversion into amyloid fibrils by copper and zinc was 
shown as well [Bocharova et al., 2005; Orem et al., 2006]. Another very recent 
publication reported that an internalization, accumulation and conversion of exogenous 
recombinant PrP into PK resistant PrPres was induced in cells by Fe3+ but not Fe2+ 
[Choi et al., 2013]. 
 
1.6 Prion strains 
Prions exist as multiple strains in a single mammalian species with identical amino acid 
sequences of PrP. Strains are associated with distinct characteristics, or phenotypes, by 
which they can be distinguished. For example, two prion strains (named Hyper and 
Drowsy) from mink have been isolated and serially passaged in outbred Golden Syrian 
hamsters. They produced a clinical disease with distinct phenotypes. While animals 
infected with Hyper showed hyperexcitability, hamsters infected with Drowsy exhibited 
progressive lethargy. Prion strains can vary in incubation times, clinical manifestations, 
neuropathological characteristics e.g. patterns of PrPSc deposition and vacuolation 
profiles in the brain. They can also differ in terms of their biochemical characteristics 
such as electrophoretic mobility and glycosylation of PrPSc, or its resistance to 
detergents and proteases (Figure 1-6). Strain properties are usually maintained upon 
serial passage in the same host species. Conventional pathogens encipher strain 
information in the nucleic acid genome. In the context of the prion hypothesis it was 
proposed that strain diversity can be enciphered in different protein conformations or 
aggregation states that can faithfully replicate at the expense of host PrPC [Bessen and 
Marsh, 1992; Collinge, 2010; Safar et al., 1998; Telling et al., 1996]. However the 
molecular principles of the strain phenomenon have not yet been completely elucidated. 
It has been also proposed that PrPSc molecules might bind to other specific host 
molecules to generate strain diversity. Such molecules could be polyanions or lipids 
[Geoghegan et al., 2007]. Furthermore, it is not clear whether posttranslational PrP 
modifications (such as glycosylation) are a determinant of strain properties [Cancellotti 
et al., 2010; Piro et al., 2009; Tuzi et al., 2008].  
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Figure 1-6:  Biochemical differences of PrP 27-30 from Syrian hamsters that were infected with 263K 
scrapie, BSE-H, ME7-H scrapie or 22A-H scrapie. BSE-H shows a different 
electrophoretic mobility of the unglycosylated band (arrow) due to different molecular 
masses of approx. 20 kDa for 263K, ME7-H and 22A-H and 19 kDa for BSE-H. 
Furthermore, ME7-H shows in this blot a different glycosylation profile from 263K. While 
the diglycosylated band is predominant in 263K, the monoglycosylated band is 
predominant in ME7-H. 
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1.7 Objectives 
 
The mechanism of prion propagation and the involvement of other molecules than PrP 
in the replication process are still poorly understood.  
In this research project the recently introduced method of PMCA which allows an in 
vitro replication of prions should be used to study the role of putative cofactor 
molecules (e.g. nucleic acids) and the mechanisms involved in the propagation of 
misfolded and aggregated prion proteins. In order to provide a better understanding of 
the molecular basis of the “prion strain phenomenon”, i.e. the existence of distinct prion 
strains that differ in their phenotypic characteristics although they are derived from the 
same cellular prion protein, the role of cofactor molecules in the propagation of four 
different hamster adapted prion agents were to be examined.  
To assess the impact of cofactor molecules on in vitro generated PrPres, the biological, 
biochemical and biophysical properties of PMCA derived PrPres should be investigated 
and compared to the native prion seeds. As a measure for the biological infectivity, the 
biological seeding activity of native prion seeds and their progeny PrPres should be 
monitored in vitro by testing the ability to infect glial cell cultures. In order to define the 
impact of putative cofactors on the molecular conversion of PrP in more detail, changes 
in the spatial structure associated with different cofactor molecule conditions during 
amplification of PrPres in PMCA should be monitored by Fourier transform-infrared 
(FT-IR) spectroscopic analysis.  
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2. Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals and reagents  
Table 2-1: Chemicals and reagents. 
Reagent Manufacturer 
2-Mercaptoethanol Sigma-Aldrich (Steinheim, D)  
Acetic acid Sigma-Aldrich (Steinheim, D) 
Acrylamide/Bisacrylamide (Rotiphorese® Gel 40) Roth (Karlsruhe, D) 
Ammonium hydroxide (NH4OH) Merck (Darmstadt, D) 
APS (Ammonium persulfate) Roth (Karlsruhe, D) 
Bromphenol blue Sigma-Aldrich (Steinheim, D) 
C16 Galactosyl(ß) Ceramide (d18:1/16:0) Avanti Polar Lipids, Inc. (Alabaster, USA) 
Chondroitin sulfate A Sigma-Aldrich (Steinheim, D) 
Citric acid Sigma-Aldrich (Steinheim, D) 
Copper(II) chloride (CuCl2) Sigma-Aldrich (Steinheim, D) 
D-Glucose Sigma-Aldrich (Steinheim, D)  
EDTA (Ethylenediaminetetraacetic acid) Sigma-Aldrich (Steinheim, D)  
Ethanol Roth (Karlsruhe, D) 
Formaldehyde (37 %) Roth (Karlsruhe, D) 
Formic acid Roth (Karlsruhe, D) 
Glutaraldehyde (25 %)  Merck (Darmstadt, D)  
Glycerol Serva (Heidelberg, D) 
Guanidinium thiocyanate Merck (Darmstadt, D) 
Iron(II) chloride (FeCl2) Sigma-Aldrich (Steinheim, D) 
Iron(III) chloride (FeCl3) Merck (Darmstadt, D) 
Magnesium chloride Roth (Karlsruhe, D) 
Manganese(II) chloride (MnCl2) Sigma-Aldrich (Steinheim, D) 
Methanol Roth (Karlsruhe, D) 
Monosodium phosphate (NaH2PO4) Sigma-Aldrich (Steinheim, D) 
N-Lauroylsarcosine Na-salt (Sarkosyl) Serva (Heidelberg, D)  
PMSF (Phenylmethylsulfonyl fluoride) Sigma-Aldrich (Steinheim, D) 
Poly(A) RNA Sigma-Aldrich (Steinheim, D) 
Poly-L-glutamate Sigma-Aldrich (Steinheim, D) 
Potassium chloride (KCl) Merck (Darmstadt, D) 
SDS (Sodium dodecyl sulfate) Serva (Heidelberg, D) 
Silver nitrate (AgNO3) Merck (Darmstadt, D) 
Skimmed milk powder Sucofin 
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Sodium bicarbonate (NaHCO3)  Merck (Darmstadt, D) 
Sodium chloride (NaCl)  Roth (Karlsruhe, D) 
Sodium hydroxide (NaOH) Merck (Darmstadt, D) 
Sphingomyelin Sigma-Aldrich (Steinheim, D) 
Sucrose Sigma-Aldrich (Steinheim, D) 
TEMED (N,N,N,N,-Tetramethylendiamin)  Roth (Karlsruhe, D)  
Tris base (Trizma® base)  Sigma-Aldrich (Steinheim, D)  
Triton X-100 Sigma-Aldrich (Steinheim, D) 
Tween-20 Serva (Heidelberg, D) 
Zinc chloride (ZnCl2) Sigma-Aldrich (Steinheim, D) 
Zwitterionic detergent 3-14 (Z3.14) Sigma-Aldrich (Steinheim, D) 
 
 
2.1.2 Buffers and solutions 
Table 2-2: Buffers and solutions. 
General buffers and solutions  
PBS (phosphate buffered saline) 8 mM Na2HPO4 
1.5 mM KH2PO4 
137 mM NaCl 
2.7 mM KCl 
pH 7.4 with HCl  
SDS/NaOH for general disinfection 0.3 % (w/v) NaOH 
0.2 % (w/v) SDS 
pH ≈ 13 
TBS 50 mM Tris 
150 mM NaCl 
pH 7.5 with HCl  
PMCA  
Conversion buffer 4 mM EDTA 
1 % (v/v) Triton X-100 
1 Protease Inhibitor Cocktail Complete Mini 
(Roche) in 10 ml buffer 
PBS 
pH 7.4 with HCl  
Protein purification for FT-IR  
Homogenization buffer 10 % Sarkosyl 
8 mM NaH2PO4 
in 0.2 mM Tris/HCl pH 7.5 
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SDS-PAGE  
Electrophoresis running buffer 25 mM Tris 
% (w/v) SDS 
192 mM Glycine 
pH 8.3 – 8.7 
Sample loading buffer  125 mM Tris 
4 % (w/v) SDS 
20 % (v/v) Glycine 
0.05 % (w/v) Bromphenol blue 
10 % (v/v) Mercaptoethanol 
pH 6.8 with HCl 
Separating gel (12.5 %) 4.3 ml ddH2O 
2.5 ml Separating gel buffer (pH 8.8) 
3.1 ml Acrylamid/Bisacrylamid 37.5:1  (40 %) 
50 µl SDS (20 %) 
30 µl APS (10 %) 
10 µl TEMED 
Separating gel (15 %) 3.65 ml ddH2O 
2.5 ml Separating gel buffer (pH 8.8) 
3.75 ml Acrylamide/Bisacrylamide 37.5:1  (40 %) 
50 µl SDS (20 %) 
30 µl APS (10 %) 
10 µl TEMED 
Separating gel buffer 1.5 M Tris 
pH 8.8 with HCl  
Stacking gel (5 %) 6.14 ml ddH2O 
2.5 ml Stacking gel buffer (pH 6.8) 
1.25 ml Acrylamide/Bisacrylamide 37.5:1  (40 %) 
50 µl SDS (20 %) 
50 µl APS (10 %) 
10 µl TEMED 
Stacking gel buffer 500 mM Tris 
pH 6.8 with HCl  
Western blotting and PrP detection  
Assay buffer 100 mM NaCl 
100 mM Tris 
pH 9.5 with HCl 
Blocking buffer 3 % (w/v) Skimmed milk powder 
0.05 % (w/v) Tween 20 
TBS 
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Blotting buffer 48 mM Tris 
38 mM Glycine 
0.037 % (w/v) SDS 
pH ~ 9,0 
20 % (v/v) Methanol (added prior to use) 
TBS-T 0.05 % (w/v) Tween 20  
TBS 
 
 
2.1.3 Cell culture equipment and media 
Table 2-3: Cell culture equipment and media. 
6-well plates (8.96 cm2/well) TPP (Trasadingen, CH) 
Cell culture flasks  (175 cm2) Nunc (Roskilde, DK)  
Cell scraper TPP (Trasadingen, CH) 
Cell strainer, pore size 40 µm  BD Falcon (Bedfort, USA)  
CO2-Incubator  
Hera Cell 150i  
 
Thermo Scientific (Langenselbold, D)  
Dimethyl sulfoxide (DMSO) Biochrom AG (Berlin, D) 
Dulbecco`s modified eagle medium  
(DMEM) without NaHCO3, with 4.5 g/l D-glucose 
Biochrom AG (Berlin, D) 
Fetal Bovine Serum (FBS-Superior)  Biochrom AG (Berlin, D)  
Freezing container (Nalgene Mr. Frosty) Thermo Scientific (Langenselbold, D) 
Freezing medium 70 % (v/v) DMEM 
20 % (v/v) FBS 
10 % (v/v) DMSO 
Glial cell isolation medium (GIM)  18.2 % (v/v) FBS 
0.5 % (v/v) D-glucose  
2.7 mM sodium bicarbonate 
1.8 mM glutamine  
90.1 U/ml / 90.1 µg/ml Penicillin/Streptomycin 
0.5 µg/ml Partricin  
DMEM 
Growth medium (GM)  10 % (v/v) FBS 
2 mM glutamine  
100 U/ml / 100 µg/ml Penicillin/Streptomycin 
0.5 µg/ml Partricin  
DMEM  
L-glutamine (200 mM) Biochrom AG (Berlin, D)  
Neubauer hemocytometer Paul Marienfeld (Lauda-Königshofen, D)  
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Partricin (50 µg/ml)  Biochrom AG (Berlin, D)  
PBS/glucose 0.6 % (v/v) D-glucose  
100 U/ml /100 µg/ml Penicillin/Streptomycin 
0.5 µg/ml Partricin  
PBS  
Penicillin/Streptomycin  
(10.000 U/ml /10.000 µg/ml)  
Biochrom AG (Berlin, D)  
Serological pipettes TPP (Trasadingen, CH)  
Trypan blue 0.5 %  Biochrom AG (Berlin, D)  
Trypsin/EDTA (0,05 %/0,02 %)  Biochrom AG (Berlin, D)  
 
 
2.1.4 Antibodies, enzymes and kits 
Table 2-4: Antibodies, enzymes and kits. 
Product Manufacturer 
Anti-PrP antibody 3F4 monoclonal (mouse) In-house cell culture [Kascsak et al., 1987]  
Benzonase Merck (Darmstadt, D) 
CDP-Star® Tropix Applied Biosystems (Foster City, USA)  
Goat Anti-Mouse IgG/AP  Dako (Hamburg, D)  
PNGase F  New England Biolabs (Beverly, USA)  
Proteinase K (Tritachium album) Roche (Mannheim, D)  
RNaseA Qiagen (Hilden, D) 
 
 
2.1.5 Consumables  
Table 2-5: Consumables. 
Product Manufacturer 
Blot membrane PVDF (Polyvinylidene fluoride), 
pore size 0.45 µm  
Millipore (Neu-Isenburg, D)  
Blotting filter paper  Schleicher Schuell (Kent, UK)  
Disposable 20 gauge needles Braun (Emmenbrücke, CH)  
Disposable syringes Omnifix®-F, 1 ml  Braun (Bad Arolsen, D)  
Glass beads, ø 0,75 – 1 mm  Roth (Karlsruhe, D)  
Paraffin Roti® Plast Roth (Karlsruhe, D)  
Precast gels Roti® PAGE 12 % Roth (Karlsruhe, D) 
Protease Inhibitor Cocktail Complete Mini Roche (Mannheim, D) 
Materials and Methods 
30 
Protease Inhibitor Cocktail Complete Mini, 
EDTA-free 
Roche (Mannheim, D) 
Reaction tubes  
1,5 ml  tubes 
Safe Lock 
Ultracentrifuge tubes 
 
Brand (Wertheim, D) 
Eppendorf (Hamburg, D)  
Beckman Coulter (Fullerton, USA) 
X-ray film Amersham Hyperfilm™ ECL  GE Healthcare Limited (Buckinghamshire, UK)  
 
 
2.1.6 Laboratory devices  
Table 2-6: Laboratory devices. 
Device Manufacturer 
Centrifuges 
Heraeus Biofuge pico  
Heraeus Labofuge 400  
Heraeus Sepatech Varifuge 3.0R 
Optima Max Ultracentrifuge  
 
Thermo Scientific (Langenselbold, D)  
Thermo Scientific (Langenselbold, D)  
Heraeus (Osterode, D)  
Beckman Coulter (Fullerton, USA)  
Electrophoresis Power Supply 
Phero-Stab 0312 
 
Biotec Fischer (Reiskirchen, D)  
Electrophoresis system  
Mini Protean 3 and Mini Protean Tetra Cell 
 
Bio-Rad (München, D)  
Fast Blot Biometra (Göttingen, D)  
FT-IR spectrometer Bruker Optics GmbH (Ettlingen, D) 
Gyro Rocker SSL3  Bibby Scientific (Staffordshire, UK)  
Inverted microscope Leica Microsystems (Wetzlar, D) 
pH meter 
pH 211 Microprocessor  
 
Hanna Instruments (Aachen, D)  
PMCA devices 
Sonicator 3000-MPD, 4000-MPX and Q500 with 
microplate horn 
 
Misonix (Farmingdale, USA) / Qsonica, LLC. 
(Newtown, USA) 
Potter Homogeniser  BBraun (Melsungen, D)  
Probe sonicator  
Sonopuls HD 2070  
 
Bandelin (Berlin, D)  
Scanner 
HP Scanjet G 4050 
 
Hewlett Packard (Palo Alto, CA, USA) 
Thermomixer Compact  Eppendorf (Hamburg, D)  
X-ray developer 
Curix 60  
 
Agfa (Düsseldorf, D)  
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2.1.7 Software 
Table 2-7: Software. 
Corel DRAW  Corel (Ottawa, Kanada)  
HP Scan  Hewlett Packard (Palo Alto, CA, USA)  
 
 
2.1.8 Animals 
All studies that involved animals or the use of material from animals were performed 
with strict observance of the legal regulations (e. g. the European Convention for the 
Protection of Vertebrate Animals used for Experimental and other Scientific Purposes 
and the German Animal Welfare Act) and where necessary on the basis of formally 
permitted animal experimentation. Euthanasia of normal animals was voluntarily 
reported to the local animal protection authority.  
Golden Syrian hamsters (Mesocricetus auratus) of both sexes were purchased from 
Charles River (Sulzfeld, Germany).  
 
2.1.9 Prion agents 
Hamster-adapted prion agents 263K scrapie, 22A-H scrapie, ME7-H scrapie and BSE-H 
were used for the experiments in this work. The TSE-infected brain tissue was obtained 
from terminally diseased Syrian hamsters that had been intracerebrally inoculated with 
hamster brain homogenates from clinically diseased donors [Thomzig et al., 2004]. 
Scrapie strain 263K showed a mean incubation time of 83 days in Syrian hamsters after 
intracerebral inoculation of 50 µl of 10 % brain homogenate from a terminally diseased 
donor animal. Hamster-adapted strains ME7-H and 22A-H originated from mice and 
were passaged in Syrian hamsters [Kimberlin et al., 1989] with a mean incubation time 
of 331 days and 206 days, respectively. BSE-H is a hamster-adapted BSE strain that had 
been isolated from a cow in Germany and was firstly transmitted to mice. Subsequently, 
the strain was passaged in Syrian hamsters with a mean incubation time of 287 days 
[Thomzig et al., 2004].  
These strains differ markedly in their incubation times. Whereas 263K scrapie and BSE-
H could be distinguished from ME7-H and 22A-H by neurological and behavioral 
symptoms, neuropathological lesion profiles, pattern of cerebral PrPSc distribution, 
electrophoretic mobilities and glycosylation pattern of PrPSc, 22A-H and ME7-H were 
indistinguishable by these methods. 
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2.2 Methods 
 
2.2.1 Preparation of normal hamster brains 
Brains from normal Syrian hamsters aged 12-15 weeks were used as donors for PrPC 
containing substrate for PMCA experiments. Adult hamsters were euthanized by 
exposure to CO2 and neonatal hamsters were sacrificed by decapitation. To remove 
blood from the tissue, adult animals were transcardially perfused with approx. 40 ml of 
5 mM EDTA/PBS (pH 7.4) after cardiac and breathing arrest. The brains were removed, 
cut into pieces with an exposable scalpel, immediately frozen in liquid nitrogen and 
stored at -70 °C until use.  
 
2.2.2 Preparation of 10 % (w/v) brain homogenate from normal hamster brains 
10 % (w/v) brain homogenate from normal hamsters (in the following referred to as 
NBH) in conversion buffer was used as PrPC substrate for PMCA. For cell culture 
experiments tissue homogenizations were performed in PBS or TBS. To minimize 
protein degradation processes in crude brain homogenate due to active enzymes all 
work was performed quickly on ice. Brains were homogenized in cooled conversion 
buffer containing protease inhibitors. To prevent contamination of the homogenate only 
sterile filtertips were used. Cylinder and plunger of the potter homogenizer were treated 
5 min with a solution of 0.2 % SDS/0.3 % NaOH for general disinfection prior to use. 
5 ml conversion buffer was added immediately to one hamster brain. Subsequently, 
brains were homogenized with the potter homogenizer. To get a 10 % (w/v) brain 
homogenate, conversion buffer was added to a final volume of 10 ml per one hamster 
brain (which weighs approx. 1 g). The homogenate was subjected to centrifugation at 
3000 rpm (Varifuge 3.OR Heraeus) and 4 °C for 5 min to remove cell debris. The 
clarified supernatant was pooled and stored in aliquots at -70 °C until use. 
 
2.2.3 Preparation of 10 % (w/v) brain homogenate from TSE-infected hamster 
brains  
Infected hamster tissue was processed in a biosafety cabinet only. Brain homogenate 
from TSE-infected tissue was used as source for PrPSc-seeds in PMCA and cell culture 
experiments. Brains were thawed quickly at room temperature and cut into small pieces 
using an exposable scalpel. 4 ml PBS were added and the material was homogenized by 
ultrasound using a probe sonicator. PBS was added to a final volume of 10 ml and 
aliquots were stored at -70 °C until use. The micro tip of the sonicator was treated with 
2 M NaOH and rinsed with aqua dest. prior and after each use. 
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One brain (about 1 g) of a diseased Syrian hamster in the clinical stage of disease 
contains about 100 µg PrPSc [Beekes et al., 1996]. Brain homogenates from 263K, 
ME7-H, 22A-H and BSE-H were digested with proteinase K (PK) and serial dilutions 
were subjected to SDS-PAGE and Western blotting. This revealed that all brain 
homogenates contained similar concentrations of PrPres. 
 
2.2.4 Protein Misfolding Cyclic Amplification (PMCA) 
The basic principle of the PMCA technology has been published previously [Bieschke 
et al., 2004; Castilla et al., 2006; Murayama et al., 2006; Saborio et al., 2001; Weber et 
al., 2006]. Within the scope of this dissertation exclusively serial automated PMCAs 
(saPMCA) with a serial transmission of PMCA product into fresh brain homogenate 
from normal hamsters according to Bieschke et al. (2004) were performed. 10 % (w/v) 
NBH from Syrian hamsters was used as PrPC containing substrate for PMCA 
experiments. A basic protocol that was recently published [Pritzkow et al., 2011] was 
utilized for the propagation of 263K by PMCA. PMCA protocols for other prion strains 
22A-H scrapie, ME7-H scrapie and BSE-H had to be adapted individually. 
 
2.2.4.1 Basic protocol for 263K scrapie 
To prevent cross contamination of samples during PMCA only sterile filtertips were 
used. PMCA experiments were performed in 0.5 ml Safe Lock Eppendorf tubes that are 
particularly leakproof and that had been subjected to steam sterilization at 121 °C and 
3 bar for 20 min prior to use. Approximately 30 µl of glass beads (equivalent to 10 mg) 
were filled into each reaction tube. Glass beads had been washed five times with 
distilled water and subsequently had been also subjected to steam sterilization at 121 °C 
and 3 bar for 20 min prior to use. 140 µl of NBH were filled into each reaction tube. An 
aliquot of 10 % (w/v) 263K brain homogenate was quickly thawed and sonicated for 
40 sec at about 200 W using the waterbath of the PMCA ultrasound device. 10 % (w/v) 
263K brain homogenate was serially diluted in NBH to obtain the final dilutions which 
were used for PMCA seeding. 10 µl of the diluted 263K brain homogenate were added 
to the reaction tubes. The specific dilution of 263K brain homogenate that was used to 
seed each individual PMCA reaction is indicated for each experiment. 
The caps of all reaction tubes were sealed with parafilm tape and liquefied paraffin wax. 
Thereafter, reaction tubes were disinfected in 0.2 % SDS/0.3 % NaOH for 5 min. 
Samples were transferred to a tube holder designed to fit in the reservoir of the 
microplate horn of the sonicator device. To prevent cross contamination during 
automated processing within the sonication apparatus samples were placed in a 4 M 
guanidinium thiocyanate filled reservoir. After an initial sonication step at approx. 
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200 W for 40 sec, samples were incubated at 37 °C for one hour followed by a next 
cycle of sonication and incubation. Unless stated otherwise one round of PMCA 
consisted of approx. 24 alternating cycles of sonication and incubation of samples at 
37 °C. Upon completion of one PMCA round (approx. 24 h) samples were disinfected 
again in 0.2 % SDS/0.3 % NaOH for 5 min and spun down gently (Heraeus Labofuge 
400). Subsequently, reaction mixtures were collected without the need to open the 
reaction tube. Disposable 20 gauge needles were used to puncture the cap of reaction tubes. 
For each reaction tube a new needle and syringe was used. Gloves were changed always 
before handling a new sample. For a next round of PMCA, aliquots of 30 µl harvested 
reaction mixtures were diluted with 120 µl fresh NBH (1:5 dilution) in a new reaction 
tube. Samples were subjected to PMCA as described above. Additionally 30 µl of the 
harvested reaction mixtures were collected for limited proteolysis with PK and subsequent 
analysis by Western blotting (chapter 2.2.5 and 2.2.7 ff.). 
 
2.2.4.2 Adapted protocol for other prion strains 
Amplification efficiency of all prion strains was found to be increased in the presence of 
20 mM EDTA in NBH, instead of 5 mM. Therefore, also 263K was propagated in the 
presence of elevated EDTA concentrations, unless stated otherwise. Furthermore, a 
cyclic incubation time of 2 h instead of 1 h was beneficial for amplification of ME7-H 
and BSE-H. Due to this prolonged incubation time one round of PMCA (approx. 24 h) 
was reduced to 12 alternating cycles. Amplification of the 22A-H prion agent was 
performed with an incubation time of 4 h and 12 cycles, hence one PMCA round lasted 
approx. 48 h. 
 
2.2.4.3 Substrate preparations for PMCA with putative cofactor molecules of PrP 
conversion 
Nucleic acids in NBH used as substrate for PMCA assays were removed by enzymatic 
digestion with benzonase. Aliquots of the prion seeding material were also treated with 
benzonase for two hours prior to performing PMCA. Benzonase degrades all kinds of 
nucleic acids (single-stranded, double-stranded, linear, circular or supercoiled DNA and 
RNA). NBH was prepared in conversion buffer without EDTA. NBH was incubated for 
approx. 20 h with 2 mM MgCl2 and 2.5 U/µl benzonase at 37 °C and 450-500 rpm 
(Thermomixer comfort, Eppendorf). Addition of 20 mM EDTA to the substrate 
inhibited benzonase enzyme activity. Substrate was stored in aliquots at -70 °C until 
use. 
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2.2.5 Limited proteolysis with proteinase K (PK) 
For the analysis of PrPSc /PrPres by Western blotting treatment of samples with PK is 
used as a standard tool to distinguish PrPC and misfolded, aggregated forms of PrP. The 
cellular form of the prion protein is readily degraded by PK whereas aggregated and 
misfolded forms of the protein (PrPSc) maintain a PK-resistant core (at least for longer 
periods of time) under the same conditions. Under limited proteolysis PrPSc as well as 
prion progeny seeds amplified by PMCA are processed to N-terminally truncated 
protease resistant core fragments (referred to as PrP27-30 or PrPres, respectively). 
PrP27-30 /PrPres can be detected in Western blot using anti-PrP antibodies. It is visible 
as a typical three band pattern (diglycosylated band: 27-30 kDa, monoglycosylated 
band: 24-26 kDa, unglycosylated band: 19-21 kDa). Samples were digested at a final 
concentration of 150 µg/ml PK, 1 % (v/v) sarkosyl and 0.06 % (w/v) SDS and 
incubated for 1 h at 55 °C and 450-500 rpm (Thermomixer comfort, Eppendorf). 
Subsequently, samples were centrifuged at 13000 rpm (Heraeus Biofuge pico) and 
ambient temperature for 1 min. 30 µl aliquots of the supernatant were mixed with an 
equal volume of sample loading buffer (Table 2-2) and incubated for 10 min at 100 °C. 
The protease inhibitor PMSF was added to a final concentration of 2.5 mM. Samples 
were stored at -20 °C until further processing. Aliquots of 10 µl were subjected to SDS-
PAGE and Western blotting. 
 
2.2.6 Deglycosylation with PNGase F 
The endoglycosidase PNGase F (Kit Biolabs) cleaves the Asn-linked oligosaccharide 
chains from the prion protein. Subsequently, the protein shows a single band upon 
detection with an anti-PrP antibody in Western blots. The unglycosylated band has a 
molecular mass in the range of 19-21 kDa. Samples were digested with PK for 1 h as 
described above (chapter 2.2.5). Subsequently, 2.2 µl 10 x denaturing buffer was added 
to 20 µl sample material and incubated at 100 °C and 450 rpm for 10 min 
(Thermomixer comfort, Eppendorf). Thereafter, 3 µl 10 x G7-buffer, 3 µl NP-40 and 
3 µl PNGase F were added and incubated at 37 °C for 2 h while shaking. Samples were 
mixed with an equal volume of sample loading buffer and boiled for 10 min under 
shaking. The protease inhibitor PMSF was added to a final concentration of 2.5 mM. 
Samples were stored at -20 °C until further processing. Aliquots of 10 µl were subjected 
to SDS-PAGE and Western blotting. 
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2.2.7 SDS-PAGE 
Proteins were separated according to their electrophoretic mobility by discontinuous, 
reducing SDS-polyacrylamide gel electrophoresis [Laemmli, 1970]. The anionic 
detergent SDS attaches to the polypeptide chain and supports its linearization and also 
confers a negative charge to the protein. Generally the binding of SDS to proteins is in 
proportion to their mass and thus they become separated by their approximate size 
during electrophoresis. The electrophoresis systems Mini Protean® 3 and Mini Protean® 
Tetra Cell (Bio-Rad) were used. In general 10 µl samples were loaded on the SDS-
polyacrylamide gel. The composition of stacking gel (5 %) and separating gel (12.5 %) 
is listed in Table 2-2. A Tris-glycine buffer was used as running buffer for 
electrophoresis (Table 2-2). In addition to handcast gels precast gels “Roti® PAGE 
12 %” (Roth) were used. When separating PNGase F treated samples a 15 % separating 
gel was loaded. Electrophoresis was performed at 15 mA for 15-20 min and 20 mA for 
approx. 30-45 min.  
 
2.2.8 Western blotting and immunodetection 
The separated proteins were transferred onto a polyvinylidene fluoride (PVDF) 
membrane using a semi-dry electroblotting procedure [Seidel et al., 2007; Thomzig et 
al., 2003]. PVDF membranes were soaked in methanol for a few seconds and kept in 
blotting buffer afterwards. Two blotting filter paper were soaked in blotting buffer and 
placed onto the graphite surface (anode) of the blotting device, followed by the PVDF 
membrane. The SDS-polyacrylamide gel was removed from between the glass plates. 
The separating gel was washed in blotting buffer and placed onto the PVDF membrane 
followed by two more filter papers. Air bubbles were removed by moving a roller 
carefully over the stack. The cathode surface of the blotting device was placed on top 
closing the device. Proteins were transferred from the gel onto the PVDF membrane by 
a current of 180 mA for 25 min. 
Detection of PrP was performed as described by Thomzig et al. (2003) and Seidel et al. 
(2007). The blocking of non-specific binding sites on the blot membrane was achieved 
by incubation in blocking buffer that contained 3 % skimmed milk powder for 1 h under 
continuous rocking. The monoclonal anti-PrP antibody 3F4 (in-house cell culture, 
[Kascsak et al., 1987]) was diluted 1:2000 in blocking buffer and incubated with the 
blot membrane overnight. The 3F4 antibody recognizes amino acids 109-112 (Met-Lys-
His-Met) of the human and hamster prion protein [Bolton et al., 1991; Lowenstein et 
al., 1990; Rogers et al., 1991]. The blot membrane was washed three times in TBS-T 
and three times in blocking buffer for 5 min. The blot membrane was incubated for 
1.5 h with the secondary goat anti-mouse antibody that was diluted 1:5000 in blocking 
buffer. The secondary antibody was conjugated to the reporter enzyme alkaline 
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phosphatase. After three washing steps in TBS-T, the blot membrane was incubated in 
blocking buffer for 1 h. For about 30 min the blot membrane was incubated in assay 
buffer that resulted in a more alkaline pH that is required for the alkaline phosphatase to 
be active. The blot membrane was dried with a filter paper and incubated 5 min in CDP-
Star diluted 1:100 in assay buffer. Subsequently the blot membrane was dried with a 
filter paper and transferred to a film cassette. The enzyme catalyzes the 
dephosphorylation of the CDP-Star which results in light emission. Light emission was 
recorded on X-ray films that were placed directly above the blot membrane after 15 min 
and were allowed to rest for a few minutes up to 1 h. Developing of X-ray films was 
carried out fully automated (Curix 60, AGFA). Subsequently films were digitalized.  
 
2.2.9  Silver staining 
Silver staining of gels was performed according to Oakley’s procedure [Oakley et al., 
1980]. Gels were placed in a glass plate and incubated for 30 min in 50 % methanol and 
7.5 % acetic acid, 30 min in 5 % methanol and 7.5 % acetic acid. After a 30-minute 
incubation in freshly prepared 5 % glutaraldehyde, gels were rinsed once in ddH2O and 
incubated in ddH2O overnight at 4 °C. The next day gels were incubated for 15 min in a 
freshly prepared solution of silver nitrate (0.4 g AgNO3 was dissolved in 2 ml ddH2O 
and added dropwise under stirring to a solution of 10.5 ml 0.36 % NaOH, 0.7 ml 25 % 
NH4OH and 36.7 ml ddH2O). Subsequent procedures were carried out each in a new 
glass plate. The gels were washed twice for 2 min in ddH2O and developed for 1-5 min 
in a fresh solution of 100 µl 5 % citric acid and 100 µl 37 % formaldehyde in 100 ml 
ddH2O. The reaction was stopped by incubation in 5 % acetic acid for 10 min. 
Subsequently gels were rinsed twice for 2 min in ddH2O. Gels were shrinkwraped in a 
clear plastic film and immediately digitalized.   
 
2.2.10 Cell culture techniques 
 
2.2.10.1 Preparation of hamster glial cell cultures  
Isolation and culture of glial cells is based on a procedure from Lima and colleagues 
[Lima et al., 2007] and was carried out with modifications as described by Pritzkow  
et al. (2011) and Boerner et al. (2013). All equipment was sterile and aseptic techniques 
were used where possible. For the preparation of glial cell cultures, normal neonatal 
Syrian hamsters were used as donors of brain tissue. Animals were sacrificed 2-3 days 
after birth by decapitation. Brains were removed and kept in PBS/glucose on ice until 
further processing. The cerebellum and the meninges were removed using a disposable 
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scalpel and a stereo microscope, and the remaining brain tissue was cut into pieces and 
kept in PBS/glucose afterwards. The tissue was centrifuged for 3 min at 1000 rpm 
(Varifuge 3.0 R Heraeus) and ambient temperature. Brain tissue was washed twice with 
9 ml of glial cell isolation medium (GIM) and was subsequently resuspended in 5 ml 
fresh GIM. Using serological pipettes (5 ml and 2 ml pipettes) the tissue pellet was 
sheared carefully to separate cells until a homogeneous single cell suspension was 
obtained. The solution was drained trough a cell strainer (pore size 40 µm) to remove 
cell debris and was subjected to centrifugation. The pellet was resuspended in 10 ml 
growth medium (GM) and density of cells was determined by vital staining with trypan 
blue. Cell count was determined using a Neubauer hemocytometer. 3x106 cells per one 
plastic cell culture flask (175 cm2, NUNC) were grown in 20 ml GM. All culture 
incubations were performed in a humidified 37 °C, 5 % CO2 atmosphere incubator. 
Cells were allowed to adhere to the bottom of the culture flask over night. The next day, 
cells were washed with 10 ml PBS to remove unattached cells. Incubation was 
continued for further seven days in fresh GM. Subsequently, cells were washed again 
with PBS and enzymatically detached from the bottom of the culture flask. Cells were 
incubated with 2.5 ml trypsin for approx. 5 min until they were floating. 20 ml GM was 
added and the cell suspension was subjected to a subsequent centrifugation to clear from 
trypsin. The cell pellet was resuspended in 10 ml GM and homogenized to obtain a 
single cell suspension using serological pipettes and a cell strainer. For 
cryopreservation, 3x106 cells were diluted in 1 ml freezing medium per cryovial. Vials 
were cooled down over night to -70 °C using a freezing container with a cooling rate of 
-1 °C/min. The next day, cryovials were transferred to liquid nitrogen for long-term 
storage. 
 
2.2.10.2 Plate cultivation 
Cryovials were thawed quickly in order to avoid toxic effects of DMSO on cells and 
were diluted with 9 ml GM and subjected to centrifugation for 3 min at 1000 rpm 
(Varifuge 3.0 R Heraeus) and ambient temperature. Cells were resuspended in GM, 
separated and the number of vital cells was determined by staining with trypan blue 
using a hemocytometer as described above. For cell infection assays, cells were 
cultivated in 6-well plates at a density of 1.5x104 cells per well and 3 ml GM for 2-
3 days prior to infection. 
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2.2.10.3 Infection of glial cell cultures 
Cell cultures were exposed to the indicated amounts of infectious or control hamster 
brain tissues or PMCA products. Cultures for negative controls were exposed to normal 
hamster brain tissue. Cells were inoculated with hamster brain tissue that was 
homogenized in PBS. PMCA products contained Triton X-100 and thus were toxic to 
cells. They were subjected to ultracentrifugation at 45000 rpm (Optima Max 
Ultracentrifuge, Beckmann Coulter) and 4 °C for 2.5 h. The pellet was resuspended in 
100 µl PBS in a ultrasound waterbath. Cells were inoculated with 10 µl suspension per 
culture well that was added to the culture medium. After three days post initial exposure 
(DPE), the inoculum was removed and the cells were washed once with PBS. 
Subsequently, cells were cultured further and harvested at the indicated time points. 
During cultivation the medium was renewed once a week. Cells were examined 
regularly for vitality and microbial contaminants with an inverted microscope.  
Metal ion solutions for cell culture applications were prepared with sterilized ddH2O. 
When cells were cultured in the presence of metal ion solutions this was done at final 
concentrations of metal ions of 20 µM or 50 µM.  
 
2.2.10.4 Harvesting 
Cell cultures were harvested at the indicated DPE as previously described [Boerner et 
al., 2013]. Cells were washed with PBS and detached with a cell scraper and collected 
in 1 ml PBS. Cells were pelleted by quick spin. The supernatant was discarded and the 
pellets were stored at -70 °C until further processing. 
 
2.2.10.5 Limited proteolysis with PK 
Pellets from cells were resuspended in 50 µl PBS and were subjected to enzymatic 
digestion with proteinase K. However, in the course of infection experiments it was 
found that the processing of cell products by PK can be optimized by resuspending 
pellets in NBH instead of PBS. In this way, the sensitivity of the detection of PrPres 
from cell cultures infected with BSE-H associated PrPres could be increased. Pellets 
were resuspended using a vortex mixer and additionally by two sonication steps at 
approx. 250 W for 40 sec in an ultrasound waterbath. Caps of reaction tubes were sealed 
tight with parafilm tape to prevent contamination of samples with water from the 
waterbath. 15 µl of the cell suspension were mixed with 3 µl PK and 1.5 µl sarkosyl for 
a final concentration of 150 µg/ml PK and 1 % (v/v) sarkosyl, respectively. Samples 
were incubated for 1 h at 37 °C and 450-500 rpm and were subsequently mixed with an 
equal volume of sample loading buffer (Table 2-2) and incubated for 10 min at 100 °C. 
1 µl PMSF was added to a final concentration of 2.5 mM. In this way samples could be 
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stored at -20 °C prior to further processing. Samples were subjected to SDS-PAGE 
(chapter 2.2.7) and Western blotting (chapter 2.2.8) as described above. 
 
2.2.10.6 Deglycosylation with PNGase F 
Cell pellets were subjected to limited proteolysis with PK and subsequently 
deglycosylated with PNGase F as described in chapter 2.2.6. 
 
2.2.11 Extraction of PrPres from PMCA products for Fourier transform-infrared 
(FT-IR) micro-spectroscopic analysis 
PrPres was purified from PMCA products and analyzed by FT-IR micro-spectroscopy 
according to a protocol by Daus et al. (2013). This protocol allowed the extraction of 
PrP from very small amounts of PrPres starting material (such as PMCA aliquots). By 
the novel approach, minute amounts (i.e. 25-75 ng per dried sample spot) of extracted 
PrPres are sufficient for analysis by FT-IR micro-spectroscopy. 
Approx. 1 ml of PMCA product was used for the extraction of PrPres for FT-IR 
measurements. This amount of PMCA product was obtained from the reaction mixtures 
of ten single PMCA samples after six PMCA rounds. These ten PMCA samples had 
been produced in one PMCA experiment under equal conditions for each sample and 
samples were pooled after each round of PMCA to ensure homogeneity between the 
samples. The pooled PMCA product was centrifuged for 1 min at 5000 rpm and 
ambient temperature. The supernatant was repeatedly centrifuged two times. 
Supernatant was mixed with homogenization buffer (Table 2-2) to a final volume of 
10 ml and was allowed to incubate for 30 min and ambient temperature. The suspension 
was subjected to ultracentrifugation at 16000 rpm (rotor TLA-55) at 20 °C for 8 min. 
The clarified supernatant was mixed with 0.8 ml 0.1 M EDTA (pH 7.6) and was 
transferred to centrifuge tubes that were underlaid with 40 µl 20 % (w/v) sucrose and 
subjected to centrifugation at 55000 rpm at 20 °C for 52 min. Supernatant was 
discarded. With the pipette tip, clear yellowish pellets were resuspended carefully (by 
gentle stirring and up and down pipetting) in 30 µl 0.1 % (w/v) Z3.14/20 mM 
Tris/HCl (pH 7.5) and were transferred to a 15 ml falcon tube. In a volume of 2 ml 
pellets were resuspended by applying ultrasound from a probe sonicator repeatedly for 
about 5 sec to obtain a homogenous suspension. Afterwards, the volume was adjusted to 
10 ml with 0.1 % (w/v) Z3.14/20 mM Tris/HCl (pH 7.5). The suspension was 
transferred to centrifuge tubes that were underlaid with 60 µl 20 % (w/v) sucrose and 
subjected to centrifugation at 55000 rpm at 20 °C for 35 min. Subsequently, pellets 
were collected in 30 µl 0.2 mM Tris/HCl (pH 7.5) and were resuspended until being 
homogenous in a volume of 2 ml in a falcon tube by the application of ultrasound. 
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Afterwards, the volume was adjusted to 6 ml with 0.2 mM Tris/HCl (pH 7.5) and the 
suspension was transferred to centrifuge tubes that were underlaid with 60 µl 20 % 
(w/v) sucrose and subjected to centrifugation at 55000 rpm at 20 °C for 35 min. Pellets 
were resuspended in 100 µl 0.2 mM Tris/HCl (pH 7.5) and 200 µl 20 mM 
Tris/HCl (pH 7.5). Using ultrasonic treatment, the suspension was homogenized. 0.6 µl 
0.5M MgCl2, 0.5µl RNaseA and 0.5µl benzonase were added and allowed to incubate 
under agitation (500 rpm thermomixer) and ambient temperature over night. The next 
day, 2 µl PK was added (final concentration of 2 µg PK) and incubated for 1 h at 
ambient temperature. 80 µl 0.1 M EDTA (pH7.6) was added and incubated further for 
15 min. Afterwards, the suspension was transferred to two centrifuge tubes, 100 µl 
0.2 mM Tris/HCl (pH 7.5) was added to a final volume of 1 ml and tubes were 
underlaid with 40 µl 20 % (w/v) sucrose. Tubes were centrifuged for 66 min at 
55000 rpm and 4 °C. Subsequently, pellets were resuspended in 200 µl 0.2 mM 
Tris/HCl (pH 7.5) and were treated repeatedly with ultrasound to obtain a homogenous 
solution. The suspension was divided in 50 µl aliquots, 0.2 mM Tris/HCl (pH 7.5) was 
added to a final volume of 1 ml and the tubes were centrifuged at 55000 rpm and 4 °C 
for 2 h. Pellets were washed three times with 1 ml ddH2O for 2 h at 55000 rpm and 
4 °C. Subsequently one pellet of each purified PMCA product was analyzed by Western 
blotting and silver staining. Remaining pellets were stored at -20 °C. As determined by 
Western blot detection with the anti-PrP antibody 3F4, some extracts still contained 
full-length PrP, i.e. not proteolytically processed PrP. In order to improve digestion with 
PK in these samples, all remaining extracted pellets of the same PMCA product were 
pooled and were again subjected to the purification protocol starting with the PK 
digestion step. This is a modification of the protocol by Daus et al. which was necessary 
because only extracts in which PrPC was completely degraded could be subjected to  
FT-IR spectroscopic analysis. Samples that were repeatedly digested with PK are 
indicated in the results. For SDS-PAGE pellets were resuspended in 12.5 µl sample 
loading buffer (Table 2-2) and boiled for 5 min. PMSF was added to a final 
concentration of 2.5 mM. For analysis by Western blot 5 µl of the sample were loaded 
on the SDS-polyacrylamide gel. For silver staining 10 µl of the sample were loaded on 
the gel and were processed as described above (chapter 2.2.7 ff.). 
 
2.2.12 FT-IR measurement of extracted PrPres 
Pellets were resuspended in approx. 5 µl ddH2O by applying ultrasound to reaction 
tubes in a waterbath (PMCA device). Tubes were treated three times with approx. 
340 W for 30 sec. Reaction tubes were sealed with parafilm tape to prevent them from 
opening. Thereafter, 1-2 µl were applied on a clean CaF2 microscope slide and left for 
drying over night. Infrared micro-spectroscopic measurements of dried protein samples 
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were carried out as described by Daus et al. (2013). The FT-IR spectrometer was 
equipped with a microscope. Background spectra were obtained before sample 
measurements at positions outside of the protein sample. For each sample spectrum 256 
scans were averaged. Approx. 5 single point absorbance spectra were acquired for each 
dried protein sample. Second derivative spectra were calculated using the instrument 
software. Spectra were recorded between 1000 and 4000 cm-1. However, the amide I 
region encompassing the region between 1600-1700 cm-1 gives information about 
secondary structure elements of proteins. The amide I band originates mainly from C=O 
stretching vibrations of amide groups of the protein backbone. The position of IR bands 
is influenced by a variety of factors, e.g. the strength of hydrogen bonds and the packing 
of β-strands [Beekes et al., 2007]. 
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3. Results 
 
3.1 Establishment of the PMCA assay for hamster adapted prion 
strains other than 263K scrapie 
In PMCA, prion associated seeding activity converts normal protease sensitive PrP into 
proteinase K resistant PrPres. This assay was already established in our laboratory for a 
sensitive and quantitative detection of 263K scrapie associated seeding activity 
[Pritzkow et al., 2011]. Within the scope of this dissertation the application of the 
PMCA assay had to be expanded to other hamster adapted prion strains, namely ME7-H 
scrapie, 22A-H scrapie and BSE-H. These strains differ markedly in their incubation 
times. Whereas 263K scrapie and BSE-H can be distinguished between each other and 
from ME7-H and 22A-H by clinical, neuropathological and immunobiochemical 
diagnostic methods, a discrimination of 22A-H and ME7-H was only possible by their 
incubation times or structural Fourier transform-infrared spectroscopical analysis of 
PrP27-30 [Thomzig et al., 2004]. Brain homogenates from all prion agents were 
digested with proteinase K (PK) and serial dilutions were subjected to SDS-PAGE and 
Western blotting. This revealed that all brain homogenates contained similar amounts of 
PrPres. 
When the standard PMCA protocol was carried out with the prion strains ME7-H,  
22A-H and BSE-H only a poor amplification was achieved (Figure 3-1). For PMCA 
1 x 10-10 g 263K, 1.5 x 10-5 g ME7-H or BSE-H and 1.0 x 10-5 g 22A-H homogenized 
hamster brain tissue were mixed with 10 % normal hamster brain homogenate (NBH) in 
a final volume of 150 µl, respectively. Samples were subjected to cycles of sonication 
and 1 h incubation at 37 °C. Sonication was performed for 40 sec at 180-200 W. After 
approx. 24 h samples were harvested and aliquots were diluted in a 1:5 ratio in fresh 
NBH. Samples were then subjected to another round of 24 cycles of incubation and 
sonication. In total four of those PMCA rounds were carried out. Prior to or after each 
PMCA round aliquots were harvested and subjected to digestion with PK, followed by 
SDS-PAGE and Western blotting. Detection of PrPres was performed using the hamster 
specific anti-PrP-antibody 3F4. Under the applied conditions a very efficient 
propagation of PrPres was achieved in 263K seeded PMCA reactions, as can be seen by 
the strong increase of PrPres within four successive PMCA rounds. In contrast, for 
samples that were seeded with ME7-H tissue a decline of detectable PrPres was 
observed during the first PMCA rounds. With the third round PrPres formation 
increased slowly. In samples seeded with BSE-H no PrP converting activity was seen at 
all. The PrPres amount in these samples corresponds merely to the serial dilution of the 
original seeding material, hence no formation of new PrPres had occurred. The finding 
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was similar when samples were seeded with the 22A-H scrapie prion strain. However, 
the fact that PrPres was still detected after four PMCA rounds indicated that 22A-H 
possessed a very low efficacy of amplification. It has to be noted that PMCA samples 
with 22A-H shown in Figure 3-1 were incubated 2 h instead of 1 h between the 
sonication steps. Nevertheless a stable autocatalytic propagation of PrPres was not 
achieved with the utilized standard PMCA procedure. Controls contained pure NBH 
without a prion seed. Reaction mixtures were processed in the same way as the other 
samples. Without the addition of a PrPSc seed no formation of PrPres was detected.  
 
 
 
Figure 3-1:  PMCA seeded with brain homogenate from hamsters infected with different prion strains. 
Amounts of prion seeding material are indicated as grams of homogenized brain tissue. 
PMCA procedure was carried out according to the standard conditions used for a very 
efficient propagation of 263K. Note: Samples seeded with 22A-H brain tissue were 
incubated for two hours instead of one hour. PMCA round 0 refers to the start sample, 
which was immediately frozen and not subjected to PMCA. ∅ – Control sample in which 
the prion seed was omitted. C – Internal Western blot control. 
 
In order to optimize the amplification of ME7-H, 22A-H and BSE-H in PMCA several 
parameters could be adjusted to influence the efficiency of the seeding reaction. 
Parameters which were modified in this work and additional parameters which had been 
adjusted in previously published studies are listed below: 
• Incubation time per PMCA cycle (1 h up to 4 h) 
• Duration of individual PMCA rounds (24 h, 48 h or longer) 
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• Strength of sonication (watts) [Yamaguchi et al., 2012] 
• Length of sonication intervals [Fujihara et al., 2009] 
• Dilution ratio of serial passage steps between PMCA rounds (1:2 vs. 1:5) [Gonzalez-
Montalban et al., 2011] 
• EDTA concentration (5-20 mM). 
 
In the following, in extensive series of PMCA experiments the effect of changes of 
selected parameters on the seeding efficiency were explored for each single prion strain. 
Thereby it was found that the incubation time per PMCA cycle and the EDTA 
concentration are of great significance. 
 
 
3.1.1 Parameters for optimized in vitro amplification of PrPres from different 
prion strains by PMCA: Dependence on EDTA 
The presence of chelating agents in reaction mixtures was found to be of great 
importance for an accelerated PrPres amplification during PMCA. The addition of the 
chelator EDTA in a concentration up to 20 mM was in general beneficial for 
amplification of all hamster prion strains (Figure 3-2). EDTA forms strong complexes 
with divalent as well as trivalent metal ions [Harris, 2010]. The standard PMCA 
procedure did not include 20 mM EDTA, it was however recommended to include 
5 mM EDTA in the conversion buffer, which is used to prepare the NBH [Barria et al., 
2012]. To assess the effect of EDTA on amplification of hamster prion strains in 
PMCA, EDTA was added to the NBH in final concentrations of 0, 1, 5, or 20 mM. To 
obtain NBH without EDTA, EDTA-free Protease Inhibitor Cocktail Complete Mini 
tablets were used for preparation of the conversion buffer. The accordingly prepared 
brain homogenates were subsequently seeded with 10-9 g 263K, 10-6 g BSE-H, 10-6 g 
22A-H or 10-5 g ME7-H brain tissue, respectively, and were subjected to up to five 
PMCA rounds. For all samples an incubation time of 2 hours was chosen between the 
sonication steps. Figure 3-2 shows Western blot results of samples before (PMCA round 
0) and after each PMCA round.  
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Figure 3-2:  Impact of the EDTA concentration on the amplification efficiency of different hamster 
prion strains in the PMCA assay. Samples were seeded with the indicated amounts of 263K, 
BSE-H, 22A-H or ME7-H brain tissue, respectively. Up to five serial PMCA rounds were 
carried out in the presence of 0, 1, 5 or 20 mM EDTA with 2 h incubation time per PMCA 
cycle. PMCA round 0 refers to the start sample, which was immediately frozen and not 
subjected to PMCA. C – Internal Western blot control. 
 
It is clearly visible that the presence of 20 mM EDTA in reaction mixtures accelerated 
the seeded conversion of PrPC to PrPres as compared to the 5 mM EDTA generally used 
in PMCA assays. This acceleration is concentration dependent and appeared to be 
basically independent from the prion strains used in this study. Higher concentrations of 
EDTA above 20 mM were not examined. Because EDTA is a metal chelator and 
seeding is more efficient in preparations that contain higher levels of EDTA, the 
presence of free metal ions seems to reduce the amplification efficiency. PrPres 
formation was never observed in non-seeded PMCA control samples containing 20 mM 
EDTA (not shown). 
 
 
3.1.2 Parameters for optimized in vitro amplification of PrPres from different 
prion strains by PMCA: Impact of incubation time 
In addition to the concentration of the chelator EDTA, the length of incubation times in 
an individual PMCA cycle was identified as another important parameter that modified 
amplification efficiency of prion agents. It was found that variations of incubation time 
had particular strong effects on the seeding activity of 22A-H associated prions. Figure 
3-3 shows results of samples that were seeded with 10-5 g or 10-6 g 22A-H brain tissue 
and were subjected to four rounds of PMCA. In set A, samples were incubated at cycles 
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of 2 hours incubation, whereas in set B the incubation time was raised to 4 hours. The 
number of 12 PMCA cycles per one PMCA round and the EDTA concentration of 
5 mM was kept constant in both sets. Under the conditions of set A no amplification of 
PrPres was achieved. The amount of detectable PrPres was reduced after four PMCA 
rounds compared to the amount of prion seeding material that is visible in round 0. In 
contrast, the samples that were incubated 4 hours in set B showed a stable amplification 
of PrPres in successive PMCA rounds. A prolonged incubation time as well as an 
elevated EDTA concentration (Figure 3-2) independently boosted the amplification of 
22A-H in PMCA. The additive or possibly synergistic effect of both of these parameters 
yielded a further increased amplification efficacy, as shown in Figure 3-3C. Here, 
PMCA was performed with 4 hours incubation and in the presence of 20 mM EDTA.  
 
 
 
Figure 3-3:  Effect of the incubation time on in vitro propagation of 22A-H associated PrPres in the 
PMCA assay. (A) PMCA was performed with a cyclic incubation time of 2 hours or (B) 
4 hours and in the presence of 5 mM EDTA. (C) PMCA was performed with 4 hours 
incubation and 20 mM EDTA. C – Internal Western blot control. 
 
For the other hamster prion strains ME7-H and BSE-H it was found that an incubation 
time of 2 h allowed a stable in vitro propagation of PrPres in PMCA reactions when 
12 incubation cycles were carried out per one PMCA round. Due to the advantage of 
time saving (with respect to the overall processing time) when performing 12 PMCA 
cycles with 2 h incubations each vs. 12 cycles with 4 h incubations each, the 2 h-
protocol was chosen for all following PMCA experiments with ME7-H and BSE-H. 
Furthermore if not stated otherwise, PMCAs were performed in the presence of 20 mM 
EDTA. 
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The findings demonstrate that the used hamster prion strains differ in their individual 
requirements for a stable and efficient PrPres propagation in PMCA assays.  
 
 
3.2 Cofactors in PMCA 
In order to examine, for different prion strains, the role of putative cofactor molecules in 
the process that converts PrPC into misfolded and aggregated PrPres, three sets of 
experiments were carried out. Firstly, by simple addition of putative cofactors to the 
reaction mixtures an environment with an excess of the molecules of interest was 
created in PMCA. This was expected to provide information as to whether an excess of 
specific molecules act as accelerators or decelerators of PrPC conversion. In a second 
approach nucleic acids were depleted in the PMCA substrate and the effect on PMCA 
was studied. Finally, in PMCA experiments with nucleic acid depleted NBH the ability 
of certain molecules to restore the amplification was assessed.  
 
3.2.1 Non-metal cofactors in PMCA 
In the following, individual experiments with simple addition of synthetic poly(A) RNA 
and the sphingolipids sphingomyelin and galactosylceramide were carried out. 
Increasing evidence suggest that lipids are involved in prion propagation and infectivity. 
It was demonstrated recently that phospholipids are required for replication of infectious 
mouse PrPSc in PMCA experiments [Deleault et al., 2012a; Deleault et al., 2012b; 
Wang et al., 2010]. Since galactosylceramide and sphingomyelin were previously 
identified in scrapie hamster prions [Klein et al., 1998] these sphingolipids were 
examined as putative cofactors in this study. Substances were added directly to the 
reaction mixtures (prior to performing PMCA) to achieve final concentrations of 25-
400 µg/ml in a reaction volume of 150 µl as indicated in Table 3-1. To rule out 
misleading results due to a degradation of cofactor molecules during a PMCA round by 
the ultrasound or remaining enzyme activities in the crude brain homogenate substrate, 
cofactor molecules were added prior to every PMCA round at the indicated 
concentrations. After each PMCA round aliquots were digested with PK and subjected 
to SDS-PAGE and Western blotting. PrPres was detected with a specific anti-PrP 
antibody (3F4). Effects of cofactor molecules on PrPres propagation were assessed by 
comparison of the Western blot signals between individual PMCA rounds of samples 
with added cofactor molecules or reference samples that did not contain such cofactor 
molecules. Figure 3-4 shows the Western blot results for the addition of poly(A) RNA 
to individual PMCA runs with all four hamster prion strains.  
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Figure 3-4:  Addition of 100-200 µg/ml poly(A) RNA to PMCA samples that were seeded with the 
indicated amounts of brain tissue from hamsters that had been infected with different prion 
strains. Poly(A) RNA was added prior to every PMCA round and PMCA was performed 
with incubation times of 1 h, 2 h, 4 h and 2 h for 263K, BSE-H, 22A-H and ME7-H seeded 
samples, respectively. Reference samples are shown in the upper line. References did not 
contain exogenous cofactor molecules and were otherwise treated equally. C – Internal 
Western blot control. 
 
RNA is generally considered to facilitate PrP conversion [Deleault et al., 2007; Deleault 
et al., 2003] and in accordance it was found in this thesis that the addition of synthetic 
RNA molecules was beneficial for the propagation of 263K and ME7-H associated 
prions. PrPres could be detected roughly one PMCA round earlier in samples with 
excess RNA molecules compared to reference samples. However, a contrary effect was 
observed for the propagation of 22A-H associated PrPres. Here, additional RNA 
molecules clearly inhibited the amplification of PrPres during four PMCA rounds. 
Addition of RNA did not show such major effects on the amplification of BSE-H prion 
seeds. Detection of BSE-H associated PrPres after six PMCA rounds in the presence of 
elevated RNA levels revealed no significant differences from reference samples. The 
sphingolipids sphingomyelin and galactosylceramide were added only to 263K seeded 
PMCA samples in concentrations up to 400 µg/ml. An effect on 263K propagation 
could not be observed. All results from PMCA experiments with addition of exogenous 
cofactor molecules are summarized in Table 3-1.  
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Table 3-1: Addition of putative cofactor molecules to the reaction mixtures during PMCA assays that 
were seeded with different hamster prion strains. Molecules were added to the indicated final 
concentrations. Effects on PrPres amplification efficacies were analyzed by Western blotting. 
Putative cofactor 263K  ME7-H  22A-H  BSE-H  
Synthetic poly(A)-
RNA 
100 µg/ml + 100-
200 µg/ml 
+ 100-
200 µg/ml 
– 100-
200 µg/ml 
Ø to – 
Sphingomyelin 25-
400 µg/ml* 
Ø N/D  N/D  N/D  
Galactosylceramide 25-
400 µg/ml* 
Ø N/D  N/D  N/D  
–  Inhibition of PrPres formation 
+  Increase of PrPres formation 
Ø  No effect on PrPres formation 
*  Sphingomyelin and Galactosylceramide were added to final concentrations of 25, 100 and  
 400 µg/ml 
N/D  no data 
 
3.2.2 PMCA after depletion of under nucleic acids in the conversion substrate 
Nucleic acids in normal brain homogenate used as PrPC substrate for PMCA assays 
were depleted by enzymatic digestion with benzonase for approx. 20 h. Aliquots of the 
prion seeding material were also treated with benzonase prior to performing PMCA for 
two hours. Benzonase is known to degrade all kinds of nucleic acids: single-stranded, 
double-stranded, linear, circular or supercoiled DNA and RNA. Addition of 20 mM 
EDTA to the PMCA substrate inhibited benzonase enzyme activity. EDTA was also 
added to reference samples which were used to carry out PMCA with NBH that still 
contained endogenous nucleic acids. Figure 3-5 depicts the Western blot results from 
PMCA assays in which either NBH or the nucleic acid free normal brain homogenate 
was used as PrPC substrate for the amplification of prion seeds. Reactions were seeded 
with 10-5 or 10-6 g hamster brain tissue, respectively. While the amplification of PrPres 
increased over the first PMCA rounds and finally reached a constant level in samples 
with endogenous nucleic acids, samples without nucleic acids in the substrate did not 
show an amplification of PrPres. The detection signal for PrPres constantly decreased 
over the PMCA rounds and eventually fell below the detection limit. This confirmed 
recent findings indicating that RNA is required for efficient prion propagation [Deleault 
et al., 2010; Deleault et al., 2003; Gonzalez-Montalban et al., 2011], and furthermore 
demonstrated that the different hamster prion strains used in this study are generally 
dependent on the presence of nucleic acids for PrPres amplification by PMCA. 
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Figure 3-5:  Propagation of prion strains is inhibited without nucleic acids in the PMCA substrate. NBH 
was incubated with the enzyme benzonase to remove all kinds of nucleic acids (normal 
brain homogenate w/o nucleic acids). Samples were seeded with 10-5 or 10-6 g infected 
hamster brain tissue as indicated and samples were subjected to PMCA procedures with 
incubation times of 2 h for263K, BSE-H and ME7-H and 4 h for 22A-H. In reference 
samples NBH that still contained endogenous nucleic acids was used. All samples 
contained 20 mM EDTA. C – Internal Western blot control. 
 
When 263K was used as seeding material in nucleic acid depleted NBH an initial 
seeding activity was consistently observed in the first PMCA round (see Figure 3-5, 
detection of PrPres in round 1 vs. round 0). This raised speculations if this seeding 
activity was mediated by residual nucleic acids in the original 263K seeding material 
that may have not been destroyed during the incubation with benzonase. In order to 
address this question the 263K seed was separately incubated with benzonase for 20 h, 
instead of 2 h, which was as long as the treatment of NBH. Subsequently, the 263K 
seeding material prepared in this way was mixed with NBH, or with nucleic acid free 
NBH, and subjected to PMCA. In a parallel PMCA reaction the nucleic acid free NBH 
was seeded with native 263K scrapie material that was not treated with benzonase. 
Results are depicted in Figure 3-6. The seeding efficiency of benzonase treated or 
untreated 263K seeds in nucleic acid depleted NBH were equal. The seeding activity of 
benzonase treated 263K brain tissue was not impaired as determined by PMCA in NBH 
and exhibited a similar conversion activity as untreated seeds (see Figure 3-4). Thus, it 
can be concluded that the initial 263K seeding was either not mediated by residual 
nucleic acids in the seeding material, or that nucleic acids possibly present in this 
material were not accessible to benzonase.  
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Figure 3-6:  Prior to PMCA 263K seeds were incubated 20 h or were not incubated with benzonase. 
PMCA was performed in NBH that was pretreated with benzonase and was thus free of 
nucleic acids. For comparison PMCA was also performed in NBH containing endogenous 
native nucleic acids. C – Internal Western blot control. 
 
A surprising observation was made when larger amounts of BSE-H prion infected tissue 
were used to seed PMCA in NBH devoid of nucleic acids. Whereas PrPres propagation 
faded after seeding with 10-6 g BSE-H brain tissue (Figure 3-5), an increase in newly 
formed PrPres was detected after 7 to 8 PMCA rounds when 10-4 g BSE-H brain tissue 
were used for seeding under equal PMCA conditions (Figure 3-7A). The new PrPres 
species formed in later PMCA rounds propagated despite the depletion of nucleic acids 
in the PMCA substrate. Further experiments revealed that this PrPres amplificate was 
able to mediate further PrP conversion when used as seeding material in new PMCA 
reactions with nucleic acid depleted NBH. They were found to propagate stable in such 
PMCAs for at least 10 rounds (data not shown). The same PMCA setup was then 
performed with 2 x 10-4 g 263K scrapie brain tissue as seed in nucleic acid free NBH. 
Interestingly, 263K did not appear to propagate in a similar way independently of 
nucleic acids. PMCA was performed for 14 rounds. Again, 263K exhibited a residual 
seeding activity that resulted in a lower decrease of PrPres as observed with BSE-H 
seeded samples until rounds 8-9. For comparison, the original BSE-H and 263K seeds 
(PMCA round 0 in Figure 3-7A) were not subjected to PMCA cycles but serially diluted 
according to the dilutions of serial PMCA rounds (Figure 3-7B). Incubation and 
sonication steps were not applied to the samples in Figure 3-7B. 
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Figure 3-7:  (A) PMCA samples were seeded with the indicated amounts of BSE-H or 263K hamster 
brain tissue and subjected to PMCA in the absence of nucleic acids in the PMCA substrate. 
For better comprehension the Western blot results were additionally visualized graphically. 
(B) Samples were seeded with identical amounts of prion tissue as in (A) but were not 
submitted to PMCA procedure. Instead only 1:5 dilutions were prepared that correspond to 
the indicated number of PMCA round. C – Internal Western blot control. 
 
 
3.2.3 PMCA after depletion of nucleic acids in the conversion substrate and 
subsequent addition of non-metal cofactors 
In this chapter the abilities of different putative cofactors to restore PrPres amplification 
by PMCA after depletion of nucleic acids in the PrPC substrate were assessed 
individually for all four hamster adapted prion agents. Previous studies gave first 
evidence that chondroitin sulfate was involved in the biogenesis of PrPSc in chronically 
prion infected mouse neuroblastoma cells (ScN2a) [Ben-Zaken et al., 2003], and poly-
L-glutamate was reported to stimulate PrPres amplification in an in vitro amplification 
assay with partially purified substrates [Deleault et al., 2005]. Chondroitin sulfate and 
poly-L-glutamate were therefore assessed as putative cofactors. The following studies 
were performed on the basis of a suppressed propagation of PrPres in nucleic acid free 
NBH (Figure 3-5). Polyanionic compounds such as poly(A) RNA, chondroitin 
sulfate A, poly-L-glutamate and the sphingolipid sphingomyelin were added in different 
concentrations to prion seeded PMCA reaction mixtures prior to every PMCA round. 
Compounds were assessed for their reconstitution ability by comparison to Western blot 
results from reference samples that contained only prion seeds in nucleic acid depleted 
NBH.  
Poly(A) RNA has been described previously to facilitate the propagation of hamster 
prion agents Sc237 and 139H in PMCA [Deleault et al., 2007]. In accordance with this 
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report, Figure 3-8 and Figure 3-9 show that poly(A) RNA also restored the 
amplification of 236K, ME7-H and BSE-H, and furthermore, was found to do so in a 
dose dependent manner. In Figure 3-8 synthetic RNA was added in final concentrations 
of 1, 10 or 100 µg/ml to reactions that were seeded with scrapie brain tissue from 263K 
or ME7-H infected hamsters. 1 µg/ml of the synthetic RNA in 263K samples and 
10 µg/ml in ME7-H samples were not sufficient to reconstitute PrPres propagation. 
However in the presence of 10 µg/ml or 100 µg/ml synthetic RNA, respectively, new 
PrPres was produced. These results show that reconstitution of PrP conversion by 
synthetic RNA is dose dependent for the examined prion strains. For reconstitution of 
PrP conversion ME7-H seeded samples required higher amounts of the polyanionic 
compound than 236K seeded samples.  
 
 
 
Figure 3-8:  Reconstitution of the seeding activities of 263K and ME7-H prions with poly(A) RNA are 
concentration dependent. Prion seeds were incubated in nucleic acid depleted NBH. Prior 
to every PMCA round the indicated amount of synthetic RNA was added to the reaction 
tubes. PMCA incubation time was 1 h for 263K seeded samples and 2 h for ME7-H seeded 
samples. C – Internal Western blot control. 
 
Furthermore it was found that poly(A) RNA alone was not sufficient to mediate a stable 
amplification of 22A-H seeded in nucleic acid depleted NBH. Addition of RNA 
facilitated a prolonged but yet decreasing propagation of 22A-H associated PrPres 
(Figure 3-9). This amplification was not stable and eventually became undetectable by 
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PMCA round five. Together with the previous finding that poly(A) RNA inhibited 
amplification of 22A-H in PMCA with crude brain homogenate (Figure 3-4), this 
showed that poly(A) RNA did not promote propagation of all the examined hamster 
prion agents in PMCA. Its effect is therefore strain specific. However amplification of 
22A-H was successfully restored by chondroitin sulfate A. 263K and BSE-H seeded 
samples could be reconstituted with both RNA and chondroitin sulfate A, whereas no 
reconstitution was observed for ME7-H seeded samples in the presence of chondroitin 
sulfate in four PMCA rounds (Table 3-2). This again indicates that the ability of 
synthetic poly(A) RNA or chondroitin sulfate A to compensate for depleted nucleic 
acids in PMCA depends on the prion strain.  
 
 
 
Figure 3-9:  Reconstitution of PrPres amplification for 236K, BSE-H and 22A-H prions in NBH 
depleted of nucleic acids by addition of poly(A) RNA or chondroitin sulfate A. Hamster 
prion brain tissues were mixed with NBH that was depleted of nucleic acids and samples 
were subjected to PMCA for the indicated number of rounds. To the sets of samples 
100 µg/ml poly(A) RNA or different amounts of chondroitin sulfate A were added before 
every PMCA round. 263K seeded samples were treated with 100 µg/ml chondroitin 
sulfate A, and a PMCA incubation time of 1 h. BSE-H and 22A-H seeded samples were 
treated with 400 µg/ml chondroitin sulfate A and the PMCA incubation time was 2 h and 
4 h, respectively. C – Internal Western blot control. 
 
Table 3-2 summarizes the results for all examined putative cofactor molecules. 
Reconstitution of PrP misfolding was assessed after 4 to 5 PMCA rounds. Poly(A) RNA 
was found to confer a stable reconstitution of PrP conversion for 263K, ME7-H and 
BSE-H seeds. Though the seeding activity of 22A-H associated PrP was sustained to 
some extent, the formation of new PrPres became unsustained in later PMCA rounds. 
Chondroitin sulfate A was found to reconstitute the seeding activity of 263K, 22A-H 
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and BSE-H prions but not ME7-H prions. Poly-L-glutamate was added solely to 
reactions with 263K and BSE-H. The effect by poly-L-glutamate on the seeding activity 
of 263K was low, and a reconstitution of BSE-H amplification was not determined with 
this cofactor. Furthermore sphingomyelin was not able to mediate a reconstitution of 
263K associated PrP conversion after depletion of nucleic acids in the PMCA substrate. 
 
Table 3-2: Reconstitution effects of putative cofactor molecules on PrP conversion in PMCA. Different 
hamster prion strains were used as seeds in NBH devoid of nucleic acids. Cofactors were added to 
reaction mixtures in defined concentrations and prior to every PMCA round. 
Cofactor 263K  ME7-H  22A-H  BSE-H  
Synthetic 
poly(A)-RNA 
1-300 µg/ml* ++ 10-
100 µg/ml 
++ 100 µg/ml Ø 100-
300 µg/ml 
+ 
Chondroitin 
sulfate A 
100-
400 µg/ml** 
+ 400 µg/ml – 400 µg/ml + 400 µg/ml + 
Poly-L-
glutamate 
200 µg/ml Ø  N/D  N/D  200 µg/ml – 
Sphingomyelin 25-
400 µg/ml*** 
– N/D  N/D  N/D  
+  PrPres propagation was successfully reconstituted 
++ Reconstitution of PrPres propagation showed concentration dependency on the cofactor 
Ø  PrPres propagation was prolonged but still decreasing 
–  PrPres propagation was not reconstituted  
*  Poly(A) RNA was added at final concentrations of 1, 10, 100 and 300 µg/ml  
**  Chondroitin sulfate A was added at final concentrations of 100, 300 and 400 µg/ml 
***  Sphingomyelin was added at final concentrations of 25, 100 and 400 µg/ml 
N/D  no data 
 
3.2.4 Metal ions as cofactors 
The involvement of metal ions in PrP misfolding and aggregation is being widely 
discussed and the stimulation by divalent metal ions of the conversion of PrPC into 
PrPres in PMCA assays was previously reported [Kim et al., 2005]. Against this 
background the effect of metal ions on 263K associated PrP conversion in PMCA was 
investigated. Specific requirements had to be considered to avoid artificial or 
superposed effects. For these reasons the metal ion chelating agent EDTA was omitted 
in the PrPC substrate. Brains of normal hamsters were perfused without EDTA in the 
perfusion solution and the conversion buffer for brain homogenization was prepared 
with EDTA-free protease inhibitor tablets. Under these conditions the seeding of 263K 
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was found to exhibit a lower efficiency. However this could be compensated by seeding 
the PMCA reaction with a higher seeding dose of 10-7 g scrapie brain tissue. 
Furthermore, artifacts due to an impaired processing by proteinase K in the presence of 
metal ions had to be considered, as it was reported that Cu2+ ions can inhibit the activity 
of proteinase K [Stone et al., 2007]. PK digestion of PrPSc in the presence of metal ions 
in equivalent concentration as used in PMCA experiments revealed no altered PrP 
processing (Figure 3-10A). Only in the presence of higher concentrations as 10 mM 
CuCl2 the digestion with PK was found to be incomplete. An addition of 20 mM EDTA 
restored complete PK digestion (Figure 3-10B).  
 
 
 
Figure 3-10:  (A) PK digestion of PrPSc was not impaired in 100 or 500 µM metal ion solution. Normal 
brain homogenate was spiked with identical amounts of 263K brain tissue and PK 
treatment was carried out in the presence of metal ions as indicated. (B) Normal brain 
homogenate was spiked with 263K tissue where indicated and limited proteolysis with PK 
was performed in the presence of 10 mM CuCl2 or NaCl with or without 20 mM EDTA as 
indicated.  
 
PMCA experiments conducted to assess the effect of metal ions on the seeding activity 
of 263K prions comprised the following sample types: 
 
• PrPC + PrPSc (as reference) 
• PrPC + PrPSc + metal ions 
• PrPC + metal ions (as control) 
• PrPC (as control) 
 
Metal ions were applied to the NBH substrate as aqueous chloride solutions at final 
concentrations of 100 and 500 µM. These concentrations were chosen to cover a 
physiologically relevant range. As mentioned in chapter 1.5.2 metal concentrations in 
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the brain are in a range of 70 µM copper, 350 µM zinc and 340 µM iron [Bush and 
Tanzi, 2008; Rana et al., 2009]. Generally brain metals are not present as free ions but 
bound to ligands. As is described in the literature about 300 µM zinc [Assaf and Chung, 
1984; Frederickson and Bush, 2001; Howell et al., 1984] are transiently present as free 
ions in the synaptic cleft in the brain and free copper is present in the extracellular space 
[Rana et al., 2009; Schlief et al., 2005]. It was reported that copper concentrations of 
15 µM are released within the synaptic cleft during synaptic vesicle release and higher 
concentrations between 100 and 300 µM are achieved during neuronal depolarization 
[Vassallo and Herms, 2003]. Metal ions were added to NBH prior to every PMCA 
round and a total of four PMCA rounds were carried out with cyclic incubation times of 
one hour. None of the tested metal ions in this PMCA setup were present in the 
conversion buffer used for the preparation of the homogenate substrate. The addition of 
500 µM NaCl served as control. 
Figure 3-11 shows representative results of the effects of metal ions on the propagation 
of PrPres from 263K scrapie seeds in the PMCA assay. The Western blot findings 
showed an inhibitory effect of some ions or none effect on the efficiency of PrP 
conversion. An increase of PrP conversion was not observed. PrPres formation was 
never detected in non-seeded control samples, regardless of whether they contained 
additional metal ions or not. The NaCl control sample showed no deviation from the 
263K reference sample that was free of additional metal ions. Zn2+, Fe2+, Fe3+ and Cu2+ 
were found to inhibit PrPres formation in a concentration dependent way. Fe2+ had the 
strongest inhibitory effect on 263K associated PrPres propagation followed by Fe3+, 
Zn2+ and Cu2+. Mn2+ did not exhibit an effect on the propagation of PrPres. 
The previous findings that higher EDTA concentrations promote PrP misfolding in 
PMCA are in good accordance with the observation that the majority of the applied 
metal ions generally inhibit PrP conversion. 
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Figure 3-11:  Western blot results show the effect of different metal ions on PrPres propagation in 
PMCA. Metal ions were added to PMCA reactions as aqueous chloride solutions at final 
concentrations of 100 and 500 µM. Samples were seeded with 10-7 g 263K scrapie hamster 
brain tissue and were subjected to four PMCA rounds. In control samples the 263K seed 
was omitted. C – Internal Western blot control. 
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3.3 Infection of glial cell cultures with other hamster adapted prion 
strains than 263K 
 
A cell culture assay from cerebral glial hamster cells was recently established in our 
laboratory to qualitatively test and verify 263K associated PrP seeding as a biologically 
active and replicative principle in vitro without experiments in animals [Pritzkow et al., 
2011]. In the following this assay was adapted to ME7-H, 22A-H and BSE-H prion 
agents. 
 
3.3.1 Cell assay with hamster brain homogenate from different prion strains 
The cell assay for in vitro propagation of PrPres originating from 263K brain 
homogenate was recently established in our laboratory. Since other hamster prion 
strains were shown to have different requirements for in vitro amplification in PMCA 
(see chapter 3.1), the propagation of these prion strains in the cell assay was examined 
in more detail. To this end brain homogenate from hamsters that were infected with 
263K, ME7-H, 22A-H, BSE-H, and brain tissue from an uninfected healthy animal, 
were applied to the cell cultures under equal conditions. Glial cell cultures were 
prepared 2-3 days prior to inoculation with hamster brain homogenates. 10-3 g or 10-5 g 
of homogenized brain tissue, as indicated in Figure 3-12, were added to the culture 
medium and cells were subsequently incubated for 3 days. At 3 days post exposure 
(DPE) to the brain tissue, cells were washed to remove inocula. Afterwards, cells were 
incubated further. At the indicated DPE, cells were harvested and analyzed for PrPres 
by detection with anti-PrP antibody 3F4 after digestion with PK. The amount of PrPres 
at 3 DPE thereby was equivalent to the original inoculum that had been attached to the 
cells. In the Western blot image of 263K infected cells, an increase of PrPres from 
3 DPE to 40 DPE and a further increase to 80 DPE is shown, indicating that cells had 
been successfully infected and further propagated 263K associated PrPres. A 
propagation of PrPres by glial cells was also observed for 22A-H and BSE-H inoculated 
cultures. Cell infection with the ME7-H agent was monitored at several time points over 
an interval of 154 days. Only a decrease of PrPres that originally persisted on the cells 
was observed, but a propagation of PrPres and thus a successful cell infection could not 
be detected. Cell cultures that were incubated with normal brain tissue from healthy 
animals (no seed) are labeled as NBH in Figure 3-12 and served as a negative control. 
In none of these samples PrPres could ever be found. 
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Figure 3-12:  PrPres amplification in glial cell cultures after incubation with the indicated amounts of 
brain tissue from hamsters that had been infected with different prion strains. Cells were 
incubated with the inocula for three days. Thereafter the inoculum was removed and cells 
were incubated further. At the indicated days post exposure (DPE) PrPres was detected 
with an anti-PrP antibody after PK digestion of the cell suspension. NBH – normal brain 
homogenate of uninfected animals served as control inoculum. C – Internal Western blot 
control. 
 
In summary, glial cell cultures could be infected with the 263K, 22A-H and BSE-H 
agent, but not with the ME7-H scrapie agent. It was found that 263K and 22A-H 
propagated PrPres formation in cell cultures with a similar efficiency, whereas BSE-H 
exhibited a lower efficiency since a larger amount of tissue was required as inoculum to 
trigger PrPres formation with a comparable efficiency. These findings correlated only 
partially with the observed in vivo incubation times: In bioassay studies 263K scrapie, 
22A-H scrapie and BSE-H prions caused clinically fully developed prion diseases in 
Syrian hamsters at 83±5, 206±8 and 287±28 days, respectively, whereas the ME7-H 
scrapie agent has an incubation time of 331±16 days [Thomzig et al., 2004]. 
 
 
3.3.2 Cell assay with PMCA products 
After establishment of a cell assay for the detection of biological seeding activity 
associated with 22A-H and BSE-H prion agents from brain homogenates of Golden 
Syrian hamsters, it was of interest to determine whether the PMCA derived PrPres 
species from all four hamster prion strains are able to induce PrPres propagation in the 
cell cultures. PMCA products contained about 1 % (v/v) Triton X-100 which disrupts 
cell integrity and was thus toxic to our cell cultures. Therefore all PMCA derived 
samples had to be ultracentrifuged in order to remove the Triton X-100. Pellets after 
centrifugation were resuspended in PBS and applied to cell culture media. Cells were 
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incubated with the inocula for 3 days. Subsequently, inocula were removed and cells 
were cultured for a duration of 80 days. Cells were analyzed for PrPres at 3, 40 and 
80 DPE. Figure 3-13 shows the Western blot results from cell cultures that were 
infected with PMCA products derived from different hamster prion strains. PMCAs 
were originally seeded with brain homogenate from 263K, ME7-H, 22A-H and BSE-H 
infected animals, respectively, and samples were subjected to 4-5 rounds of serial 
PMCA to ensure a cell exposure to newly formed PrPres. After 4-5 PMCA rounds PrPSc 
from the original seeding tissue was diluted below the detection limit in the Western 
blot. The amount of PrPres from PMCA samples that was utilized for cell infection was 
approximately identical for the prion strains 263K, ME7-H and BSE-H as determined 
by Western blot analysis. A lower amount of 22A-H associated PrPres was used for 
incubation of the cells. Inoculation of cell cultures with PMCA products sampled after 
4 rounds of unseeded PMCA (NBH only) served as a negative control. Due to some 
variations between samples of the same kind, duplicates for each sample are displayed. 
The results show that PMCA generated PrPres derived from all prion agents induced an 
accumulation of PrPres in glial cell cultures, hence are infectious to the cell cultures of 
this assay. Interestingly also ME7-H progeny PrPres was biological seeding active, 
whereas the original ME7-H brain homogenate previously failed to cause PrPres 
amplification in the cell culture. As expected, the unseeded PMCA product with NBH 
only did not produce detectable PrPres in the cell assay.  
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Figure 3-13:  Accumulation of PrPres in glial cell cultures after incubation of cells with PMCA products 
derived from 263K, 22A-H, ME7-H or BSE-H seeds. Cells were incubated with the inocula 
for three days. Thereafter the inoculum was removed and cells were incubated further up to 
80 days. At the indicated days post exposure (DPE) PrPres was detected with an anti-PrP 
antibody after PK digestion of the cell suspension. NBH – PMCA seed was omitted.  
C – Internal Western blot control. 
 
 
Another relevant aspect is the ability of PMCA products that had been derived in the 
presence or absence of specific cofactor molecules to induce PrPres propagation in glial 
cell cultures. In the following, cell cultures were exposed to PMCA products which had 
been obtained under the presence or absence of specific cofactor molecules. PMCA 
samples were seeded with BSE-H in nucleic acid depleted NBH. As shown in Figure 3-
7, BSE-H prions induced an accumulation of PrPres under nucleic acid free conditions. 
Reaction products after 12 PMCA rounds were used for cell infection. The assay was 
performed as described above. Figure 3-14 shows an accumulation of PrPres in glial 
cells after 40 and 80 DPE that was induced by the BSE-H PMCA product generated in 
nucleic acid depleted NBH. Further PMCA products were generated by seeding nucleic 
acid depleted NBH with 263K prions in the presence of a polyanion. A reconstitution of 
PrPres amplification under these conditions could be achieved by the addition of 
poly(A) RNA or chondroitin sulfate A (Figure 3-9). PMCA samples that were used for 
cell infection had been produced in presence of 300 µg/ml of each cofactor molecule by 
four rounds of PMCA. Both of these PMCA samples were found to produce an 
infection in the cell assay with an accumulation of PrPres until 80 DPE. Thus, all three 
tested samples were biological seeding active. This demonstrated that poly(A) RNA and 
chondroitin sulfate A did not only restore the capability to amplify PrPres but also the 
propagation of infectivity in PMCA. Furthermore, BSE-H associated PrPres preserved a 
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biological seeding activity, i.e. cell culture infectivity, independently of the depletion of 
nucleic acids in the PMCA substrate. 
 
 
 
Figure 3-14:  PrPres accumulation in glial cell cultures after exposure to PMCA products which had 
been obtained in the presence or absence of specific cofactor molecules. Cells were 
incubated with the inocula for three days. Subsequently the inoculum was removed and 
cells were incubated further. PrPres was detected at the indicated DPE. Cells were infected 
with BSE-H or 263K seeded PMCA samples in nucleic acid free NBH substrate. 263K 
seeded PMCA samples were reconstituted with poly(A) RNA or chondroitin sulfate A.  
C – Internal Western blot control. 
 
 
3.3.3 Metal cofactors in the cell assay 
As shown above, certain metal ions exert an inhibitory effect on PrPres propagation in 
PMCA (chapter 3.2.4). To address the question whether the same effect of Cu2+, Zn2+, 
Fe2+, Fe3+ and Mn2+ can be also observed for the biological propagation of 263K prions 
in the cell culture assay the following study was performed. See Figure 3-15 for a 
schematic illustration of the experimental design. Glial cells were cultured 2-3 days 
prior to infection. The cells were then incubated in the constant presence of metal ions 
starting with the day of inoculation with 10-5 g 263K brain tissue, and were cultured up 
to 74 DPE (Figure 3-15A). Cells were incubated with the 263K inoculum for three days, 
thereafter the inoculum was removed as described above. Metal ions were applied to the 
culture medium as aqueous chloride solutions at final concentrations of 20 and 50 µM. 
According to the manufacturer the cell culture medium DMEM did not contain any of 
the metal ions that were applied in the assay, except for 6.4 g/l (~110 mM) NaCl and 
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0.1 mg/l (~0.25 µM) iron(III) nitrate nonahydrate (Fe(NO3)3 ·  9H2O). The concentration 
of approx. 0.25 µM Fe(NO3)3 ·  9H2O was well below the lowest applied concentration 
of 20 µM FeCl3 and is therefore negligible. Similar concentrations of metal ions were 
used in studies that involved primary neuronal cells [Cuajungco et al., 2000; Lovell et 
al., 1999]. Higher concentrations resulted in cell damage, as was observed by 
microscopic monitoring. With the renewal of culture medium every week the metal ion 
solutions were again newly applied.  
 
 
 
Figure 3-15:  Experimental design for the determination of metal ion mediated effects on prion 
propagation in the cell assay. (A) Cells were cultured in the presence of metal ions for the 
whole duration of the cell infection experiment beginning with the day of exposure to 263K 
hamster brain homogenate. (B) Cells were incubated with 263K brain tissue and further 
cultured without any additional metal ion solutions. (C) Metal ions were added to the 
culture medium for 20 days before infection. Thereafter cells were infected with 263K and 
further cultured without metal ions. 
 
Cell cultures that were incubated with 263K brain tissue without any additional metal 
ion solutions served as a reference to evaluate metal ion mediated effects (Figure 3-
15B). To assess whether metal ions might have implications on cell metabolism which 
in turn could possibly result in an impaired ability to produce PrPres, an additional 
control was included. Cultures were incubated for about 20 days in the presence of 
metal ions. Thereafter cells were infected with 263K and were cultured further 49 days 
in normal medium without additional metal ions (Figure 3-15C). PrPres formation in 
these cultures was compared to reference cultures that were not exhibited to metal ions 
but inoculated with 263K after 20 days incubation in normal culture medium. These 
controls are marked with * in Figure 3-16. A thorough examination of cells by at least 
weekly microscopy was of high importance to assess cell membrane integrity, since 
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there are no data available that describe the long-term effect of metal ions on cell 
vitality of isolated hamster glial cells (appearance of cell death by apoptosis or 
necrosis). Indeed manganese was found to be toxic to cells in this assay even at a 
concentration as low as 20 µM. A constant loss of cells exposed to manganese was 
observed upon microscopic inspection. Therefore results for manganese were excluded 
from further analyses.  
 
Figure 3-16 shows the Western blot results. Reference samples showed a constant 
increase in PrPres levels up to 74 DPE. Cells that were infected 20 days later had higher 
PrPres contents at 49* DPE than cells after 47 DPE. Apparently, PrPres was more 
efficiently propagated by these cells. Furthermore a solution of NaCl was applied as a 
mock control. As the cell culture medium DMEM already contained 6.4 g/l (~110 mM) 
NaCl, this was used as general control to exclude that any effects are caused by the pure 
addition of exogenous chloride solutions, e.g. on cell vitality. The detected PrPres levels 
for these controls were found to be similar to the reference samples with only minor 
variations. The susceptibility to prion infection after 20 days culture with ZnCl2 was not 
impaired, as assessed by the amount of PrPres at 49* DPE. When cell infection was 
performed in the presence of 20 µM ZnCl2 no change in PrPres formation was observed, 
whereas PrPres production was decreased when 50 µM ZnCl2 were present. An 
inhibitory concentration dependent effect of ZnCl2 on the seeding activity of 263K 
prions was already observed in the PMCA assay. For the ions Fe2+, Fe3+ and Cu2+ also 
lower levels of PrPres were detected at 47 and 74 DPE as compared to the reference and 
control samples. The inhibitory effect of 20 µM FeCl2 could not be enhanced in the 
samples containing 50 µM FeCl2. The control at 49* DPE for 50 µM CuCl2 did not 
show a proper PrPres production compared to the reference which might be due to 
impaired cell metabolism. A damage of cells was not observed by microscopy.  
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Figure 3-16:  Glial cell assay with 263K scrapie prions to assess the impact of different metal ions on 
PrPres propagation. Cell infection was performed in the presence of 20 or 50 µM metal 
ions, except for references or controls. Metal ion solutions were added directly to the 
culture medium. PrPres was detected at the indicated DPE. The signal at 3 DPE resulted 
from 263K inocula that remained attached to the cells. Samples marked with * were 
cultured for 20 days in the presence of metal ions prior to infection with 263K. Thereafter, 
cell infection and subsequent cultivation of control cell cultures was performed in the 
absence of additional metal ions. C – Internal Western blot control. 
 
 
In accordance with the findings from PMCA assays all examined metal ions were found 
to inhibit the propagation of 263K associated PrPres in glial cell cultures. This effect 
appeared to be dose dependent between 20 and 50 µM for Zn2+ and Fe3+. In contrast to 
PMCA, Cu2+ (20 µM) had the strongest inhibitory effect on 263K amplification 
followed by Fe2+, Fe3+ and Zn2+. 
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3.4 Comparative biochemical and biophysical characterization of 
native prion seeds and their progeny PrPres from PMCA- or cell 
assays  
 
Brain derived PrPSc associated with 263K, ME7-H, 22A-H and BSE-H were shown to 
exhibit distinct combinations of biochemical and physical properties [Thomzig et al., 
2004]. In the following chapter biochemical and biophysical features of PrPres 
generated by PMCA or in glial cell cultures were determined and compared to the 
parental prion agents. 
 
3.4.1 Amplification efficiency of parent and progeny seeds in PMCA 
The following procedure allowed a parallel monitoring of the seeding efficiencies of 
PrPSc from 263K and ME7-H associated brain homogenate and their respective PMCA 
derived PrPres. A PMCA was carried out with identical treatment of all samples. 
Samples were seeded with identical amounts of PrPres from brain homogenate or 
PMCA products. Identical amounts of PrPres seeds were adjusted based on comparison 
of Western blot signal intensities. PMCA derived PrPres was generated beforehand by 
subjecting 263K and ME7-H brain homogenates to three rounds of PMCA (see Figure 
3-17A). Comparative PMCA with brain- and PMCA derived seeds was subsequently 
performed for four rounds and in identical NBH substrate for all samples. The Western 
blot results are presented in Figure 3-17B. Staining intensities of PrPres from samples 
that were seeded with 263K brain homogenate or its derived PMCA product are 
identical for same PMCA rounds. Thus both seed types exhibit similar seeding 
efficiency in PMCA. In contrast, the formation of PrPres in samples seeded with ME7-
H brain homogenate increases very slowly, starting with the second round of PMCA. 
However, PMCA derived ME7-H seeds have a higher efficiency in the production of 
PrPres which already started in the first PMCA round. The seeding efficiency of this 
material is similar to that of 263K associated prion seeds. Hence, brain ME7-H and its 
PMCA product differ from each other with respect to their seeding efficiency.  
Furthermore a change in the glycosylation profile of the PMCA derived ME7-H PrPres 
was observed. The ME7-H prion strain displays similar staining intensities of the 
diglycosylated and the monoglycosylated protein band [Thomzig et al., 2004], whereas 
its PMCA product shows a stronger appearance of the diglycosylated protein band, as 
can be clearly seen in the start sample (round 0). 
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Figure 3-17:  Amplification efficiencies of native 263K and ME7-H seeds and their progeny PrPres from 
PMCA assays. (A) Schematic representation of experiment. (B) PMCA reactions were 
seeded with 1 x 10-5 g brain tissue (referred to as BH) from ME7-H or 263K infected Syrian 
hamsters or with an identical amount of PrPres from a 3-round PMCA (referred to as 
PMCA product) that was seeded with native ME7-H or 263K, respectively. C – Internal 
Western blot control. 
 
 
3.4.2 Impact of cofactors on the seeding activity of parent and progeny seeds 
The same experimental design was applied to assess the efficiency of the polyanions 
poly(A) RNA and chondroitin sulfate A to reconstitute PrP conversion by PMCA in 
nucleic acid depleted NBH. Identical amounts, in terms of PrPres, of brain homogenate 
and PMCA products of 263K and ME7-H associated PrP were seeded in nucleic acid 
free NBH and samples were subjected to four rounds of PMCA (Figure 3-18, first line). 
As mentioned above (chapter 3.2.2) a propagation of misfolded PrP could not be 
achieved under nucleic acid depletion in NBH for both prion strains. Figure 3-18 shows 
that this also applied to samples seeded with PMCA derived PrPres of both prion 
strains. Nevertheless a change in one detail was observed. The samples that had been 
seeded with native 263K prions exhibited a residual seeding activity that caused a 
transient amplification of PrPres in the first PMCA round (see chapter 3.2.2). A similar 
effect was also observed in samples that had been seeded with PMCA derived ME7-H, 
but was absent with the ME7-H brain homogenate. Propagation of 263K parent (from 
brain) and progeny (from PMCA) seeds was efficiently restored by the addition of 
synthetic poly(A) RNA molecules (Figure 3-18, middle line). A similarly efficient 
reconstitution was achieved for the amplification of PMCA derived ME7-H seeds, 
whereas reconstitution was only weak for the ME7-H brain seed in this experiment, 
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with a recovery of PrPres formation in the fourth PMCA round (cp. Figure 3-8 where 
the same effect appears in a more pronounced way). A further difference was observed 
when PrPres propagation was effectively restored with chondroitin sulfate A in samples 
that had been seeded with native and progeny 263K material as well as the sample that 
had been seeded with PMCA derived ME7-H associated PrPres, but not in the sample 
that had been seeded with ME7-H brain tissue (Figure 3-18, last line).  
 
 
 
Figure 3-18:  Impact of cofactors on the seeding activity of native 263K and ME7-H seeds and their 
PMCA derived progeny seeds in PMCA. PMCA was performed in NBH that had been 
depleted of nucleic acids and in similar samples to which 100 µg/ml poly(A) RNA or 
400 µg/ml chondroitin sulfate A were added during PMCA. C – Internal Western blot 
control. 
 
 
3.4.3 Electrophoretic mobility of deglycosylated parent and progeny seeds in 
SDS-PAGE 
One biochemical method to distinguish 263K and BSE-H is an enzymatic 
deglycosylation of both PrPres species with PNGase F. After incubation with this 
enzyme the prion protein shows a single band upon detection with an anti-PrP antibody 
in the Western blot. After digestion with PK the unglycosylated band of 263K and BSE-
H exhibit a different electrophoretic mobility due to different molecular masses of 
approx. 20 kDa and 19 kDa, respectively [Thomzig et al., 2004]. In the following 
PrPres produced in vitro by PMCA or in cell cultures was analyzed, and compared to 
the native PrPres from 263K- or BSE-H brain homogenates by this approach. Analyses 
were performed with reaction mixtures after at least four serial PMCA rounds or with 
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PrPres from harvested cells. In both cases the amount of starting seeding material or 
inoculum was below the detection limit of the Western blot. 
In Figure 3-19A the electrophoretic mobilities of unglycosylated PrPres from 263K, 
BSE-H, ME7-H and 22A-H originating from brain homogenate or derived by PMCA 
after four PMCA rounds are shown. Discrimination between brain homogenates from 
BSE-H and all other prion strains on the basis of the characteristic band shift was 
possible. Furthermore a direct comparison of BSE-H derived PMCA product with brain 
BSE-H shows that the characteristic band shift for BSE-H was still preserved in its 
PMCA derived progeny PrPres. The PMCA derived BSE-H PrPres is clearly different 
from all PMCA products that had been seeded with 263K, ME7-H or 22A-H. Next, 
BSE-H associated PrPres that had been generated in previous PMCA experiments under 
various cofactor conditions (chapter 3.2) was analyzed for its electrophoretic mobility. 
In Figure 3-19B BSE-H seeded PMCA samples are directly compared to 263K seeded 
PMCA samples. The first PMCA sample was seeded with BSE-H brain tissue in normal 
hamster brain homogenate and additional 200 µg/ml poly(A) RNA (Figure 3-4). The 
other BSE-H seeded samples were generated in nucleic acid depleted NBH and by 
addition of 100 µg/ml poly(A) RNA or 400 µg/ml chondroitin sulfate A, respectively. 
The polyanions were required for amplification in nucleic acid depleted NBH as 
presented above (Figure 3-9). The characteristic shift of the unglycosylated protein band 
was also preserved in PMCA samples after six amplification rounds that were generated 
in the presence of synthetic RNA or after PMCA reconstitution with synthetic RNA or 
chondroitin sulfate A, respectively. Since the different molecular masses of 263K and 
BSE-H of approx. 20 kDa and 19 kDa after digestion with PK probably reflect 
differences in protein conformation, the findings indicated that characteristic 
conformational features of native brain BSE-H were transferred to the PMCA generated 
PrPres in the presence of poly(A) RNA or chondroitin sulfate A. In contrast, the PMCA 
generated BSE-H species that was found to propagate in nucleic acid depleted NBH 
(Figure 3-7) did not differ with respect to the electrophoretic mobility of its 
unglycosylated band from 263K as shown in Figure 3-20B. This indicated that a lack of 
nucleic acids in the substrate of BSE-H PMCA resulted in the amplification of 
conformationally changed PrPres. 
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Figure 3-19:  Electrophoretic mobility of PrPres species before and after PMCA. PrPres was 
deglycosylated with PNGase F. (A) Brain homogenate (BH) of 263K, BSE-H, ME7-H and 
22A-H infected hamsters was used to seed PMCA reactions and was compared to its 
corresponding PMCA derived progeny PrPres (PMCA). (B) Progeny PrPres derived from 
native 263K or BSE-H seeds by PMCA under the indicated cofactor conditions. 
 
Electrophoretic mobilities of PMCA samples that were used as inocula for the infection 
of glial cell cultures and of the corresponding cell culture derived PrPres are depicted in 
Figure 3-20. PrPres produced by glial cells after incubation with PMCA derived BSE-H 
inoculum also exhibited an electrophoretic migration pattern different from that of 263K 
PMCA- and cell products (Figure 3-20A). In contrast, the PMCA generated BSE-H that 
had been amplified in the absence of endogenous nucleic acids in NBH substrate 
showed no different molecular mass from 263K. The same hold true for PrPres that had 
been produced by cell culture infection with this particular BSE-H derived PrPres. 
However, for this material the protein band was not as dense as expected and a thinner 
ghost band appeared repeatedly with a slightly lower molecular mass (Figure 3-20B). 
This result was therefore ambiguous and remained to be further investigated.  
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Figure 3-20:  Comparison of the electrophoretic mobility of PrPres species used for infection of glial cell 
cultures and the glial cell-amplified PrPres harvested at 80 DPE. After digestion with PK 
samples were enzymatically deglycosylated using PNGase F. (A) PMCA derived BSE-H 
and 263K PrPres prior to and after amplification in the cell culture. (B) Cell infection was 
performed with PMCA derived BSE-H PrPres produced by PMCA with nucleic acid 
depleted NBH. Some samples were serially diluted for better resolution. 
 
 
3.4.4 Secondary structure analysis of parent and progeny seeds by FT-IR 
spectroscopy 
The hamster adapted prion strains 263K, ME7-H, 22A-H and BSE-H were recently 
described to be distinguishable by the biophysical method of Fourier transform-infrared 
(FT-IR) spectroscopy [Thomzig et al., 2004]. This method enabled a swift 
differentiation of TSE agents, even of ME7-H and 22A-H which were not 
distinguishable by biochemical, clinical or neuropathological features but only by 
incubation time. Differentiation with FT-IR spectroscopy was based on conformational 
diversity, attributed mainly to differences in β-sheet structure and to variations in other 
secondary structure elements of PrPres from different hamster prion strains. The 
biochemical characterization of BSE-H progeny seeds produced by PMCA in nucleic 
acid depleted NBH described above (chapter 3.4.3) indicated that the lack of nucleic 
acids in the reaction substrate resulted in amplification of conformationally changed 
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PrPres. To investigate if the presence or absence of specific cofactors during PMCA 
caused detectable alterations in protein conformations, FT-IR spectroscopy was used in 
order to structurally characterize PrPres amplificates. For this purpose PMCA products 
were purified according to a protocol by Daus et al. and dried protein samples were 
subjected to Fourier transform-infrared micro-spectroscopy established by this author 
[Daus et al., 2013]. By this novel approach, it was possible to analyze very small 
amounts of PrPres as 25-75 ng per dried sample spot. This is relevant due to the small 
protein amounts produced by PMCA. 
PrPres was purified from PMCA products to obtain extracts suitable for FT-IR 
measurements as described in materials and methods (chapter 2.2.11). This procedure 
included a very mild digestion with PK in order to degrade other proteins in the 
suspension with a high yield of PrPres (which maintains a PK-resistant core for longer 
periods of time). Quality of PrPres extracts was analyzed by Western blotting and silver 
staining of gels. As determined by Western blot detection with the anti-PrP antibody 
3F4, some extracts still contained full-length PrP, presumably not degraded PrPC. In 
order to improve digestion with PK in these samples, all remaining extracted pellets of 
the same PMCA product were pooled and were again subjected to the purification 
protocol starting with the PK digestion step. This is a modification of the protocol by 
Daus et al. (2013). However, only extracts in which PrPC was completely degraded 
were eventually subjected to FT-IR spectroscopic analysis. Samples that were 
repeatedly digested with PK are indicated in Table 3-3 and Table 3-4. Due to the 
difficulties with PK digestion and due to remaining impurities revealed in the silver 
stained gels, all data shown in this chapter have to be considered preliminary and were 
obtained under not yet optimal conditions. 
PMCA products derived from 263K seeds using nucleic acid depleted NBH but with 
addition of 100 µg/ml poly(A) RNA or 300 µg/ml chondroitin sulfate A, respectively, 
were generated in three independent PMCA experiments and with different ultrasonic 
devices. Each PrPres sample was amplified to a final volume of 1 ml in six PMCA 
rounds. Purification of PrPres was also performed in independent runs, and quality of 
purified protein samples was analyzed by Western blot and silver staining prior to 
measurement by FT-IR spectroscopy. Although silver gels still showed the presence of 
impurities in the PrPres extracts spectra were tentatively obtained from dried protein 
samples in a set of preliminary pilot experiments as exemplarily shown in Figure 3-21.  
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Figure 3-21:  (A) Silver staining of PrPres extracts from PMCA samples. (B) The presence of PrPres 
after purification was confirmed by Western blot. (C) Purified PrPres was transferred onto 
CaF2 slides and dried samples were subjected to FT-IR spectroscopy. (D) FT-IR absorption 
spectra were obtained of dried protein samples. Amide I region encompasses the range 
from 1610-1700 wavenumbers (cm-1). 
 
 
The peak positions that were identified in the spectra for each sample are listed in Table 
3-3. Peak positions of the 263K seeded samples reconstituted with polyanions are 
compared to available data [Daus et al., 2013] from i) 263K parent seeds and ii) 263K 
progeny seeds that had been produced by standard PMCA. Samples that were extracted 
and purified in three independent runs showed nearly identical peak positions in their 
spectra. From the PMCA experiment in which the NBH had been first depleted for 
endogenous nucleic acid and was subsequently reconstituted with exogenous RNA only 
two sample preparations were suitable for FT-IR measurement. Mean values of 
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absorption maxima were calculated and are listed in bold and marked with ∅. To assess 
putative spectral interference of cofactors that had been added to reconstituted PMCA 
substrate, solutions of poly(A) RNA and chondroitin sulfate A were separately dried 
and subjected to FT-IR measurement. No absorption peaks were observed for 
chondroitin sulfate in the amide I region. One peak was obtained for pure poly(A) RNA 
at 1656 cm-1 which however differed from the protein peak position and was only 
obtained with high concentrations of RNA that were equivalent to the reaction 
conditions during PMCA. The extraction of PrPres from PMCA products involved 
nucleic acid degrading procedures, so that theoretically no residual nucleic acids should 
be present in the final extract.  
 
Table 3-3: FT-IR absorption maxima of purified 263K parent and progeny PrPres in the amide I region. 
Samples marked with * had been repeatedly digested with PK. 
 Structure component peak positions (cm-1) 
 ß-sheet  
(low frequency) 
α-helix turns/loops ß-sheet  
(high frequency) 
Cofactor molecules    
Poly(A) RNA 
Chondroitin sulfate A 
- 
- 
1656 
- 
- 
- 
- 
- 
BH      
263K [Daus et al., 2013] 1626/1635 1659  1694 
PMCA products     
263K [Daus et al., 2013] 
263K + poly(A) RNA* 
 
∅ 
263K + chontroitin sulfate A* 
 
 
∅ 
1627 
1628 
1628 
1628 
1629 
1629 
1628 
1628.7 
1658 
1657 
1658 
1657.5 
1657 
1657 
1658 
1657.3 
1681 
1682 
1682 
1682 
1682 
1681 
1681 
1681.3 
1694 
1695 
1695 
1695 
1695 
1695 
1695 
1695 
 
The data do not allow a clear discrimination between samples from PMCA that had 
been reconstituted with RNA or chondroitin sulfate. Determination whether these 
spectral data are significantly different from 263K progeny seeds that had been 
generated under conventional PMCA conditions is, due to little sample number, not 
feasible yet and remains to be done in future studies. However, all progeny PrPres 
forms produced by PMCA were clearly different from authentic brain associated 263K 
PrPres. The latter showed a spectral double peak at the position that is assigned to  
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β-sheet (low frequency), whereas all progeny PrPres forms have a single peak in this 
part of the amide I region of the spectrum.  
 
Additionally, first preliminary FT-IR spectral data were obtained for PMCA produced 
PrPres derived from ME7-H, 22A-H and BSE-H under various cofactor conditions. 
Table 3-4 shows these preliminary data that were obtained from one or two sample 
preparations. At this point, a clear and robust differentiation of these PMCA products 
from each other is not possible.  
However, FT-IR spectra of PrPres from parent brain homogenates of different prion 
strains are clearly distinguishable from those of the respective PrPres amplificates. 
Differences were observed with respect to peak positions indicating β-sheets (low 
frequency). For example ME7-H parent PrPres showed a double peak at  
1626/1633 cm-1, whereas a single peak at 1629 cm-1 was found for the ME7-H derived 
PMCA product. For further structural analyses the spectral database has to be further 
improved and expanded.  
 
Table 3-4: FT-IR absorption maxima of ME7-H, 22A-H and BSE-H associated parent and progeny 
PrPres in the amide I region. Samples marked with * had been repeatedly digested with PK. 
 Structure component peak positions (cm-1) 
 ß-sheet  
(low frequency) 
α-helix turns/loops ß-sheet  
(high frequency) 
BH (M. Daus unpublished)     
ME7-H 
22A-H 
BSE-H 
1626/1633 
1631 
1627 
1659 
1659 
1659 
1680 
1682 
1680 
1695 
1695 
1695 
PMCA products     
ME7-H* 
 
22A-H* 
BSE-H 
1627 
1629 
1628 
1627 
1658 
1659 
1655 
1659 
1682 
1681 
1682 
1683 
1695 
1695 
1696 
1695 
PMCA w/o nucleic acids    
BSE-H 1627 
1627 
1656 
1655/59 
1683 
1683 
1696 
1696 
Reconstituted PMCA products    
22A-H + chondroitin sulfate* 
BSE-H + poly(A) RNA* 
BSE-H + chondroitin sulfate* 
1626 
1628 
1628 
1658 
1658 
1654 
1681 
1682 
1684 
1695 
1695 
1696 
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In summary, the ME7-H derived progeny PrPres differed from its ME7-H parent seeds 
with respect to the glycosylation pattern, the seeding activity, the ability to induce glial 
cell infection and the dependency on specific cofactors for PrP conversion. For BSE-H 
associated PrPres a typically lower molecular mass of the unglycosylated band was 
exhibited by parent and progeny seeds, when the latter were generated in the presence 
of polyanionic factors. In contrast, BSE-H progeny seeds produced in the absence of 
such cofactors did not show such lower molecular mass of the unglycosylated PrPres 
band. Biophysical analysis of purified PrPres using FT-IR spectroscopy revealed 
spectral differences between parent and progeny PrPres for prion strains 263K, ME7-H, 
22A-H and BSE-H. The preliminary findings from this FT-IR analytical pilot study 
need to be validated and expanded in the future.  
 
 
3.5 PMCA and cell culture assays as alternative in vitro methods for 
prion infectivity titrations  
The findings presented below evolved during this dissertation project and perspectively 
facilitate the reduction or even replacement of animal bioassays in prion research. This 
part of the doctoral thesis was published recently in the journal Laboratory Animals 
[Boerner et al., 2013] and is presented in brief in the following paragraphs.  
It has been recently demonstrated that the PMCA assay is not only a simple method for 
the qualitative detection of 263K seeding activity but that this assay also allows a 
quantitative determination of 263K seeding activity [Chen et al., 2010; Pritzkow et al., 
2011; Wilham et al., 2010]. This previously established PMCA procedure could be 
further adapted for an efficient amplification and detection of BSE-H and 22A-H prions 
as described above. These adapted PMCA assays are also suitable for a quantitative 
titration of the seeding activity of both prion strains. Figure 3-22 shows that propagation 
of PrPres from BSE-H and 22A-H in PMCA is consistently dose-dependent. A 
quantitative PMCA assay for 263K is shown comparatively. By endpoint titrations of 
prion seeding activity using these PMCA assays median PMCA seeding doses (SD50) 
can be determined. One SD50 is the dose of seeding activity that converts PrPC into 
PrPres in 50% of PMCA samples. SD50 values of unknown samples can be determined 
by parallel endpoint titrations of reference and unknown samples in PMCA as described 
by Boerner et al. (2013).  
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Figure 3-22:  Dose-dependent propagation of BSE-H- and 22A-H-derived PrPres by PMCA. PMCA 
assays were seeded with 10-5 and 10-6 g 22A-H or BSE-H brain tissue. For comparative 
reasons, a quantitative PMCA assay for 263K prions is shown as well. The amounts of 
seeding tissue are indicated. PMCA protocols were specifically adapted for efficient 
propagation of PrPres from 22A-H and BSE-H (see chapter 3.1). C – Internal Western blot 
control. 
 
Similarly to the titration of seeding activity by PMCA, 263K scrapie infectivity can be 
quantitatively titrated by the glial cell assay. As shown above, glial cell cultures can 
also be infected with other hamster prion strains. BSE-H and 22A-H, but not ME7-H 
are able to infect such cultures. Furthermore, though the cell assays for these prion 
strains were not yet fully developed regarding a quantitative titration of prion associated 
infectivity, they hold the potential for this purpose as shown in Figure 3-23. Cells 
showed a clear correlation between the amount of formed PrPres at defined incubation 
times and the prion inoculation dose. In analogy to the determination of SD50 values by 
PMCA, the cell assay can be used for a determination of the median cell culture 
infective dose (CCID50). One CCID50 is the dose of prions that causes infection (in 
terms of PrPres propagation) in 50% of inoculated cell cultures. CCID50 values of 
unknown samples can be determined by parallel endpoint titrations of reference and 
unknown samples in the cell assay as described by Boerner et al. (2013). In order to 
increase the sensitivity of BSE-H infections in glial cell cultures further improvements 
could be made that have not been published yet. Due to an optimization in the 
procedure for proteinase K digestion (see chapter 2.2.10.5) an amount of 10-5 g brain 
tissue inoculum was sufficient to produce a detectable PrPres amplification after 
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80 DPE. This additionally reduced the overall processing time of the assay for future 
BSE-H titrations.  
 
 
 
Figure 3-23:  PrPres amplification in glial cell cultures after incubation with the indicated amounts of 
BSE-H brain tissue is dose dependent. An optimized PK processing protocol devised based 
on the published work by Boerner et al. (2013) improved the sensitivity and reduced the 
incubation time. C – Internal Western blot control. 
 
“Quantitative prion bioassays in animals usually determine infectivity titers in terms of 
the median infective doses (ID50) that had been present in the inoculated sample 
material. One prion ID50 is the dose of prions that causes infection in 50% of inoculated 
animals. Based on empirically established quantitative correlations among SD50, 
CCID50 and ID50 in reference standards such as homogenized 263K scrapie hamster 
brain tissue, SD50 and CCID50 values detected in test samples can be tentatively 
translated into ID50 values. PMCA and cell assays represent profoundly different cell-
free and cell-based test principles for the biochemical and biological titration, 
respectively, of prion activity in vitro. Therefore, if these assays independently deliver 
consistent ID50 assessments, this substantially backs up the overall test reliability as 
compared with titrations based on either PMCA or cell assays alone. An integrated 
approach for the reduction and replacement of prion bioassay titrations in animals that 
includes both the measurement of seeding activity and the determination of cell culture 
infectivity by quantitative, sensitive and robust PMCA and cell assays, respectively, is 
suggested“ [Boerner et al., 2013]. 
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4. Discussion 
 
4.1 Propagation of ME7-H, 22A-H and BSE-H prion strains in 
PMCA and cell assay 
 
4.1.1 PMCA 
The hamster prion strain 263K scrapie is often used as a model prion agent for research 
purposes in laboratories. Very efficient propagation of 263K in serial PMCA with an 
optimized protocol was recently described by our group [Pritzkow et al., 2011]. 
However, other hamster adapted prion strains, such as ME7-H, 22A-H and BSE-H 
could not be amplified, or amplified only with poor efficiencies, using this PMCA 
protocol. As mentioned above (chapter 3.1) these prion strains were distinguishable by 
their respective in vivo incubation times and by biophysical FT-IR spectroscopic 
measurements. As previously reported, these prion strains differed in part with respect 
to clinical, neuropathological and biochemical features [Thomzig et al., 2004].  
Amplification of ME7-H, 22A-H and BSE-H by the PMCA technique could only be 
achieved by addition of the metal chelator EDTA and a prolongation of the cyclic 
incubation time. Each prion strain had slightly different minimal requirements with 
respect to amplification conditions. Whereas 22A-H required an incubation time of 
4 hours, amplification of BSE-H and ME7-H required only 2 hours intervals of 
incubation time. This indicates that BSE-H and ME7-H exhibit faster seeding activities 
than 22A-H under the applied PMCA conditions.  
According to the “protein-only” hypothesis the infectious prion agent consists mainly if 
not entirely of misfolded protein without coding nucleic acids [Prusiner, 1982]. Since 
different prion strains exist in a single species which share the same amino acid 
sequence, they must originate from different protein conformations or be due to 
different cofactor attachments or effects [Collinge et al., 1996; Geoghegan et al., 2007; 
Safar et al., 1998]. Extension of the incubation times during PMCA cycles was 
beneficial for the amplification of strains with long in vivo incubation times (ME7-H, 
22A-H and BSE-H).  
Nucleation-dependent, or seeded, PrP polymerization was proposed by Jarrett and 
Lansbury [Jarrett and Lansbury, 1993] as the molecular mechanism underlying PrP 
fibril elongation. It was assumed that fibrils are elongated by template-mediated 
selection of the amyloidogenic conformation from a pre-existing equilibrium of 
different PrP conformers [Bhak et al., 2009]. If there are multiple conformers present in 
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an equilibrium in the PrP substrate, then the need for appropriate selection of molecules 
with the complementary conformation to the template could plausibly influence the 
efficiency of fibril elongation. Alternatively, PrPC monomers may experience a 
structural transition to the amyloidogenic conformation complementary to the template 
upon binding. This transition may occur slower for ME7-H, 22A-H and BSE-H than for 
263K, and thus result in a delayed elongation of seeds. Furthermore, it was speculated 
that PrPSc fibrils require further maturation after breakdown into aggregates by the sonic 
treatment before efficient conversion of PrPC can take place [Eiden et al., 2006]. If the 
sonication is applied too early, this would interfere with the elongation or maturation of 
PrPSc seeds, respectively, and would impair the amplification process. In any case, 
differences in prion strains are reflected by differing individual requirements for 
efficient PMCA.  
In contrast, amplification of prions from various strains and various species with an 
apparently unchanged PMCA protocol was described by Soto and others [Barria et al., 
2011; Castilla et al., 2008b; Deleault et al., 2010; Piro et al., 2009]. In accordance with 
the data presented in this thesis, different seeding efficiencies for different hamster 
prion strains in serial PMCA have been described recently by others [Gonzalez-
Montalban and Baskakov, 2012] and were experimentally addressed by using adapted 
dilution ratios for serial transmission steps between PMCA rounds [Gonzalez-
Montalban et al., 2011].  
The addition of EDTA in a concentration up to 20 mM instead of 5 mM to reaction 
mixtures yielded higher amplification rates of all four prion strains in this study. The 
standard PMCA procedure does not use 20 mM EDTA, it was however recommended 
to include 5 mM EDTA in the conversion buffer, which is used to prepare the NBH 
[Barria et al., 2012; Castilla et al., 2006]. By using elevated EDTA concentrations and 
optimizing the incubation times both parameters additively yielded higher amplification 
efficiencies (Figure 3-3). A putative mechanism for the action of EDTA is described in 
chapter 4.2.4.3.  
A serial PMCA procedure for a successful and efficient amplification of PrPres from 
BSE-H and 22A-H prions was not reported previously. However, Ayers et al. showed 
an amplification of 22A-H associated PrPres after one round of PMCA and therefore 
demonstrated that this prion agent in principle can propagate in a one round PMCA 
assay [Ayers et al., 2011]. Our group recently demonstrated that the PMCA assay 
allows a quantitative determination of 263K seeding activity [Boerner et al., 2013; 
Pritzkow et al., 2011]. Moreover the results in this thesis and in [Boerner et al., 2013] 
demonstrate that propagation of ME7-H, 22A-H and BSE-H is dose dependent (though 
the sensitivity for 263K prions is much higher), and thus a quantitative assay similar to 
263K titrations in PMCA may also be established.  
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4.1.2 Cell assay 
Autocatalytic propagation of prions by PMCA is a very fast method for the biochemical 
amplification of prions in vitro under cell-free non-physiological conditions. In contrast, 
glial cell cultures represent a biological in vitro amplification assay for prions under 
physiological conditions. They provide information about the biological seeding activity 
of prions in terms of biological infectivity. The susceptibility of primary hamster glial 
cell cultures to 263K prions was described previously [Pritzkow et al., 2011]. In this 
thesis, ME7-H, 22A-H and BSE-H prions were applied to cell cultures as well. Cells 
were susceptible to infection with 22A-H and BSE-H prions [Boerner et al., 2013] but 
not to ME7-H prions. Infection of primary cells or cell lines with hamster adapted prion 
agents ME7-H, 22A-H or BSE-H has not been reported previously. Similar efficiencies 
of cell infection by 263K and 22A-H prions were observed. For the BSE-H agent a 
lower efficiency of infection was determined. The cell assay findings show a trend that 
is consistent with bioassay data from studies in hamsters: In bioassay studies 263K 
scrapie, 22A-H scrapie and BSE-H prions caused the full-blown clinical picture of prion 
diseases in Syrian hamsters at 83±5, 206±8 and 287±28 days, respectively [Thomzig et 
al., 2004], whereas the ME7-H scrapie agent had the longest incubation time of 331±16 
days. The inability of ME7-H to propagate in glial cell cultures may be explained by 
these bioassay findings. In contrast, ME7-H amplification by PMCA with whole brain 
homogenate was efficient. One explanation of this apparent discrepancy may be that 
biological replication of ME7-H depends on a specific cell tropism not met in the glial 
cell preparations, while a molecular fit between PrPSc and PrPC in the PMCA reaction 
was possible. Interestingly, Ayers et al. recently investigated the deposition of PrPSc 
from different hamster prion agents in the brain tissues by antibody staining and 
observed a low immunoreactivity of PrPSc within neurons, astrocytes and microglia in 
ME7-H infected animals compared to the other hamster prion agents [Ayers et al., 
2011] while the deposition in the neuropil was rather the same as for the other prion 
strains. On the other hand, ME7-H replication may rely on other conversion factors that 
are available in PMCA but not in the cell assay, e.g. due to cell compartmentalization. 
Similar observations were reported for the mouse RML prion strain [Herva and 
Weissman, 2012]. While RML prions could replicate in the PK1 cell line, R332H11 cells 
were resistant to infection. The efficiency of RML propagation in PMCA with cell 
lysates as substrate was however equal for both cell lines. This showed that 
susceptibility of cells to infection with a prion strain was not reflected in PMCA and 
implicated that other factors additionally to PrPC are involved in the PrP seeding 
activity. Cell dependent factors, which are critical for susceptibility to prion infection 
include specific clearance of PrPSc [Ayers et al., 2011]. Alternatively, co-internalization 
of PrP with other proteins has been suggested, and several potential receptors involved 
in the binding and uptake of PrPSc by cells have been proposed, including 
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glycosaminoglycans (GAGs) [Grassmann et al., 2013]. Thus, if prion strains arise from 
association with different cofactor molecules such as GAGs, it would be conceivable 
that cofactors influence receptor mediated PrP internalization.  
We recently demonstrated that PMCA and glial cell assays allow a quantitative 
determination of 263K seeding activity and infectivity [Boerner et al., 2013; Pritzkow et 
al., 2011]. Since the efficiency of BSE-H cell infection depends on the administered 
inoculation dose (Figure 3-23) a prospective quantitative assay for BSE-H titrations in 
cell cultures may be established as well. The findings show, that glial cell cultures can 
not only be used for the titration of 263K infectivity, but in principle also for the 
titration of infectivity associated with BSE-H prions (and 22A-H). A further increase of 
the cell assay sensitivity might be achieved by successive infection passages [Arellano-
Anaya et al., 2011]. As shown in this thesis an increase in sensitivity of BSE-H in the 
glial cell assay, could already be achieved by an optimization of the PK digestion step 
(Figure 3-23). 
 
4.2 Role of cofactor molecules for prion propagation in PMCA 
In this study the suitability of synthetic poly(A) RNA to enhance the in vitro conversion 
and amplification process of prions from four hamster strains was assessed by serial 
PMCA. The in vitro amplification of 263K and ME7-H prions by standard PMCA could 
be enhanced by addition of synthetic RNA to whole crude brain homogenates, while the 
effect on BSE-H propagation was negligible. In contrast, the addition of synthetic RNA 
to PMCA reaction mixtures was found to reduce the seeding efficiency of 22A-H. Thus, 
RNA did modulate the seeding efficiencies of four hamster prion strains in a different 
way.  
However, PrPSc from all four prion strains was unable to propagate efficiently in nucleic 
acid depleted hamster brain homogenate, which demonstrates that all examined prion 
agents rely on endogenous nucleic acids as a cofactor for propagation. A subsequent 
addition of exogenous synthetic RNA, after previous depletion of nucleic acids in the 
reaction substrate, did reconstitute a stable amplification of 263K, ME7-H and BSE-H 
prions, pointing to RNA as a putatively essential cofactor molecule.  
In this setup the amplification of 22A-H prions was prolonged but eventually became 
unsustainable. Synthetic RNA showed a substitution effect in the first PMCA rounds 
but was not sufficient for a longer stable propagation. This indicates that 22A-H either 
requires other certain kinds of nucleic acids than the precise synthetic poly(A) RNA, or 
that this prion strain requires another conversion cofactor than nucleic acids for stable 
propagation in PMCA that was destroyed alongside with nucleic acids during benzonase 
treatment.  
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Another polyanionic compound, chondroitin sulfate A, facilitated a stable amplification 
of 22A-H. In contrast, for ME7-H prions a successful reconstitution was observed with 
RNA but not with chondroitin sulfate A. These results indeed support the notion that 
prion strains can use and rely on cofactor molecules quite selectively for their 
replication at least in PMCA reactions.  
In addition, it was found that BSE-H could propagate in a stable manner and completely 
independent of nucleic acids in nucleic acid depleted hamster brain homogenate when 
large amounts of seeding tissue and a high number of PMCA rounds were used. Hence 
the BSE-H agent was not entirely dependent on nucleic acids or other polyanions, in 
PMCA, but was able to adapt to nucleic acid free replication conditions. 
Other candidate cofactors such as poly-L-glutamate and the sphingolipid sphingomyelin 
were not found to be able to successfully reconstitute the amplification reactions with 
263K scrapie.  
263K seeded samples that were reconstituted with synthetic RNA or chondroitin 
sulfate A were also biologically seeding active as was demonstrated in cell culture 
infection assay. Furthermore, also BSE-H associated PrPres that replicated 
independently of nucleic acids in PMCA could be subsequently propagated by glial 
cells. This provides a strong indication that these in vitro generated PrPres species may 
be also infectious in vivo in Syrian hamsters.  
 
 
4.2.1 Cofactors are required for in vitro prion propagation  
The findings from this work, that a depletion of nucleic acids from the PMCA substrate 
inhibits the cell-free prion propagation from all hamster prion strains, are in accordance 
with results published elsewhere. It was reported that treatment of crude brain 
homogenates with RNase or micrococcal nuclease, which digests DNA and RNA, 
abolished Sc237 hamster scrapie amplification in serial PMCA experiments using 
purified PrPC [Deleault et al., 2007; Deleault et al., 2010; Deleault et al., 2003]. In a 
recent study from Baskakov and colleagues, amplification of six hamster prion strains 
(including 263K and ME7-H) was shown to be suppressed in PMCA after RNase 
treatment of brain homogenate [Gonzalez-Montalban et al., 2011]. This dependence on 
nucleic acids seems to be a general requirement for all hamster prion strains. In contrast, 
the absence of nucleic acids was not found to abolish amplification of mouse prions in 
serial PMCA experiments (own results, not shown and [Deleault et al., 2010]), leading 
to the assumption that the requirement for nucleic acids may be species dependent. 
However more recent experimental data from Saa et al. show that RNA depletion by 
RNase A impairs in vitro amplification of mouse prions in a prion strain dependent 
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fashion [Saa et al., 2012]. RNA was shown to enhance in vitro amplification of nine 
murine prion strains. Therefore, the effect of RNA as a cofactor for PMCA is not 
restricted to hamster prions, but seems to be a prion specific phenomenon.  
 
4.2.2 Nucleic acids are not essential for BSE-H prion propagation in PMCA and 
infectivity in the cell assay 
In this study it was found that BSE-H could propagate, under specific experimental 
conditions, independently of nucleic acids in the PMCA substrate. Such phenomenon 
has not yet been reported in the scientific literature for a hamster prion strain. Together 
with the initial observation that addition of synthetic RNA could not enhance BSE-H 
amplification in normal PMCA with whole brain homogenate (unlike 263K or ME7-H), 
this indicates that the BSE-H agent is not entirely dependent on RNA (or other nucleic 
acids) for replication. However, a long lag phase without apparent amplification was 
observed for BSE-H propagation in nucleic acid depleted PMCA substrate. Only at later 
PMCA rounds amplification became very efficient.  
For propagation of prions in PMCA it is commonly assumed that prion seed 
fragmentation by sonication results in the formation of novel seeds. In this manner an 
exponential growth can be assumed under optimal PMCA conditions [Saborio et al., 
2001]. A lag phase was not observed for BSE-H propagation under normal PMCA with 
nucleic acids. There are several different explanations for the occurrence of the lag 
phase in BSE-H amplification in nucleic acid depleted PMCA substrate.  
Firstly, the findings suggest that some kind of BSE-H prion adaptation occurred. Such 
adaptations could encompass changes of the protein conformation an in cofactor 
selection. It is thought that different prion strains in a mammalian species are 
enciphered essentially in different PrP conformations. Accordingly, the original  
“BSE-H protein conformation” may have changed during the first PMCA rounds under 
nucleic acid-free conditions and may have adapted to a different conformation that is 
able to propagate in such environment. Indeed the observed differences in 
electrophoretic mobility after limited proteolysis (Figure 3-20B) indicate another 
conformation of the BSE-H PMCA product that had been generated in the absence of 
nucleic acids. This is reflected in the altered accessibility of the PK cleavage site in the 
N-terminal region of the respective PrPres. A pilot analysis of the PrPres structures by 
FT-IR spectroscopy did not clearly reveal structural differences between PMCA 
amplificates of BSE-H that had been either produced in the presence or absence of 
nucleic acids. However, slight spectral differences were seen with respect to an 
absorption peak at 1655 cm-1 that was present in the BSE-H PMCA product produced in 
the absence of nucleic acid but absent in the PMCA product generated in the presence 
of nucleic acids. 
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Secondly, non-nucleic acid cofactors such as GAGs or lipids present in the PMCA 
substrate may compensate for nucleic acid deficiency in a way that may or may not 
influence the protein conformation. In this sense nucleic acids may have been 
substituted by other molecules. This explanation is also conceivable, since prion strain 
diversity may also be based on different cofactors that act during prion replication or are 
attached to the prions. In PMCA prion strains do not only rely on a single cofactor 
molecule but exhibit some strain dependent preferences for different molecules. As was 
shown in this study, amplification of BSE-H could be reconstituted with RNA and 
chondroitin sulfate. ME7-H was reconstituted with RNA but not with chondroitin 
sulfate whereas RNA was not effective to mediate a lasting amplification of 22A-H that, 
however, could be reconstituted with chondroitin sulfate.  
Thirdly, BSE-H amplification under nucleic acid deficiency was only observed when 
large amounts of seeding tissue were used. It has been suggested that prion strains 
consist not only of a single protein conformation but comprise a pool of different 
conformations, so called quasi species [Collinge, 2010; Li et al., 2010]. Based on this 
concept it is assumed that a quasi species has a dominant component with recognizable 
biochemical and biological properties and that subspecies are present in a lower 
abundance. Under conditions of natural selection as they may be present in hosts that 
are unable to propagate the dominant species, a subspecies may be preferentially 
replicated accompanied by changes in biochemical and biological properties of the 
prion strain. In PMCA artificial selection may be created by nucleic acid deficiency, 
hence only formerly invisible subspecies of the pool may be able to propagate 
efficiently. Thus, the lag phase of BSE-H was possibly required to select the proper 
subspecies which achieves high amplification efficiency in later PMCA rounds. The 
subspecies eventually amplified under the selection pressure of nucleic acid deficiency 
then differed in its conformation and/or certain cofactor utilization as well as further 
phenotypic properties.  
In this study a cell assay which was performed with BSE-H progeny seeds produced 
under nucleic acid deficiency demonstrated that this BSE-H amplificate was infectious 
to glial cells. This seeding material was propagated over 80 days, and PrPres 
accumulated in the cells. Infectivity in the cell assay suggests that the tested BSE-H 
derived amplificate is also infectious in animals. Furthermore, the cell assay data 
showed that nucleic acids were not necessarily required for infectivity and replication of 
the BSE-H agent.  
Another recent study used a different approach and showed that nucleic acids are not 
essential for maintaining infectivity of Sc237 seeded PMCA prions generated from 
purified PrPC [Piro et al., 2011]. In the study by Piro et al. synthetic photocleavable 
nucleic acids were required for amplification of prions by PMCA and were incorporated 
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into PMCA generated prions. Prior to inoculation of PMCA generated prions into 
reporter animals the incorporated photocleavable nucleic acids were degraded into 
5 base fragments by UV light. Nucleic acids with a length of 5 bases are ineffective as 
cofactors for PrP conversion in PMCA. However, in the animal bioassay all recipient 
hamsters developed prion disease. In ongoing experiments of the same group it was 
recently demonstrated that PrPres could be formed in a seeded PMCA reaction with 
recombinant PrP as substrate in the absence of any cofactor molecules [Deleault et al., 
2012b]. In the mentioned study a recombinant prion strain was propagated by PMCA in 
the presence of α-helical recombinant prion protein and phospholipids for a number of 
rounds. This strain was subsequently subjected to PMCA in the presence of rPrP alone. 
An adaptation to the cofactor-depleted conditions was described and propagation was 
maintained. This adapted prion strain did appear to have a lower molecular weight than 
the parental prion strain after PK treatment, also indicating altered protein 
conformations. However, a bioassay in mice showed that this adapted recombinant 
prion strain was not infectious, irrespective of its seeding activity detected in PMCA. 
Only PMCA products that were produced in the presence of phospholipids were 
infectious in animals.  
In this study, the cell assay with BSE-H progeny seeds that had been generated in the 
absence of nucleic acids demonstrated that the adapted BSE-H was infectious to glial 
cells. However, PMCA was performed in brain homogenate, i.e. not with purified 
substrates. Considering the findings from the study by Deleault et al. this indicates that 
other cofactor molecules such as possibly phospholipids were involved in BSE-H 
amplification and infectivity under experimental conditions of nucleic acid depletion. 
As mentioned above the replication of some mouse prion strains in PMCA without 
nucleic acids is not impaired. Saa et al. showed that amplification of RML prions in 
serial PMCA remained unaffected for up to 9 rounds in RNase treated substrates. 
Subsequent inoculation of wildtype mice with the resulting PMCA products showed 
that RML prion strain identity was maintained after in vitro amplification under 
conditions of RNA depletion. However, an unusual clinical symptom was observed with 
a statistically higher incidence in the group of mice inoculated with RML prions 
amplified under RNA-depleted conditions. The authors concluded that this observation 
cannot be considered as a strain change but was attributed to the possibility that a shift, 
below the threshold of a true strain change, had occurred in the PrP quasi species under 
the particular replication conditions, that resulted in a transient change of the clinical 
phenotype [Saa et al., 2012].  
When assessing the electrophoretic mobility of the BSE-H PMCA product, that had 
been generated in the absence of nucleic acids after its propagation by glial cell cultures, 
the precise molecular size of the unglycosylated band could not be clearly determined 
Discussion 
89 
(Figure 3-20B). Though this band of the “nucleic acid independent” BSE-H PMCA 
product used for cell culture infection did not exhibit a lower molecular mass compared 
to 263K, the cell-derived protein band appeared together with an additional “ghost” 
band of lower molecular mass. The molecular mass of this “ghost” band appeared 
identical to that of the unglycosylated band of authentic BSE-H. This suggests that this 
original biochemical feature may re-emerge from the PMCA products upon biological 
propagation in a cell culture. Accordingly, the altered electrophoretic mobility observed 
after 12 PMCA rounds may be only transiently present as long as in vitro propagation is 
performed under nucleic acid depletion. However, further clarification of this question 
would require additional studies.  
In such future studies, the cell derived BSE-H isolate should be subjected to further 
passages in glial cell cultures. Subsequently, the electrophoretic mobilities of the cell-
derived isolates could be assessed and compared as described above. After 12 PMCA 
rounds the original BSE-H tissue is practically diluted out due to serial PMCA, and only 
newly formed PrPres should be present in reaction samples. Accordingly, cells were 
inoculated only with newly generated PrPres. This excludes the possibility that 
remnants of original BSE-H could have caused a (partial) reversion of the 
electrophoretic mobility to the original pattern. Therefore one might speculate that this 
original feature is still preserved, and may thus potentially re-emerge from the PMCA 
derived PrPres. The conformational change in PMCA derived PrPres that was 
underlying the altered electrophoretic mobility obviously resulted from the selection 
pressure of nucleic acid deficiency during PMCA. In the cell assay such selection 
pressure is absent due to the presence of nucleic acids in this biological system. Thus, if 
the original conformational information coding for a smaller digestion product after 
limited proteolysis is still present, then it can be propagated by the cells. If this feature 
is generally favored under biological conditions of nucleic acid presence, then it will be 
re-established in a few cell culture passages. PMCA under nucleic acid deficiency may 
thus be regarded as a transient artificial disturbance that forces the BSE-H agent into a 
different conformation or a transient quasi species. If the original electrophoretic 
mobility of BSE-H were eventually re-established in the “nucleic acid independent” 
BSE-H isolate upon cell culture passages this would suggest that nucleic acids are not 
essentially required to maintain strain specific information in the BSE-H seeds. 
In other PMCA studies of this thesis with 22A-H prions it was demonstrates that the 
addition of synthetic RNA to the standard PMCA in whole brain homogenate 
suppressed PrPres amplification. Furthermore, a sustained amplification of 22A-H in 
nucleic acid depleted homogenate was not mediated by synthetic RNA. These 
observations indicate that 22A-H may also be able to propagate under nucleic acid 
deficiency. However, this has not been examined and remains to be further explored in 
future studies.  
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As can be seen from the Western blots in Figure 3-7 263K showed an initial apparently 
authentic amplification under nucleic acid deficiency. Nevertheless, this amplification 
could not be sustained. This shows once more, that prion strains have different 
requirements in terms of conversion cofactors. The initial seeding ability of 263K is 
discussed below (chapter 4.2.3). 
 
4.2.3 Different molecules can substitute for cofactor function in PMCA 
It was demonstrated above that under standard PMCA conditions all examined hamster 
prion strains rely on nucleic acids for in vitro propagation. PMCA reconstitution, after 
nucleic acid depletion, with different polyanionic compounds was successful in this 
work which is in agreement with previous studies by others [Deleault et al., 2005; 
Deleault et al., 2007; Deleault et al., 2010]. Propagation of 263K, ME7-H and BSE-H 
was successfully reconstituted with synthetic RNA, and propagation of 263K, 22A-H 
and BSE-H could be reconstituted with chondroitin sulfate A (Table 4-1). 
Glycosaminoglycans such as chondroitin sulfate are linear polyanions with a structure 
that resembles single-stranded nucleic acids. This demonstrates that, in principle, 
different polyanions can act as stimulators of PrPres amplification in PMCA. The 
observed differences for ME7-H and 22A-H prions may reflect strain specific 
preferences for certain conversion cofactors, and indicate higher cofactor selectivity for 
both strains as compared to 263K and BSE-H which could be efficiently amplified by 
addition of either synthetic RNA or chondroitin sulfate. In accordance with these 
findings different cofactor selectivities were recently observed for different mouse prion 
strains in RNA depleted PMCA [Saa et al., 2012]. While amplification of mouse RML 
was restored by the addition of poly(A), poly(G) or DNA, amplification of mouse ME7 
was only reconstituted by poly(A) but not by poly(G) or DNA.  
In any case such data indicate that several different molecules can substitute for natural 
conversion cofactors and mediate amplification in PMCA. This indicates that prions 
may be potentially able to use a variety of different cofactor molecules for their 
propagation in vivo. Furthermore, it can be speculated that strains with a broader 
cofactor specificity might replicate more effectively and faster than strains with higher 
selectivity. As demonstrated in this study, 263K amplification was enhanced by 
synthetic RNA, and its propagation was restored by RNA as well as chondroitin sulfate. 
This was unique for 263K among the prion strains examined in this thesis. All other 
strains showed a higher degree of cofactor selectivity and have substantially longer in 
vivo incubation times than 263K. Table 4-1 summarizes the effects of cofactor 
molecules on PMCA with the hamster strains examined in this study. BSE-H 
amplification after nucleic acid depletion was restored by RNA and chondroitin sulfate, 
but its propagation was not enhanced by addition of RNA to PMCA substrate that had 
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not been depleted of nucleic acids. ME7-H amplification was enhanced as well as 
restored by RNA, but reconstitution of the PMCA reaction with chondroitin sulfate was 
not possible after nucleic acid depletion. In contrast, amplification of 22A-H was even 
inhibited by RNA. After nucleic acid depletion, PMCA could be reconstituted by 
chondroitin sulfate but not by RNA. 
 
Table 4-1: Summary of cofactor effects on the propagation of PrPres from different hamster prion strains 
by PMCA. 
 In vivo 
incubation 
times* in days 
Effect of synthetic 
RNA on 
propagation in 
PMCA with NBH 
Reconstitution with 
synthetic RNA after 
nucleic acid depletion  
Reconstitution with 
chondroitin sulfate A 
after nucleic acid 
depletion  
263K 83 ± 5 + + + 
22A-H 206 ± 8 – – + 
BSE-H 287 ± 28 ± + + 
ME7-H 331 ± 16 + + – 
*  In vivo incubation times according to [Thomzig et al., 2004] 
+  Promotion 
–  Inhibition or no reconstitution 
±  None effect 
 
Abid et al. showed that various types of molecules can act as conversion factors in vitro. 
The authors utilized a one-round PMCA assay with purified PrPC and PrPSc, in which 
PrP conversion was basically only facilitated by addition of whole brain homogenates 
from mammalian species, e.g. rabbit or PrP knockout mice but not by the sole presence 
of normal conversion buffer. They reported that treatment of brain homogenates with 
various enzymes that specifically destroy certain classes of molecules, including nucleic 
acids (benzonase), proteins, lipids (lipase A) and proteoglycans (heparinase II and III 
and chondroitinase ABC) did not impair the reconstitution of PrP conversion [Abid et 
al., 2010]. These results suggested that each putative cofactor may partially replace the 
conversion factor activity in vitro. 
However, the results by Abid et al. seem to be contradictory to the findings reported in 
this thesis for benzonase treated samples, and to findings from other groups who 
performed RNase treatments of PMCA substrates [Deleault et al., 2010; Gonzalez-
Montalban et al., 2011]. One explanation for the apparent discrepancies might be that a 
single PMCA round only was performed in the study by Abid et al., which may have 
lead to artifactual or misleading results. One consistent observation in this thesis is that 
263K exhibited a limited intrinsic seeding activity when propagated in benzonase 
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treated brain homogenate. This resulted in an initial increase of PrPres in the first 
PMCA round but not in subsequent PMCA rounds (Figure 3-5, Figure 3-7). This effect 
was never observed for the other hamster prion strains and thus seemed to be 263K 
strain specific. Theoretically, the residual seeding activity of 263K prions in nucleic 
acid depleted PMCA substrates may have originated from remaining nucleic acids in 
the infected seeding tissue. But a longer treatment of the seeding tissue with benzonase 
for 20 hours did not reduce the effect (Figure 3-6), which excludes the possibility that 
freely accessible nucleic acids mediated the initial 263K seeding. A similar effect is also 
visible in experimental data from Deleault and colleagues [Deleault et al., 2007; 
Deleault et al., 2010]. However, this observation has not been discussed by these 
authors. Deleault et al. used purified Sc237 and PrPC substrates and conversion was 
only facilitated by addition of RNA or whole PrP knockout brain homogenate, similar 
to the PMCA system of Abid and colleagues. Recently, Piro et al. [Piro et al., 2011] 
showed that a 100-base oligonucleotide was incorporated into complexes of PrPSc 
molecules during serial PMCA reactions and became resistant to benzonase digestion 
by this incorporation. Several lines of evidence indicate that polyanionic molecules such 
as RNA may be incorporated into stable complexes of PrP molecules during the 
formation of native hamster prions [Geoghegan et al., 2007; Simoneau et al., 2009]. In 
such nucleoprotein complexes nucleic acids are possibly not accessible for benzonase 
digestion due to protection by PrP and can thus co-purify with brain PrPSc used as 
seeding material for PMCA experiments.  
RNAs were shown to promote the conversion of PrPC into PrPSc in vitro [Deleault et al., 
2005; Deleault et al., 2007; Deleault et al., 2010; Wang et al., 2010]. Furthermore, in 
this thesis it was demonstrated that the amplification efficiency of 263K and ME7-H in 
PMCA can be enhanced by addition of synthetic RNA. In a study from Baskakov and 
colleagues, six hamster prion strains (including 263K and ME7-H) were shown to be 
dependent on RNA in PMCA [Gonzalez-Montalban et al., 2011]. However, studies that 
have determined reconstitution capacities of other different polyanionic compounds for 
the set of different hamster prion agents examined in this thesis have not yet been 
reported.  
Moreover, a reduction of the amplification efficiency due to the addition of synthetic 
RNA has not been reported before to the best of the author’s knowledge. In this thesis it 
could be clearly demonstrated that addition of RNA suppressed 22A-H propagation by 
PMCA in whole brain homogenate. In addition, synthetic RNA was not sufficient to 
mediate a sustained amplification in nucleic acid depleted brain homogenate. This 
strikingly shows that poly(A) RNA is not a generic accelerator of hamster prion 
propagation, but rather facilitates or impedes amplification in a strain dependent 
manner. In this regard, an application of polyanions or putative cofactor molecules in 
prion detection assays with the aim of increasing the speed and/or sensitivity of prion 
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detection as suggested previously [Deleault et al., 2005; Deleault et al., 2003; 
Yokoyama et al., 2011] should be considered very carefully. Since chondroitin sulfate 
mediated a stable restoration of PrP amplification in nucleic acid depleted brain 
homogenate, it may exhibit an accelerating effect on 22A-H propagation under standard 
PMCA conditions. However, this remains to be determined in future studies. 
Furthermore it was demonstrated in this thesis that elevated EDTA concentrations 
yielded higher conversion efficiencies of all tested hamster prion strains and thus 
facilitated a quicker detection of amplified PrPres than previously used standard PMCA 
procedures. If this effect applied to other prion strains as well, this may generally 
improve the sensitivity of PMCA detection assays. 
It was recently reported that phospholipids are required for replication of infectious 
mouse related PrPSc [Deleault et al., 2012a; Deleault et al., 2012b; Wang et al., 2010]. 
Sphingolipids such as galactosylceramide and sphingomyelin were previously detected 
in scrapie hamster prions [Klein et al., 1998] and were therefore experimentally added 
to hamster brain PMCA substrate in this study. A sphingomyelin-mediated 
reconstitution of 263K propagation in PMCA after nucleic acid depletion was not 
possible, nor were sphingomyelin and galactosylceramide able to mediate an 
accelerated prion amplification in standard PMCA carried out without nucleic acid 
depletion.  
Taken together the results of this thesis show that prion strains have different 
requirements with respect to the amplification conditions in PMCA. Under nucleic acid 
deficiency the examined prion strains exhibited different abilities to use certain 
polyanions for the reconstitution of PrP conversion. Thus, these prion agents clearly 
showed differences in PMCA cofactor selectivity. It has to be considered, however, that 
PMCA cofactor molecules could merely function as artificial helpers for PrPres 
amplification under unphysiological cell-free conditions. But if the cofactor findings 
from the PMCA studies are indicative of the mechanisms underlying prion replication 
in vivo, prion strains may also require different cofactors, or respond differently to 
them, under “real-life” conditions. 263K scrapie prions seem to have a broader ability to 
use a variety of cofactors for their replication than the other hamster prion strains. This 
may also provide one explanation for their extremely fast replication in vivo.  
 
  
Discussion 
94 
4.2.4 Impact of metal ions on in vitro prion propagation 
 
The presented experiments also assessed the role of the metal ions Zn2+, Fe2+, Fe3+, Cu2+ 
and Mn2+ in 263K seeded PrPres amplification in two independent and profoundly 
different cell-free and cell-based assays, serial PMCA and glial cell cultures. The 
addition of 100 or 500 µM metal ion solution to PMCA reaction mixtures affected the 
propagation of 263K differently. While Zn2+, Fe2+, Fe3+ and Cu2+ were found to 
suppress PrPres formation in a concentration dependent way, Mn2+ did not exhibit an 
effect on the propagation of 263K (Figure 3-11). Fe2+ had the strongest inhibitory effect 
on PMCA-mediated 263K amplification followed by Fe3+, Zn2+ and Cu2+. An 
acceleration of PrP misfolding was not observed with any of the ions. Moreover, PrPres 
formation was never detected in non-seeded control samples that contained additional 
metal ions. In accordance with the findings from PMCA assays metal ion solutions were 
found to suppress propagation of 263K in glial cell cultures. This effect appeared to be 
dose dependent for Zn2+ and Fe3+ (Figure 3-16). In contrast to PMCA, Cu2+ had the 
strongest inhibitory effect on 263K propagation in glial cell cultures followed by Fe2+, 
Fe3+ and Zn2+. Due to cellular toxicity the effect of Mn2+ on glial 263K propagation 
could not be examined.  
 
4.2.4.1 Discussion of PMCA findings 
The addition of metal ions to PMCA reaction mixtures created an excess of specific 
metal ions in the NBH substrate. Under these conditions an overall tendency of metal 
ions to suppress 263K propagation was observed. This is in good accordance with the 
previous findings that higher EDTA concentrations up to 20 mM promoted PrP 
conversion in PMCA of four different hamster adapted prion agents. This clearly 
demonstrated that free metal ions can suppress prion propagation in vitro. Consistent 
with this, a formation of PrPres was not induced by any metal ion in PMCA samples 
that contained only PrPC substrate without a prion seed. This, however, is in contrast 
with published data by Kim et al. [Kim et al., 2005] who showed that conversion of 
PrPC from normal hamster brain homogenate into a protease resistant form could be 
induced by Mn2+, Cu2+ and Fe2+ during PMCA in the absence of a prion seed. It is 
important to note that these authors added very high concentrations of metal ions to the 
brain homogenate, up to 350 mM MnCl2 and up to 87.5 mM CuCl2 and FeCl2. Even 
when 10 mM CuCl2 was present during seeded PMCA in the experimental setup of this 
thesis, an inhibition of 263K propagation was observed (data not shown, PK digestion 
was performed in the presence of 20 mM EDTA). Furthermore, Kim et al. used a 
different experimental setup in regard to the buffer of brain homogenate, incubation 
times, number of PMCA cycles and conditions for PK digestion compared to the 
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experiments described in this thesis. Under treatment with PK authentic PrPSc is usually 
processed to an N-terminally truncated protease resistant core fragment of 27-30 kDa, 
while non-PK treated full-length PrP possesses a molecular weight of 33-35 kDa. 
However, in the report by Kim et al. the molecular weight of PrPres generated in the 
presence of metal ions seemed unaltered before and after PK treatment, hence a PK-
mediated truncation of PrP at the N-terminus, which is typically observed with 
conventional PrPSc, was not apparent. Additionally, Bocharova et al. reported that Cu2+ 
ions increased the resistance against proteolysis of full-length recombinant non-
amyloidogenic PrP without changing its α-helical conformation, as was assessed by CD 
spectroscopy [Bocharova et al., 2005]. This PK resistant PrP was also not digested to a 
PrP27-30 like fragment. As demonstrated in Figure 3-10B the presence of 10 mM 
CuCl2 during limited proteolysis by PK resulted in an inhibited digestion of PrP. The 
samples in this figure had not been subjected to PMCA. Addition of EDTA restored 
complete PK digestion. Since it was reported that Cu2+ ions can inhibit the activity of 
PK [Stone et al., 2007] this is another plausible explanation for the observed differences 
between this and the study by Kim et al.. Unfortunately, it has not been examined 
previously if other metal ions can also inhibit PK activity. Therefore, in this thesis a PK 
digestion of PrPSc in the presence of metal ions in equivalent concentration as used in 
PMCA experiments was performed (Figure 3-10A). This revealed no altered PrP 
processing in these samples. To answer, however, the question whether higher 
concentrations of metal ions specifically mediate an authentic resistance of PrPC against 
PK, or whether merely the enzyme activity is impaired by the ions, a simple experiment 
can be performed:  
The samples in which PrPC was detected, though they had been digested with PK (in the 
presence of millimolar amounts of metal ions and without EDTA), could be analyzed, in 
future studies, for the presence of other brain proteins that are usually degraded by PK 
(e.g. glial fibrillary acidic protein, actin or glyceraldehyde 3-phosphate dehydrogenase) 
with specific antibodies. If PK activity were inhibited by the metal ions, other proteins 
from NBH would not be degraded and could be detected. Alternatively, the total protein 
content in these samples could be determined and compared to the total protein content 
in samples that had not been PK digested. However, in the experiments of this thesis 
only micromolar amounts of metal ion solution were applied, and PK digestion was not 
affected by these concentrations. 
The finding that specifically Zn2+ and Cu2+, but not Mn2+ suppressed PrPres formation 
is in agreement with previous reports by Bocharova et al. and Orem et al. [Bocharova et 
al., 2005; Orem et al., 2006]. Using an amplification system with purified PrPres 
different from PMCA, Orem et al. showed that the seeded amplification of PrPres with 
a purified PrPC substrate was potently inhibited by CuCl2 in a dose dependent way. 
ZnCl2 had also inhibitory effects, but with a 20-fold lower potency. An inhibition by 
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MnCl2 was not observed. Moreover the authors determined that even an excess of Mn2+ 
could not prevent the Cu2+ mediated inhibition of PrPres amplification, whereas metal 
chelators did. The authors suggested that the inhibitory effect of Cu2+ was likely 
mediated by a metal binding site on PrPC. Furthermore, Bocharova et al. found that 
Cu2+ and Zn2+ (to a lesser degree) but not Mn2+, inhibited a conversion of bacterially 
expressed full-length PrP into amyloid fibrils [Bocharova et al., 2005]. They suggested 
that Cu2+ inhibited the structural conversion of PrP by stabilizing a non-amyloidogenic 
PK-resistant form of α-helical recombinant PrP (as mentioned above). In this context, it 
would be very interesting to know whether different metal ions can specifically mediate 
resistance of PrPC against PK as mentioned above and thereby suppress PrP conversion.  
In a PrPres amplification system with purified substrates Cu2+ was the most potent 
inhibitor of PrP conversion, followed by Zn2+. In this system Mn2+ did not show any 
effect. These results correlated with the binding affinities of the ions to the octapeptide 
repeat region of PrP. Binding of metal ions to the octarepeats of PrP was found to occur 
with different affinities. Cu2+ has a high affinity while Zn2+ binds with an affinity that is 
two to three orders of magnitude lower [Pan et al., 1992]. Mn2+ binds with a yet lower 
affinity [Bocharova et al., 2005; Brazier et al., 2008].  
However, the PMCA experiments performed in this thesis with whole brain 
homogenate led to different results, since Fe2+ was the strongest inhibitor of 263K 
amplification followed by Fe3+, Zn2+ and Cu2+. This may be due to binding of Cu2+ and 
Zn2+ to other proteins in the homogenate, resulting in a different availability of these 
ions for PrPC. Binding sites and affinities of PrP for iron have not been established yet. 
It was suggested that the octarepeat region is not essential in this context, and that iron 
binding to PrP may depend on its conformation or may be very transient [Singh et al., 
2010]. Furthermore it was suggested that iron is associated with PrPSc in form of 
insoluble PrPSc-ferritin complexes [Singh et al., 2009]. However, the addition of iron 
ions to PMCA experiments in this thesis resulted in a strong inhibition of PrPres 
amplification.  
Further investigations might use chelators that are specific for a certain metal ion to 
reveal the contribution of individual ions to the in vitro conversion of PrP in PMCA 
experiments using normal brain homogenate as PrPC substrate. 
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4.2.4.2 Discussion of cell culture findings 
In this study metal ions were applied for the first time to primary hamster glial cell 
cultures to investigate metal effects on prion propagation for a long-term duration of 
approx. 80 days. Because free metal ions may be toxic to cells depending on the specific 
kind of ion and its concentration they were applied to cell cultures with caution. A 
regular, at least weekly, inspection of cell cultures by microscopy was of high 
importance to assess cell vitality, since there are no data available that describe the 
long-term effects of metal ions on the viability of glial cells. The applied µmolar 
concentrations of metal ions on cell cultures were adjusted to amounts published in the 
literature. Similar concentrations of metal ions (20 µM ZnCl2 or CuCl2) had been used 
in studies that involved primary neuronal cells [Cuajungco et al., 2000; Lovell et al., 
1999]. In these studies cell viability was determined after shorter incubation time 
intervals of about 24-72 h. Cell viability is reflected in a variety of parameters, but is 
commonly measured either directly at the cellular level by staining of living or dead 
cells (e.g. MTT [Mosmann, 1983] or trypan blue, respectively), or by analysis of the 
culture supernatant. Damaged cells release components from the cytoplasm into the 
culture medium, e.g. nucleic acids or lactate dehydrogenase, which can be determined. 
However these compounds underlie a naturally occurring degradation. For this reason, 
assessment of cell viability by analysis of culture medium compounds is rather suitable 
for assays with shorter incubation times. In contrast, the glial cell assay was performed 
for durations of up to 80 days, which makes an analysis of compounds in the culture 
medium not straightforward. Therefore, in addition to regular microscopic inspection 
for detecting the occurrence of cell damage, it is suggested to perform the cell culture 
experiments with multiple replicates of the same sample (at least 4 replicates). At the 
appropriate DPE of PrPres detection, two replicates of the sample are used for Western 
blot detection and the other replicates are used for cell viability measurements 
preferentially with an appropriate staining method. Alternatively, metabolic activities of 
cells could be determined, e.g. by measurement of ATP levels or reduction of 
tetrazolium salts [Roche-Diagnostics, 2008]. 
In accordance with the findings from PMCA assays metal ions were found to suppress 
amplification of 263K in glial cell cultures. Cu2+ had the strongest inhibitory effect on 
263K amplification in the cell assay. Copper in form of CuSO4 had been previously 
applied to a permanently scrapie infected neuroblastoma cell line (ScN2a) [Hijazi et al., 
2003], which resulted in a reduced accumulation of PrPSc. Cultivation of normal N2a 
cells in the presence of copper resulted in increased accumulation of total PrP. 
Furthermore, Hijazi et al. showed that cultivation of N2a cells in the presence of 
500 µM CuSO4 24 h prior to cell infection with scrapie brain homogenate inhibited the 
binding and internalization of PrPSc. Knowing that copper can enhance PrPC 
internalization into cells [Pauly and Harris, 1998; Perera and Hooper, 2001], it was 
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hypothesized that PrPC internalization by copper may hinder interaction with PrPSc and 
thereby prion propagation. Thus the observation presented in this thesis that PrPres 
formation was impaired in glial cell cultures that had been incubated in the presence of 
50 µM CuCl2 20 days prior to cell infection (control sample, Figure 3-16) can be 
possibly explained by a Cu2+ induced PrPC deficiency on the cell surface. As a damage 
of cells was not visible by microscopy the inhibition of cellular PrP conversion by Cu2+ 
does not seem to be due to copper cell toxicity.  
In addition to copper, Zn2+ was shown to stimulate PrPC endocytosis, though to a lesser 
extent than Cu2+ [Perera and Hooper, 2001]. The study presented in this thesis found no 
impairment of prion propagation when cultures were incubated 20 days in the presence 
of Zn2+ ions prior to cell infection. However, Zn2+ mediated inhibition of prion 
propagation was effective only in the constant presence of 50 µM ZnCl2 during cell 
incubation.  
In a study by Basu et al. human neuroblastoma cells were exposed to FeCl2 which 
bound to PrPC and transformed it into a PrPres-like form [Basu et al., 2007]. Another 
recent publication reported that an internalization, conversion into PrPres and 
accumulation and of exogenously administered recombinant PrP was induced in cells by 
Fe3+ but not Fe2+ [Choi et al., 2013]. In contrast to these findings, the administration of 
FeCl2 and FeCl3 to PMCA samples or cell cultures in this study did suppress the 
formation of PrPres in both in vitro assays. In this regard, FeCl2 as well as FeCl3 were 
similarly effective. The results of this thesis provide no indication that iron ions 
promoted prion propagation. This discrepancy to published data could be due to 
different experimental designs and assays used in this and the published studies. In the 
studies by Basu et al. and Choi et al. relatively high concentrations of 100 µM-300 µm 
FeCl2 and 600 µM ferric ammonium citrate (Fe3+), respectively, were examined for 
effects on the conversion of PrP. In this thesis, however, concentrations of 20 and 
50 µM were used (since 100 µM were found to cause cell damage in long-term 
experiments) together with authentic PrPC as conversion substrate. In this context it has 
to be noted that the data on the influence of metal ions on PrP conversion presented in 
this thesis are still preliminary and need to be further substantiated in future studies.  
 
4.2.4.3 Conclusion and outlook 
There are many reports that address the involvement of copper in the etiology and 
pathogenesis of prion diseases. In the literature it has been discussed that elevated 
extracellular copper levels cause PrPC to attain a PrPSc like structure that accumulates on 
the cell surface and eventually forms amyloid like aggregates (for review see [Rana et 
al., 2009]). This assumption was supported, inter alia, by the findings that the 
application of Cu2+ chelators delayed the onset of prion disease in infected mice 
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[Sigurdsson et al., 2003] and that Cu2+ in vitro increases the resistance of PrP against 
PK [Kim et al., 2005; Sigurdsson et al., 2003]. However, the specific role of copper in 
prion diseases may be complex. In this study copper ions consistently decreased the 
propagation of PrPSc seeds by PMCA and in glial cell cultures. 
Though PMCA and cell assay represent profoundly different cell-free and cell-based 
test principles for the biochemical and biological propagation of prion activity in vitro 
they delivered basically similar findings when metal ions were applied. Due to the 
absence of cellular structures, PMCA experiments provide insight into the effects of 
metal ions on prion replication on the molecular level. In the cell culture assay, 
however, additionally to molecular effects cell mediated effects of metal ions, such as 
ion induced PrP internalization, influence prion propagation. Therefore, findings from 
PMCA and cell assay do not need to be identical. Indeed, the suppressing effect of 
copper was relatively stronger in the cell assay and less pronounced in PMCA. This 
indicated that the cell mediated inhibition of prion propagation by copper is more 
effective than its mere action on PrP misfolding at the molecular level. While FeCl2 was 
the most effective compound in suppressing PrP misfolding in PMCA it did not cause a 
similarly strong inhibition of PrPres formation in the cell assay, showing that an 
inhibitory molecular effect on PrP misfolding in PMCA is not necessarily sufficient to 
prevent biological prion propagation. Together, these data suggest that a combined 
application of FeCl2 and CuCl2 could best prevent prion propagation in cell cultures, by 
a molecular as well as cell mediated non-cytotoxic mode of action.  
The experimental results in this thesis showed examples for the in vitro inhibition of 
seeded prion propagation by elevated metal ion concentrations. Primary PrP nucleation, 
i.e. the de novo formation of a prion seed, has not been addressed in this experimental 
setup. In the context of the nucleation-polymerization model of prion replication, the 
observed inhibitory effects of metal ions are rather explained by a metal ion-mediated 
interference with seed elongation than metal ion-mediated impairment of seed 
fragmentation. The experiments of this thesis could, however, not clearly identify by 
which precise mechanisms PrP conversion had been inhibited by metal ions. Metal-
induced structural stabilization of PrPC has been hypothesized to mediate inhibition of 
PrPres amplification [Levin et al., 2005]. This would affect the interaction with PrPSc 
seeds in the course of seed elongation, and is a conceivable mode of action in the 
PMCA experiments of this thesis. Figure 4-1 depicts a hypothetical diagram of the 
possible mechanisms that explain the metal ion-mediated inhibition of PrP conversion 
in seeded PMCA experiments observed in this thesis. PrPC is known to bind copper ions 
in vivo, whereas PrPSc becomes depleted of copper and enriched in manganese [Brown 
et al., 1997; Thackray et al., 2002; Wong et al., 2001a]. Inhibitory effects of Cu2+ on 
PrPres formation observed by others were suggested to be mediated by binding of Cu2+ 
to PrPC and a structural stabilization of the PrPC [Levin et al., 2005; Orem et al., 2006]. 
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It has been hypothesized that copper binding to PrPC would affect PrPC structure and the 
ability to aggregate [Levin et al., 2005]. Additional evidence comes from a study by 
Thakur et al., who showed that the inhibition of formation of PrP amyloid fibrils by 
copper at physiological temperature is accompanied by two novel intra-protein 
interactions that render the PrP structure more compact and thus stabilize it [Thakur et 
al., 2011]. If binding of metal ions, in particular copper, with high affinity to PrPC 
stabilizes the structure of this protein and make it therefore more resistant to adaptation 
to the PrPSc conformation, conversion into and amplification of PrPres would be 
plausibly inhibited. The addition of EDTA captures metal ions. In the presence of 
EDTA the structure of PrPC would not longer be stabilized by metal binding, and an 
adaptation to the PrPSc conformation would be facilitated. However, manganese may 
bind to PrP in either conformation, but does not stabilize PrPC. Hence, conversion 
would not be affected. A pro-aggregatory effect of manganese that was previously 
described in the literature [Kim et al., 2005; Levin et al., 2005] which may result in 
accelerated PrPres formation was however not observed in the PMCA assay in this 
thesis. 
 
 
Figure 4-1:  Hypothetical model of a molecular mechanism of metal ion mediated inhibition of PrP 
amplification in seeded PMCA. Metal ions may affect the elongation step of PrPSc seeds by 
stabilizing PrPC substrate conformation and thus impeding PrP misfolding and attachment 
to the PrPSc seed. Addition of EDTA captures metal ions and facilitates accelerated PrPSc 
propagation. Manganese may bind to PrPC and PrPSc but without implications for 
conversion of PrP and propagation of PrPSc. 
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It has been established by a variety of studies that different modes of action exist with 
respect to the influence of metal ions on PrP conversion. Manganese has been discussed 
to propagate prion replication by inducing structural changes in PrP, binding to 
monomeric PrPSc thereby stabilizing it and propagating its aggregation, or by inhibiting 
proteasomal activity and increasing the PrPSc levels [Choi et al., 2006]. The findings in 
this work did however not indicate a stimulation of PrP misfolding and prion replication 
by Mn2+.  
Furthermore, metal ions may play a role in the prion strain phenomenon [Wadsworth et 
al., 1999], or may affect the incubation times of prion strains. Within the scope of the 
present study, PMCA and glial cell assays for other hamster adapted prion strains  
22A-H, BSE-H and ME7-H, respectively, have been established. Using the same 
experimental setup of PMCA and cell assay as applied for 263K, the effect of metal 
ions on PrP misfolding associated with these other prion strains can be examined easily 
in future studies.  
 
 
4.3 Characterization of the amplified PrPres species 
Comparison of biochemical properties of brain PrPSc and PMCA generated PrPres from 
each prion strain revealed some alterations from the original properties. During in vitro 
propagation of ME7-H a change from the original glycosylation profile was observed. 
The diglycosylated protein band was most pronounced in PMCA derived PrPres, while 
mono- and diglycosylated protein bands showed an approximately equal intensity in 
brain PrPSc. Similar observations were reported previously by others [Gonzalez-
Montalban and Baskakov, 2012] using PMCA with other hamster prion agents. PMCA 
derived PrPres was reported to be depleted of monoglycosylated PrP and the 
percentages of diglycosylated PrP glycoforms was increased compared to brain PrPSc. 
However, diglycosylated PrPSc was already predominant in the original PrPSc seeds. The 
authors suggested that PMCA propagates the same molecular features in an 
undifferentiated manner, i.e. at least partially independent of the strain characteristics of 
PrPSc parent seeds, and that the properties of PrPres derived from different prion strains 
basically converge during in vitro amplification [Gonzalez-Montalban and Baskakov, 
2012]. As discussed above, PMCA conditions cause an artificial environment and 
selection pressure for PrPres replication. Under such amplification conditions 
diglycosylated PrP may be the favored protein species for prion replication. 
Furthermore, it was demonstrated that propagation of hamster prions requires 
diglycosylated PrPC whereas propagation of mouse prions requires unglycosylated PrPC 
in PMCA [Nishina et al., 2006]. On the other hand, however, other authors had reported 
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that PrP glycosylation is not required to maintain strain-specific properties such as 
patterns of cerebral PrPSc deposition and neuronal vacuolation [Piro et al., 2009]. 
Accordingly, it can be hypothesized that the change in the glycoform pattern of PMCA 
derived ME7-H observed in this thesis has no implications for its strain specific 
properties in vivo. Yet, the PMCA derived ME7-H differed also with respect to other 
properties from the original inoculum. Compared to brain PrPSc PMCA derived ME7-H 
exhibited a higher efficiency to induce PrP conversion in PMCA (Figure 3-17B). 
Moreover, amplification of PMCA derived ME7-H under nucleic acid deficiency was 
equally well restored by synthetic RNA and chondroitin sulfate, whereas propagation of 
brain ME7-H PrPSc was facilitated by synthetic RNA only and with a lower efficiency 
than found for PMCA derived ME7-H. Amplification under nucleic acid deficiency 
revealed a residual seeding ability of PMCA derived ME7-H that was otherwise only 
observed for the fast replicating 263K scrapie strain. The most striking difference was 
observed in the cell assay. While authentic ME7-H from hamster brains failed to 
replicate in glial cell cultures, the PMCA derived ME7-H had gained the ability to do 
so. Several studies found that PMCA generated PrPres exhibited extended incubation 
times when inoculated into animals [Klingeborn et al., 2011; Piro et al., 2009]. The 
findings shown in this thesis, that PMCA derived ME7-H acquired a faster seeding 
efficiency in PMCA, and more importantly, that it gained the ability to infect glial cell 
cultures suggests that the ME7-H PMCA product may have an increased or “faster” 
infectivity in animals (i.e. PMCA derived ME7-H may well cause disease after shorter 
incubation times than authentic ME7-H which does only after about 330 days). 
Structural analyses of FT-IR spectra from brain ME7-H and PMCA derived ME7-H 
revealed different spectral features of PMCA derived PrPres that, however, resembled 
those of all other examined PMCA samples. This further shows that PMCA derived 
ME7-H structurally differs from its brain ME7-H parent seed. From the data available 
so far it cannot be concluded whether the observed altered properties of PMCA derived 
ME7-H are permanent or transient (the latter seems to be likely for the BSE-H PMCA 
product produced under nucleic acid deficiency, see chapter 4.2.2 above). Again, the 
findings for ME7-H may reflect a dynamic selection process in terms of preferentially 
propagated PrPres species under certain amplification conditions, as discussed above for 
BSE-H. Further clarification of this issue will require additional studies. 
 
Apart from these findings, it was demonstrated in this study that other strain specific 
properties were preserved during PMCA. The electrophoretic mobility of BSE-H from 
brain or PMCA was similar, and was distinguishable from brain PrPSc and PMCA 
derived PrPres associated with 263K, ME7-H or 22A-H. The findings for BSE-H were 
only different, when PMCA conditions had been specifically modified for permanent 
nucleic acid deficiency (discussed above). When, however, BSE-H was generated in 
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PMCA under an excess of synthetic RNA, or when its amplification under nucleic acid 
deficiency had been restored with synthetic RNA or chondroitin sulfate, the 
electrophoretic mobility was still unchanged. Thus, if suitable cofactor molecules were 
continuously present during amplification, the electrophoretic mobility typical of 
original BSE-H seeds was preserved in PMCA. Since in the present study only a 
proportion of the biochemical, biological and structural properties of PMCA generated 
PrPres species were characterized and compared to the corresponding brain PrPSc, it 
cannot be ruled out that further differences with respect to other properties exist.  
 
There is an ongoing debate whether PMCA propagates all prion strain characteristics 
faithfully. First publications reported that major characteristics are preserved [Castilla et 
al., 2008b; Castilla et al., 2005a]. Such properties were assessed by different methods 
on different PMCA propagated prion strains. This included analyses of the 
electrophoretic mobility, glycosylation profile, resistance to PK and resistance to 
denaturation with guanidine hydrochloride, as well as inoculations of animals and 
subsequent analyses of the incubation times until development of disease and the 
clinical symptoms. However, recently evidence has accumulated that some properties of 
parent PrPSc seeds are modified in PMCA products [Daus et al., 2013; Gonzalez-
Montalban and Baskakov, 2012; Klingeborn et al., 2011]. The analysis of structural 
components of brain PrPSc and PMCA derived PrPres by FT-IR spectroscopy aimed to 
determine whether alterations in protein structure can be detected and may be attributed 
to strain specificities and certain experimental cofactor conditions in PMCA. FT-IR 
spectroscopy has been used to distinguish 263K, ME7-H, 22A-H and BSE-H [Thomzig 
et al., 2004]. In this thesis, FT-IR spectroscopy was applied to investigate if the 
presence or absence of specific cofactor molecules during PMCA caused detectable 
alterations in protein conformations. Analysis of 263K generated by PMCA under 
different cofactor amplification conditions (263K in standard PMCA or PMCA 
reconstituted with synthetic RNA and chondroitin sulfate, respectively) indicated no 
major differences in structural components between these samples based on preliminary 
FT-IR data. However, due to limited sample number this has to be considered only as a 
tentative indication, that needs further substantiation. If future measurements provide 
similar results, this would indicate that protein conformations are similar and that 
PMCA products derived by PMCA from the same parent strain may share similar 
conformations after generation under different cofactor conditions. The ability of the 
different 263K PMCA products (standard PMCA or PMCA reconstituted with synthetic 
RNA and chondroitin sulfate, respectively) to induce PrP conversion in glial cell 
cultures was not impaired, which demonstrates that the biological seeding activity was 
unaffected by the substitution of endogenous cofactor molecules using synthetic RNA 
or chondroitin sulfate. However, it has to be noted that all 263K associated PMCA 
Discussion 
104 
generated PrPres samples are clearly different from brain 263K. In FT-IR spectra brain 
PrPSc differs from PMCA derived PrPres of 263K scrapie in certain peak positions 
[Daus et al., 2013]. Preliminary data from PMCA derived PrPres associated with ME7-
H, 22A-H and BSE-H (in standard PMCA, PMCA under nucleic acid deficiency or 
PMCA reconstituted with synthetic RNA and chondroitin sulfate, respectively) showed 
an overall spectral similarity for all samples. Spectra of brain PrPSc of these prion strains 
were clearly distinguishable and different from the corresponding PMCA generated 
PrPres samples. However, a clear and robust differentiation of these PMCA products 
from each other was not possible. On the one hand this may be due to the limited 
number of samples. On the other hand it may also indicate a previously unrecognized 
challenge for the differentiation of PMCA products by FT-IR spectroscopy. PMCA 
seems to select PrP subspecies that have a high replication efficiency under the specific 
amplification conditions. As discussed above, it has been suggested by Gonzalez-
Montalban and Baskakov (2012) that basically converging molecular features are being 
propagated in PMCA. If similar subspecies present in the quasi species ensemble of PrP 
conformers of different prion strains are selected under equal PMCA conditions, this 
could result in the propagation of identical or similar PrP subspecies from different 
prion strains and thus complicate the differentiation of PMCA products by FT-IR 
spectroscopy. Such effect could account for the similar spectra of PMCA derived PrPres 
from different prion strains, and for the spectral differences to the corresponding 
parental brain PrPSc. However, additional experiments are required to definitely resolve 
this issue. 
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4.4 Contribution of PMCA and cell culture assays for the reduction 
of animal bioassays 
On the basis of joined applications of PMCA and cell culture in vitro assays, titrations 
of prion infectivity of unknown samples can be performed in vitro without the need of 
titrations in laboratory animals [Boerner et al., 2013]. This was demonstrated with 
established PMCA and cell culture assays for 263K hamster prions and was 
perspectively shown for other prion strains. By parallel endpoint titrations of samples of 
known and unknown prion seeding activity in PMCA, SD50 values can be determined. 
In analogy to the determination of SD50 values by PMCA, the cell assay is used for 
determinations of cell culture infectivity in terms of CCID50 by parallel endpoint 
titrations of reference and test samples in the cell assay. Due to correlations among 
SD50, CCID50 and ID50 in reference standards such as homogenized 263K scrapie 
hamster brain tissue, SD50 and CCID50 values detected in test samples can be tentatively 
translated into ID50 values. PMCA and cell assays are established for each prion strain 
and the correlation factors between SD50, CCID50 and ID50 have to be determined 
individually. By this approach seeding- and cell culture infectivity titers can be 
determined in vitro and tentatively translated into animal infectivity titers without the 
need for ethically critical, expensive and time consuming titrations in animals. 
“This rationale and methodology for a progressive reduction and eventual replacement 
of prion bioassay titrations in laboratory rodents will also facilitate studies on the anti-
prion effectiveness of (re-)processing procedures for medical devices and biological 
products, and help to further harness prions as test agents for the development of broad-
range disinfectants and as bio-indicators for sterilization processes [Wagenfuhr and 
Beekes, 2012]. However, in order to definitely prove that combinations of PMCA and 
cell assays provide an effective or even superior alternative to bioassays in laboratory 
rodents, prion titre estimates from such jointly performed in vitro assays remain to be 
further validated by actual ID50 data from – preferably completed – in vivo studies.” 
[Boerner et al., 2013] 
This rationale and methodology for the reduction and replacement of animal bioassays 
in prion research was submitted as a proposal to the contest for the Scientific Award for 
the Protection of Laboratory Animals of Berlin (Berliner Forschungspreis für 
Alternativen zu Tierversuchen) in October 2012, and was appreciated as the second best 
contribution. 
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